OR (anticoagulant AND medication) OR (medication AND dabigatran)
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"UNLABELLED: The long-lasting anticoagulant effect of vitamin K antagonists can be problematic in cases of adverse drug reactions or when patients are switched to another anticoagulant therapy. The objective of this study was to examine in silico the anticoagulant effect of rivaroxaban, an oral, direct Factor Xa inhibitor, combined with the residual effect of discontinued warfarin. Our simulations were based on the recommended anticoagulant dosing regimen for stroke prevention in patients with atrial fibrillation. The effects of the combination of discontinued warfarin plus rivaroxaban were simulated using an extended version of a previously validated blood coagulation computer model. A strong synergistic effect of the two distinct mechanisms of action was observed in the first 2-3 days after warfarin discontinuation; thereafter, the effect was close to additive. Nomograms for the introduction of rivaroxaban therapy after warfarin discontinuation were derived for Caucasian and Japanese patients using safety and efficacy criteria described previously, together with the coagulation model. The findings of our study provide a mechanistic pharmacologic rationale for dosing schedules during the therapy switch from warfarin to rivaroxaban and support the switching strategies as outlined in the Summary of Product Characteristics and Prescribing Information for rivaroxaban.","fulltextAvailable":false,"journal":"Frontiers in physiology","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patient Safety","uri":{"id":"D061214","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Atrial Fibrillation","uri":{"id":"D001281","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Vitamin K","uri":{"id":"D014812","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Drug-Related Side Effects and Adverse Reactions","uri":{"id":"D064420","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Blood Coagulation","uri":{"id":"D001777","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Computer Simulation","uri":{"id":"D003198","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Factor Xa","uri":{"id":"D015951","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Appointments and Schedules","uri":{"id":"D001071","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Computer Simulation","uri":{"id":"D003198","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Computers","uri":{"id":"D003201","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pharmaceutical Preparations","uri":{"id":"D004364","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Safety","uri":{"id":"D012449","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Vitamins","uri":{"id":"D014815","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Asian Continental Ancestry Group","uri":{"id":"D044466","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Medicalization","uri":{"id":"D062528","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anticoagulants","uri":{"id":"D000925","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Warfarin","uri":{"id":"D014859","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Nomograms","uri":{"id":"D049451","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"25426077","title":"Computational investigation of potential dosing schedules for a switch of medication from warfarin to rivaroxaban-an oral, direct Factor Xa inhibitor.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"OBJECTIVES: Oral anticoagulation therapy (OAT) with vitamin K inhibitors protects the patients from thromboembolic events. It may however lead to excessive hemorrhage during and after an oral surgery procedure. The aim of this systematic review was to evaluate the justifications to reduce, withdraw, or alter OATs prior to minor oral surgery procedures to manage bleeding events. MATERIALS AND METHODS: A systematic MEDLINE search was conducted for clinical studies in English or German language from 1994 to 2014 comparing patients treated with OAT, without OAT, as well as patients with altered OAT for oral surgery purposes. Relevant outcome parameters were: postoperative local hemostasis, bleeding episodes, occurrence of thromboembolic events, and other complications due to the anticoagulation medication. A hand search for references cited in the identified publications completed the review. RESULTS: After screening of 1755 abstracts, 16 clinical studies were identified according to the selection criteria. Due to the heterogeneity of the obtained data, aggregation and synthesis were not possible. There was no significant difference in bleeding events comparing patients under continued OAT to those with reduced, altered, and/or discontinued OAT medications. Minor bleeding events in the test and control groups were successfully stopped with local measures. However, no superiority of a single hemostatic measure could be identified. Neither the international normalized ratio (INR), within the therapeutic range (2-4), nor the extent of the minor oral surgery procedure had an influence on postoperative bleeding episodes. DISCUSSION: There is strong evidence that OAT patients undergoing minor oral surgery should not discontinue their medication in order to prevent thromboembolic complications. CLINICAL RELEVANCE: Nonetheless, INR should be less than 4, local hemostatic measures are of high importance and patients need to be instructed and closely monitored as minor bleedings might occur more often in OAT patients.","fulltextAvailable":false,"journal":"Clinical oral investigations","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Surgical Procedures, Minor","uri":{"id":"D013511","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Data Collection","uri":{"id":"D003625","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Vitamin K","uri":{"id":"D014812","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patient Selection","uri":{"id":"D018579","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Control Groups","uri":{"id":"D035061","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Surgery, Oral","uri":{"id":"D013515","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"International Normalized Ratio","uri":{"id":"D019934","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Abstracting and Indexing as Topic","uri":{"id":"D000043","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Classification","uri":{"id":"D002965","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Evaluation Studies as Topic","uri":{"id":"D005069","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hemorrhage","uri":{"id":"D006470","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hemostatics","uri":{"id":"D006490","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Language","uri":{"id":"D007802","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Methods","uri":{"id":"D008722","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Population Characteristics","uri":{"id":"D011154","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Publications","uri":{"id":"D011642","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"General Surgery","uri":{"id":"D013502","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Therapeutics","uri":{"id":"D013812","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Thromboembolism","uri":{"id":"D013923","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Vitamins","uri":{"id":"D014815","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Complicity","uri":{"id":"D028661","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Minors","uri":{"id":"D033242","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Medicalization","uri":{"id":"D062528","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hemostasis","uri":{"id":"D006487","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"MEDLINE","uri":{"id":"D016239","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"International Normalized Ratio","uri":{"id":"D019934","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"25413495","title":"Oral surgery during therapy with anticoagulants-a systematic review.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"OBJECTIVE: The aim of this study was to assess the cost effectiveness of the novel fixed-dose anticoagulant rivaroxaban compared with the current standard of care, warfarin, for the prevention of stroke in patients with atrial fibrillation (AF). METHODS: A Markov model was constructed to model the costs and health outcomes of both treatments, potential adverse events, and resulting health states over 35 years. Analyses were based on a hypothetical cohort of 65-year-old patients with non-valvular AF at moderate to high risk of stroke. The main outcome measure was cost per quality-adjusted life-year (QALY) gained over the lifetime, and was assessed from the German Statutory Health Insurance (SHI) perspective. Costs and utility data were drawn from public data and the literature, while event probabilities were derived from both the literature and rivaroxaban's pivotal ROCKET AF trial. RESULTS: Stroke prophylaxis with rivaroxaban offers health improvements over warfarin treatment at additional cost. From the SHI perspective, at baseline the incremental cost-effectiveness ratio of rivaroxaban was <euro>15,207 per QALY gained in 2014. The results were robust to changes in the majority of variables; however, they were sensitive to the price of rivaroxaban, the hazard ratios for stroke and intracranial hemorrhage, the time horizon, and the discount rate. CONCLUSIONS: Our results showed that the substantially higher medication costs of rivaroxaban were offset by mitigating the shortcomings of warfarin, most notably frequent dose regulation and bleeding risk. Future health economic studies on novel oral anticoagulants should evaluate the cost effectiveness for secondary stroke prevention and, as clinical data from direct head-to-head comparisons become available, new anticoagulation therapies should be compared against each other.","fulltextAvailable":false,"journal":"PharmacoEconomics","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Health Care Costs","uri":{"id":"D017048","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Costs and Cost Analysis","uri":{"id":"D003365","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Secondary Prevention","uri":{"id":"D055502","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Atrial Fibrillation","uri":{"id":"D001281","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cost-Benefit Analysis","uri":{"id":"D003362","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Outcome Assessment (Health Care)","uri":{"id":"D017063","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Standard of Care","uri":{"id":"D059039","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Insurance, Health","uri":{"id":"D007348","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Intracranial Hemorrhages","uri":{"id":"D020300","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Evaluation Studies as Topic","uri":{"id":"D005069","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Forecasting","uri":{"id":"D005544","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hemorrhage","uri":{"id":"D006470","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Literature","uri":{"id":"D008091","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Probability","uri":{"id":"D011336","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Publications","uri":{"id":"D011642","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Medicalization","uri":{"id":"D062528","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anticoagulants","uri":{"id":"D000925","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Insurance","uri":{"id":"D007341","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Insurance Carriers","uri":{"id":"D007343","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Warfarin","uri":{"id":"D014859","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Quality-Adjusted Life Years","uri":{"id":"D019057","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"25404426","title":"Cost Effectiveness of Rivaroxaban for Stroke Prevention in German Patients with Atrial Fibrillation.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"BACKGROUND: Nonsteroidal anti-inflammatory drugs (NSAIDs) are assumed to increase bleeding risk, but their actual relation to serious bleeding in patients with atrial fibrillation (AF) who are receiving antithrombotic medication is unknown. OBJECTIVE: To investigate the risk for serious bleeding and thromboembolism associated with ongoing NSAID and antithrombotic therapy. DESIGN: Observational cohort study. SETTING: Nationwide registries. PATIENTS: Danish patients with AF hospitalized between 1997 and 2011. MEASUREMENTS: Absolute risk for serious bleeding and thromboembolism with ongoing NSAID and antithrombotic therapy, assessed by using Cox models. RESULTS: Of 150 900 patients with AF (median age, 75 years [interquartile range, 65 to 83 years]; 47% female), 53 732 (35.6%) were prescribed an NSAID during a median follow-up of 6.2 years (interquartile range, 2.1 to 14.0 years). There were 17 187 (11.4%) and 19 561 (13.0%) occurrences of serious bleeding and thromboembolism, respectively. At 3 months, the absolute risk for serious bleeding within 14 days of NSAID exposure was 3.5 events per 1000 patients compared with 1.5 events per 1000 patients without NSAID exposure. The risk difference was 1.9 events per 1000 patients. In patients selected for oral anticoagulant therapy, the absolute risk difference was 2.5 events per 1000 patients. Use of NSAIDs was associated with increased absolute risks for serious bleeding and thromboembolism across all antithrombotic regimens and NSAID types. An NSAID dosage above the recommended minimum was associated with a substantially increased hazard ratio for bleeding. LIMITATION: Observational design and unmeasured confounders. CONCLUSION: Use of NSAIDs was associated with an independent risk for serious bleeding and thromboembolism in patients with AF. Short-term NSAID exposure was associated with increased bleeding risk. Physicians should exercise caution with NSAIDs in patients with AF. PRIMARY FUNDING SOURCE: None.","fulltextAvailable":false,"journal":"Annals of internal medicine","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Atrial Fibrillation","uri":{"id":"D001281","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cohort Studies","uri":{"id":"D015331","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Proportional Hazards Models","uri":{"id":"D016016","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anti-Inflammatory Agents","uri":{"id":"D000893","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pharmaceutical Preparations","uri":{"id":"D004364","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Female","uri":{"id":"D005260","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hemorrhage","uri":{"id":"D006470","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hospitalization","uri":{"id":"D006760","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hospitals","uri":{"id":"D006761","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Physicians","uri":{"id":"D010820","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Registries","uri":{"id":"D012042","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Thromboembolism","uri":{"id":"D013923","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Exercise","uri":{"id":"D015444","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Medicalization","uri":{"id":"D062528","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anti-Inflammatory Agents, Non-Steroidal","uri":{"id":"D000894","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anticoagulants","uri":{"id":"D000925","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"25402512","title":"Relation of Nonsteroidal Anti-inflammatory Drugs to Serious Bleeding and Thromboembolism Risk in Patients With Atrial Fibrillation Receiving Antithrombotic Therapy: A Nationwide Cohort Study.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"INTRODUCTION: Post-marketing surveillance of drugs relies on spontaneous reporting of adverse drug events to the Danish Health and Medicines Authority. A number of new oral anticoagulants (NOAC) have recently been marketed in Denmark. The purpose of this study was to evaluate the reporting of serious adverse drug events in patients treated with a NOAC and admitted for gastrointestinal bleeding. METHODS: This study is based on an electronic free text search in patient records and a search in the electronic medication records of all patients admitted to the Department of Gastroenterology, Surgical Section, Hvidovre Hospital, during a one-year-period. Patients in treatment with NOAC and admitted for gastrointestinal bleeding were identified. Relevant patients were cross-checked for a reported adverse drug event in the Danish Health and Medi-cines Authority's database on adverse medical events. RESULTS: A total of 20 patients were acutely admitted for gastrointestinal bleeding while in treatment with a NOAC, an adverse medical event was reported for one of these patients (5%; 95% confidence interval: 0-25%). CONCLUSION: Serious adverse events in patients treated with NOAC are underreported which questions the current effectiveness of post-marketing surveillance of adverse drug effects. FUNDING: not relevant. TRIAL REGISTRATION: The study was registered with clin-icaltrials.gov (NCT02107651).","fulltextAvailable":false,"journal":"Danish medical journal","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Evaluation Studies as Topic","uri":{"id":"D005069","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Medical Records","uri":{"id":"D008499","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Confidence Intervals","uri":{"id":"D016001","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Drug-Related Side Effects and Adverse Reactions","uri":{"id":"D064420","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Electronics, Medical","uri":{"id":"D004582","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Electronic Health Records","uri":{"id":"D057286","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pharmaceutical Preparations","uri":{"id":"D004364","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Electronics","uri":{"id":"D004581","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Electrons","uri":{"id":"D004583","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Evaluation Studies as Topic","uri":{"id":"D005069","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hemorrhage","uri":{"id":"D006470","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hospitalization","uri":{"id":"D006760","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hospitals","uri":{"id":"D006761","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Medicine","uri":{"id":"D008511","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Personal Autonomy","uri":{"id":"D026684","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Research Report","uri":{"id":"D058028","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Text Messaging","uri":{"id":"D060145","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Medicalization","uri":{"id":"D062528","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anticoagulants","uri":{"id":"D000925","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Denmark","uri":{"id":"D003718","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Gastroenterology","uri":{"id":"D005762","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"25370961","title":"Gastrointestinal bleedings during therapy with new oral anticoagulants are rarely reported.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"Antiplatelet and anticoagulant agents have been extensively researched and developed as potential therapies in the prevention and management of arterial and venous thrombi. These medications are associated with an increase in bleeding time and risk of intraoperative and postoperative hemorrhage in the dental office. There is some controversy regarding whether these agents should be temporarily discontinued before dental procedures. In order to gain insight into this controversy, a survey of 50 cardiologists was conducted regarding suggested guidelines for dentists in the management of patients who are taking anticoagulant medication.","fulltextAvailable":false,"journal":"General dentistry","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anticoagulants","uri":{"id":"D000925","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Bleeding Time","uri":{"id":"D001760","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Dental Offices","uri":{"id":"D003770","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Research","uri":{"id":"D012106","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Postoperative Hemorrhage","uri":{"id":"D019106","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arteries","uri":{"id":"D001158","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Data Collection","uri":{"id":"D003625","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Dentists","uri":{"id":"D003815","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hemorrhage","uri":{"id":"D006470","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Methods","uri":{"id":"D008722","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Medicalization","uri":{"id":"D062528","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anticoagulants","uri":{"id":"D000925","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"25369390","title":"Perspective of cardiologists on the continuation or discontinuation of antiplatelet therapy before dental treatment: a questionnaire-based study.","year":"2014 Nov-Dec"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"Heparin-based anticoagulant drugs have been widely used for the prevention of blood clotting during surgical procedures and for the treatment of thromboembolic events. However, bleeding risks associated with these anticoagulants demand continuous monitoring and neutralization with suitable antidotes. Protamine, the only clinically approved antidote to heparin, has shown adverse effects and ineffectiveness against low-molecular weight heparins and fondaparinux, a heparin-related medication. Alternative approaches based on cationic molecules and recombinant proteins have several drawbacks including limited efficacy, toxicity, immunogenicity, and high cost. Thus, there is an unmet clinical need for safer, rapid, predictable, and cost-effective anticoagulant-reversal agents for all clinically used heparins. We report a design strategy for a fully synthetic dendritic polymer-based universal heparin reversal agent (UHRA) that makes use of multivalent presentation of branched cationic heparin binding groups (HBGs). Optimization of the UHRA design was aided by isothermal titration calorimetry studies, biocompatibility evaluation, and heparin neutralization analysis. By controlling the scaffold's molecular weight, the nature of the protective shell, and the presentation of HBGs on the polymer scaffold, we arrived at lead UHRA molecules that completely neutralized the activity of all clinically used heparins. The optimized UHRA molecules demonstrated superior efficacy and safety profiles and mitigated heparin-induced bleeding in animal models. This new polymer therapeutic may benefit patients undergoing high-risk surgical procedures and has potential for the treatment of anticoagulant-related bleeding problems.","fulltextAvailable":false,"journal":"Science translational medicine","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Molecular Weight","uri":{"id":"D008970","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Models, Animal","uri":{"id":"D023421","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anticoagulants","uri":{"id":"D000925","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Blood Coagulation","uri":{"id":"D001777","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Recombinant Proteins","uri":{"id":"D011994","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Animals","uri":{"id":"D000818","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Calorimetry","uri":{"id":"D002151","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cations","uri":{"id":"D002412","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Dendrites","uri":{"id":"D003712","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pharmaceutical Preparations","uri":{"id":"D004364","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Evaluation Studies as Topic","uri":{"id":"D005069","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hemorrhage","uri":{"id":"D006470","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Heparin","uri":{"id":"D006493","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Methods","uri":{"id":"D008722","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Polymers","uri":{"id":"D011108","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Proteins","uri":{"id":"D011506","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Safety","uri":{"id":"D012449","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Therapeutics","uri":{"id":"D013812","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Thromboembolism","uri":{"id":"D013923","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Universities","uri":{"id":"D014495","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Nature","uri":{"id":"D019368","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Research Report","uri":{"id":"D058028","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Medicalization","uri":{"id":"D062528","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anticoagulants","uri":{"id":"D000925","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Antidotes","uri":{"id":"D000931","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Protamines","uri":{"id":"D011479","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"25355700","title":"Affinity-based design of a synthetic universal reversal agent for heparin anticoagulants.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"BACKGROUND: Several novel oral anticoagulants have been studied for the prevention and treatment of venous thromboembolism (VTE) in different patient populations. Clinicians will increasingly encounter scenarios in which they must choose among these and conventional anticoagulants for the treatment of this potentially fatal condition. OBJECTIVE: To review the results of Phase III clinical trials that investigated the novel oral anticoagulants for the treatment of deep vein thrombosis and pulmonary embolism. Potential advantages and disadvantages of these anticoagulant agents with respect to each other and conventional therapy will also be explored through a case-based approach. METHODS: A literature search in PubMed was conducted that identified Phase III clinical trials investigating the novel oral anticoagulant agents for the treatment of VTE. RESULTS: The new oral anticoagulant agents have been shown to be as safe and effective for the treatment of VTE as conventional therapies. CONCLUSIONS: These novel, oral anticoagulant agents are legitimate options for the treatment of VTE. A careful assessment of a patient׳s comorbidities, medication use, and laboratory results should be undertaken before prescribing the new oral anticoagulant agents for patients with VTE.","fulltextAvailable":false,"journal":"Current therapeutic research, clinical and experimental","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Embolism and Thrombosis","uri":{"id":"D016769","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Proxy","uri":{"id":"D019727","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Venous Thrombosis","uri":{"id":"D020246","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anticoagulants","uri":{"id":"D000925","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pulmonary Embolism","uri":{"id":"D011655","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Venous Thromboembolism","uri":{"id":"D054556","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Laboratories","uri":{"id":"D007753","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Literature","uri":{"id":"D008091","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Thromboembolism","uri":{"id":"D013923","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Thrombosis","uri":{"id":"D013927","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Comorbidity","uri":{"id":"D015897","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"PubMed","uri":{"id":"D039781","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Medicalization","uri":{"id":"D062528","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anticoagulants","uri":{"id":"D000925","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"25352938","title":"The new oral anticoagulants for the treatment of venous thromboembolism: a new paradigm shift in antithrombotic therapy.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"BACKGROUND: Oral anticoagulants are prescribed to millions of Americans, and consequently are among the medications most likely to contribute to emergency department visits and hospitalizations. Although guidelines and consensus statements promote systematic approaches to therapy, anticoagulation (AC) management is often suboptimal. Electronic health records (EHRs) have the potential to improve safety and quality but have not yet incorporated specialized features necessary to optimize therapy. OBJECTIVE: To generate a comprehensive, consensus-based list of EHR features clinically necessary to deliver optimized AC management, provide a \"language bridge\" to accelerate incorporation of features into EHR systems, and suggest mechanisms for the objective evaluation of available EHRs. METHODS: A multidisciplinary panel of AC specialists utilized the framework of a previously published consensus statement to map outpatient AC management and developed a comprehensive array of sequential computer logic steps using a restricted language scheme. Logic steps were then translated into narrative descriptions of potential EHR features, which were refined through multiple group evaluations. A finalized list of proposed features was ranked according to perceived clinical necessity by physician, pharmacist, and nurse panelists in a blinded manner using a 5-point Likert scale. Features receiving no more than 1 dissenting opinion were included in a finalized list of clinically necessary features. RESULTS: The task force generated 78 recommended EHR features across 20 key discrete areas and 425 individual logic steps. All recommended features received Strongly Agree or Agree rankings regarding their perceived clinical necessity, and no feature received more than a single Disagree response. CONCLUSION: The incorporation of key AC-related features into existing EHRs or specialized AC management systems has the potential to systematize the delivery of optimal AC care by health care professionals at the point of care. Optimized AC management has the potential to reduce adverse drug events associated with anticoagulant therapy in the outpatient setting.","fulltextAvailable":false,"journal":"The Annals of pharmacotherapy","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Delivery of Health Care","uri":{"id":"D003695","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Health Care","uri":{"id":"health_care_category","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Delivery of Health Care","uri":{"id":"D003695","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Emergency Service, Hospital","uri":{"id":"D004636","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Advisory Committees","uri":{"id":"D026683","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Drug-Related Side Effects and Adverse Reactions","uri":{"id":"D064420","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"New York","uri":{"id":"D009518","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Electronic Health Records","uri":{"id":"D057286","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Acceleration","uri":{"id":"D000054","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Classification","uri":{"id":"D002965","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Computers","uri":{"id":"D003201","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pharmaceutical Preparations","uri":{"id":"D004364","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Electronics","uri":{"id":"D004581","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Electrons","uri":{"id":"D004583","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Emergencies","uri":{"id":"D004630","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Evaluation Studies as Topic","uri":{"id":"D005069","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hospitalization","uri":{"id":"D006760","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hospitals","uri":{"id":"D006761","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Language","uri":{"id":"D007802","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Nurses","uri":{"id":"D009726","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Nursing","uri":{"id":"D009729","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Outpatients","uri":{"id":"D010045","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pharmacists","uri":{"id":"D010595","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Physicians","uri":{"id":"D010820","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Publishing","uri":{"id":"D011643","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Safety","uri":{"id":"D012449","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Specialization","uri":{"id":"D013038","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Consensus","uri":{"id":"D032921","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Medicalization","uri":{"id":"D062528","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anticoagulants","uri":{"id":"D000925","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Logic","uri":{"id":"D008128","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"25325906","title":"Features of Electronic Health Records Necessary for the Delivery of Optimized Anticoagulant Therapy: Consensus of the EHR Task Force of the New York State Anticoagulation Coalition.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"OBJECTIVES: To develop reference ranges for platelet aggregation using the Multiplate analyzer (Roche Diagnostics, Mannheim, Germany) in blood anticoagulated with sodium citrate (Na-citrate), lithium heparin (Li-heparin), or hirudin. METHODS: The study was performed at three sites on consented, healthy adults (n = 193) not taking antiplatelet medication. Platelet aggregation was evaluated in response to adenosine-5'-diphosphate, arachidonic acid, collagen, thrombin receptor activating peptide, ristocetin, and adenosine-5'-diphosphate combined with prostaglandin E1. Precision testing was conducted using healthy donors and donors taking aspirin. RESULTS: Whole-blood platelet aggregation showed anticoagulant-dependent differences in platelet responses to all agonists. Samples collected in Na-citrate demonstrated the lowest responses to all agonists. The highest responses were obtained using Li-heparin. Precision testing revealed high variability in platelet aggregation at lower agonist doses, regardless of anticoagulant. Highest platelet response variations occurred in response to arachidonic acid in blood anticoagulated with hirudin from participants taking aspirin. CONCLUSIONS: These data demonstrate the importance of establishing locally relevant reference ranges.","fulltextAvailable":false,"journal":"American journal of clinical pathology","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Receptors, Peptide","uri":{"id":"D018000","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Receptors, Collagen","uri":{"id":"D038981","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Reference Values","uri":{"id":"D012016","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Alprostadil","uri":{"id":"D000527","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arachidonic Acids","uri":{"id":"D001095","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Platelet Aggregation","uri":{"id":"D010974","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arachidonic Acid","uri":{"id":"D016718","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Receptors, Thrombin","uri":{"id":"D018179","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Adult","uri":{"id":"D000328","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Blood Platelets","uri":{"id":"D001792","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Collagen","uri":{"id":"D003094","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Evaluation Studies as Topic","uri":{"id":"D005069","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Heparin","uri":{"id":"D006493","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Lithium","uri":{"id":"D008094","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Peptides","uri":{"id":"D010455","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Sodium","uri":{"id":"D012964","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Thrombin","uri":{"id":"D013917","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Tissue Donors","uri":{"id":"D014019","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Medicalization","uri":{"id":"D062528","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anticoagulants","uri":{"id":"D000925","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Aspirin","uri":{"id":"D001241","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Citrates","uri":{"id":"D002951","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Germany","uri":{"id":"D005858","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hirudins","uri":{"id":"D006629","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prostaglandins","uri":{"id":"D011453","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Ristocetin","uri":{"id":"D012310","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Citric Acid","uri":{"id":"D019343","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"25319980","title":"Reference range determination for whole-blood platelet aggregation using the multiplate analyzer.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"BACKGROUND: Amiodarone is an effective medication in preventing atrial fibrillation (AF), but it interferes with the metabolism of warfarin. OBJECTIVES: This study sought to examine the association of major thrombotic clinical events and bleeding with the use of amiodarone in the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) trial. METHODS: Baseline characteristics of patients who received amiodarone at randomization were compared with those who did not receive amiodarone. The interaction between randomized treatment and amiodarone was tested using a Cox model, with main effects for randomized treatment and amiodarone and their interaction. Matching on the basis of a propensity score was used to compare patients who received and who did not receive amiodarone at the time of randomization. RESULTS: In ARISTOTLE, 2,051 (11.4%) patients received amiodarone at randomization. Patients on warfarin and amiodarone had time in the therapeutic range that was lower than patients not on amiodarone (56.5% vs. 63.0%; p < 0.0001). More amiodarone-treated patients had a stroke or a systemic embolism (1.58%/year vs. 1.19%/year; adjusted hazard ratio [HR]: 1.47, 95% confidence interval [CI]: 1.03 to 2.10; p = 0.0322). Overall mortality and major bleeding rates were elevated, but were not significantly different in amiodarone-treated patients and patients not on amiodarone. When comparing apixaban with warfarin, patients who received amiodarone had a stroke or a systemic embolism rate of 1.24%/year versus 1.85%/year (HR: 0.68, 95% CI: 0.40 to 1.15), death of 4.15%/year versus 5.65%/year (HR: 0.74, 95% CI: 0.55 to 0.98), and major bleeding of 1.86%/year versus 3.06%/year (HR: 0.61, 95% CI: 0.39 to 0.96). In patients who did not receive amiodarone, the stroke or systemic embolism rate was 1.29%/year versus 1.57%/year (HR: 0.82, 95% CI: 0.68 to 1.00), death was 3.43%/year versus 3.68%/year (HR: 0.93, 95% CI: 0.83 to 1.05), and major bleeding was 2.18%/year versus 3.03%/year (HR: 0.72, 95% CI: 0.62 to 0.84). The interaction p values for amiodarone use by apixaban treatment effects were not significant. CONCLUSIONS: Amiodarone use was associated with significantly increased stroke and systemic embolism risk and a lower time in the therapeutic range when used with warfarin. Apixaban consistently reduced the rate of stroke and systemic embolism, death, and major bleeding compared with warfarin in amiodarone-treated patients and patients who were not on amiodarone.","fulltextAvailable":false,"journal":"Journal of the American College of Cardiology","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Atrial Fibrillation","uri":{"id":"D001281","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Confidence Intervals","uri":{"id":"D016001","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Proportional Hazards Models","uri":{"id":"D016016","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Treatment Outcome","uri":{"id":"D016896","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Propensity Score","uri":{"id":"D057216","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hemorrhage","uri":{"id":"D006470","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Metabolism","uri":{"id":"D008660","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Mortality","uri":{"id":"D009026","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Random Allocation","uri":{"id":"D011897","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Therapeutics","uri":{"id":"D013812","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Thromboembolism","uri":{"id":"D013923","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Medicalization","uri":{"id":"D062528","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Amiodarone","uri":{"id":"D000638","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Warfarin","uri":{"id":"D014859","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"25301455","title":"Amiodarone, anticoagulation, and clinical events in patients with atrial fibrillation: insights from the ARISTOTLE trial.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"BACKGROUND: We compared the clinical outcomes of persistent atrial fibrillation (PeAF) and paroxysmal atrial fibrillation (PAF) in patients with cardioembolic stroke caused by nonvalvular atrial fibrillation (NVAF) because the nature of the fibrillation can cause persistent cerebral infarction. METHODS: We classified 619 of 964 patients hospitalized with cardioembolic stroke between April 2007 and December 2013 within 24 hours of onset as having PeAF (n = 447) and PAF (n = 172) according to a retrospective analysis of their clinical records, including National Institutes of Health Stroke Scale (NIHSS) scores on admission, clinical outcomes (modified Rankin Scale [mRS] scores) at 90 days after admission, and major cerebral artery occlusion. RESULTS: The PeAF group was significantly older (P < .001) and had a higher prevalence of hypertension (P = .007), diabetes (P = .039), heart failure (P = .004), previous coronary artery disease (P = .002) and cerebral infarction (P < .001), medication with anticoagulants (P < .001), and elevated blood glucose on admission (P = .002). Neurologic severity assessed by NIHSS scores on admission was significantly worse in the PeAF than in the PAF group (P < .001). Significantly more patients in the PAF group had favorable outcomes (mRS, 0-2) after 90 days (P < .001). The incidence of major cerebral artery occlusion was significantly higher in the PeAF group (P < .001). CONCLUSIONS: Patients with PeAF and cardioembolic stroke due to NVAF had more severe neurologic deficits on admission, more frequent major arterial occlusion, and poorer outcomes than those with PAF.","fulltextAvailable":false,"journal":"Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Coronary Disease","uri":{"id":"D003327","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Atrial Fibrillation","uri":{"id":"D001281","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Heart Failure","uri":{"id":"D006333","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Blood Glucose","uri":{"id":"D001786","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cerebral Arteries","uri":{"id":"D002536","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cerebral Infarction","uri":{"id":"D002544","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Coronary Artery Disease","uri":{"id":"D003324","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Coronary Vessels","uri":{"id":"D003331","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"National Institutes of Health (U.S.)","uri":{"id":"D009316","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neurologic Manifestations","uri":{"id":"D009461","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Academies and Institutes","uri":{"id":"D000047","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arteries","uri":{"id":"D001158","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Glucose","uri":{"id":"D005947","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hospitalization","uri":{"id":"D006760","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hospitals","uri":{"id":"D006761","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hypertension","uri":{"id":"D006973","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Incidence","uri":{"id":"D015994","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prevalence","uri":{"id":"D015995","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Nature","uri":{"id":"D019368","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Medicalization","uri":{"id":"D062528","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anticoagulants","uri":{"id":"D000925","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Infarction","uri":{"id":"D007238","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"25294056","title":"Clinical Outcomes of Persistent and Paroxysmal Atrial Fibrillation in Patients with Stroke.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"UNLABELLED: We report a case where a 64-year-old woman treated with dabigatran developed life-threatening bleeding due to lack of dose adjustment following identification of acute renal failure. Many commonly used drugs, e.g. new oral anticoagulants, digoxin, ACE-inhibitors, antibiotics, are eliminated by the kidneys. The case illustrates that lack of medication reconciliation can lead to serious adverse events in case of deteriorating organ function. The use of medication reconciliation should be performed on a daily basis and special attention should be exercised in case of reduced kidney function.","fulltextAvailable":false,"journal":"Ugeskrift for laeger","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pediatric Obesity","uri":{"id":"D063766","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Physiological Processes","uri":{"id":"D055705","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Adolescent","uri":{"id":"D000293","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Ecology","uri":{"id":"D004463","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Obesity","uri":{"id":"D009765","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Epidemics","uri":{"id":"D058872","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Microbiota","uri":{"id":"D064307","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"25293571","title":"[Life-threatening bleeding during dabigatran treatment because of acute renal failure.]","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"BACKGROUND: Depressive symptoms have detrimental effects on quality of life and mortality. Poor adherence to treatment regimen is a potential mechanism for the increased risk for adverse medical events associated with depression. Regarding oral anticoagulation with vitamin K antagonists, adherence is crucial for the outcome. Little is known about the clinical relevance of current depressiveness for anticoagulation treatment. OBJECTIVES: To examine the impact of current depressiveness on anticoagulation treatment in regular medical care. PATIENTS/METHODS: We examined the association between clinically significant depressiveness as assessed by the Patient Health Questionnaire-2 ≥ 2 (PHQ-2 ≥ 2) with the percentage of time in the therapeutic range (TTR), self-rated compliance, several aspects of health literacy, anticoagulation side-effects and treatment satisfaction in a cross-sectional study of 1,790 oral anticoagulation outpatients. RESULTS: 716 participants (40.0%) had clinically significant depressive symptoms. Depressed persons reported lower compliance with intake of prescribed medication and regular visits for control of anticoagulation, more unspecific side-effects (e.g. pruritus) and lower satisfaction with the anticoagulation treatment and their doctors' expertise and empathy. Depressed as compared with non-depressed individuals had a lower TTR (-4.67, 95%CI -8.39 to -0.95). Increasing severity of depressiveness was related with decreasing TTR. However, depressiveness lost its significant impact on TTR after multivariable adjustment (-3.11, 95%CI -6.88 to 0.66). CONCLUSIONS: Clinically significant depressiveness was highly prevalent and impaired several aspects of anticoagulation treatment. Depressiveness should be regarded as a clinically significant condition that needs to be addressed in the management of anticoagulation patients. This article is protected by copyright. All rights reserved.","fulltextAvailable":false,"journal":"Journal of thrombosis and haemostasis : JTH","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Immunity, Innate","uri":{"id":"D007113","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Public Health","uri":{"id":"D011634","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Health Promotion","uri":{"id":"D006293","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Insect Control","uri":{"id":"D007300","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Insecticide Resistance","uri":{"id":"D007305","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Life Cycle Stages","uri":{"id":"D008018","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Malaria","uri":{"id":"D008288","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Sodium Channels","uri":{"id":"D015222","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Point Mutation","uri":{"id":"D017354","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anopheles gambiae","uri":{"id":"D048169","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Voltage-Gated Sodium Channels","uri":{"id":"D061566","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Genes","uri":{"id":"D005796","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Genotype","uri":{"id":"D005838","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Insecticides","uri":{"id":"D007306","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Malaria","uri":{"id":"D008288","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Culicidae","uri":{"id":"D009033","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Mutation","uri":{"id":"D009154","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Parasites","uri":{"id":"D010271","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pressure","uri":{"id":"D011312","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Publications","uri":{"id":"D011642","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Sodium","uri":{"id":"D012964","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Vaccination","uri":{"id":"D014611","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Vaccines","uri":{"id":"D014612","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prevalence","uri":{"id":"D015995","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Nature","uri":{"id":"D019368","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Life","uri":{"id":"D019369","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Asian Continental Ancestry Group","uri":{"id":"D044466","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Research Report","uri":{"id":"D058028","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Medicalization","uri":{"id":"D062528","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Agriculture","uri":{"id":"D000383","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anopheles","uri":{"id":"D000852","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"DDT","uri":{"id":"D003634","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Gambia","uri":{"id":"D005714","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pyrethrins","uri":{"id":"D011722","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"25292317","title":"Relevance of depression for anticoagulation management in a routine medical care setting: Results from the ThrombEVAL study program.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"UNLABELLED: : In any cervical spine trauma involving dislocation of the facet joints or transverse foramen, a concomitant injury of the vertebral arteries must be excluded. Early diagnosis of an arterial occlusion is important because therapeutic intervention can prevent further complications, such as irreversible vertebrobasilar ischemia. Conservative and surgical treatment strategies are chosen depending on patient symptoms, fracture morphology, and grade of vascular injury. The benefit of anticoagulant medication after blunt injuries of the vertebral arteries in preventing thromboembolic events remains a matter of debate in the current literature. We present a case report of a professional biathlete with a unilateral vertebral artery injury. Adequate interpretation of both initial clinical and radiological findings is essential to detect this injury and to determine appropriate therapeutic intervention to optimize clinical outcome.","fulltextAvailable":false,"journal":"Clinical journal of sport medicine : official journal of the Canadian Academy of Sport Medicine","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Early Diagnosis","uri":{"id":"D042241","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Vertebral Artery","uri":{"id":"D014711","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Vertebrobasilar Insufficiency","uri":{"id":"D014715","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Wounds, Nonpenetrating","uri":{"id":"D014949","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Zygapophyseal Joint","uri":{"id":"D021801","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Vascular System Injuries","uri":{"id":"D057772","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arteries","uri":{"id":"D001158","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Diagnosis","uri":{"id":"D003933","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Ischemia","uri":{"id":"D007511","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Literature","uri":{"id":"D008091","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Therapeutics","uri":{"id":"D013812","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Thromboembolism","uri":{"id":"D013923","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Vertebrates","uri":{"id":"D014714","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Wounds and Injuries","uri":{"id":"D014947","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Complicity","uri":{"id":"D028661","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Research Report","uri":{"id":"D058028","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Medicalization","uri":{"id":"D062528","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anticoagulants","uri":{"id":"D000925","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Dislocations","uri":{"id":"D004204","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"25290101","title":"Transposition of the Vertebral Artery After a Unilateral C1 Lateral Mass Fracture: A Case Report and Review of the Literature.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"BACKGROUND: Patients undergoing spinal surgery while under anticoagulation therapy are at risk of developing bleeding complications, even though lower incidences have been reported for joint arthroplasty surgery. There is a gap in the medical literature examining the incidence of postoperative spinal bleeding in patients who were under anticoagulation medication at the time of surgery. METHODS: We prospectively followed a consecutive cohort of 100 patients (58 male, 42 female) undergoing spinal surgery. The average patient age was 48.7 years and the minimum follow up time was 12 months. Diagnosis was lumbar spinal stenosis in 20, herniated lumbar discs in 63, degenerative cervical disc disease in 3, and cervical disc herniation in 14 cases. In our study, platelet aggregation inhibitors (clopidogrel and/or acetylsalicylic acid) were given for the treatment of cardiovascular and cerebrovascular thrombotic events, to reduce risk of stroke in patients who have had transient ischemia of the brain or acute coronary syndrome, and as secondary prevention of atherosclerotic events (fatal or nonfatal myocardial infarction (MI). A cessation of anticoagulants (acetylsalicylic acid or clopidogrel) in our patients in the peri- and postoperative period was contraindicated. RESULTS: Sixty-three patients were on both clopidogrel and acetylsalicylic acid and 37 on acetylsalicylic acid only. None of the patients suffered any postoperative bleeding complication. Three patients suffered postoperative wound dehiscence and one patient had an infection that required reoperation. CONCLUSION: The question of whether preoperative platelet aggregation inhibitors must be stopped before elective spinal surgery has never been answered in the literature. In our prospective series, we have found no increase in the risk of postoperative spinal bleeding with the use of clopidogrel or acetylsalicylic acid. This finding suggests that spine surgery can be done without stopping anticoagulation. Lacking specific guidelines, each patient should be treated on an individual basis, and the potential benefits of anticoagulation should be compared with the potential risks (risk-benefit ratio).","fulltextAvailable":false,"journal":"Surgical neurology international","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Odds Ratio","uri":{"id":"D016017","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Coroners and Medical Examiners","uri":{"id":"D003334","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Intervertebral Disc Displacement","uri":{"id":"D007405","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Platelet Aggregation Inhibitors","uri":{"id":"D010975","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Postoperative Complications","uri":{"id":"D011183","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Platelet Aggregation Inhibitors","uri":{"id":"D010975","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Spinal Stenosis","uri":{"id":"D013130","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Aspirin","uri":{"id":"D001241","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Intervertebral Disc Displacement","uri":{"id":"D007405","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Myocardial Infarction","uri":{"id":"D009203","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Platelet Aggregation","uri":{"id":"D010974","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Postoperative Period","uri":{"id":"D011184","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Acute Coronary Syndrome","uri":{"id":"D054058","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Secondary Prevention","uri":{"id":"D055502","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthroplasty","uri":{"id":"D001178","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Blood Platelets","uri":{"id":"D001792","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Constriction, Pathologic","uri":{"id":"D003251","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Diagnosis","uri":{"id":"D003933","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Female","uri":{"id":"D005260","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hemorrhage","uri":{"id":"D006470","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Ischemia","uri":{"id":"D007511","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Literature","uri":{"id":"D008091","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Male","uri":{"id":"D008297","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"General Surgery","uri":{"id":"D013502","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Syndrome","uri":{"id":"D013577","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Incidence","uri":{"id":"D015994","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Complicity","uri":{"id":"D028661","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Research Report","uri":{"id":"D058028","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Medicalization","uri":{"id":"D062528","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anticoagulants","uri":{"id":"D000925","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Infarction","uri":{"id":"D007238","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Reoperation","uri":{"id":"D012086","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"25289165","title":"Continuation of medically necessary platelet aggregation inhibitors - acetylsalicylic acid and clopidogrel - during surgery for spinal degenerative disorders: Results in 100 patients.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"BACKGROUND AND OBJECTIVES: Oral anticoagulant therapy is complex due to the need for control and the hemorrhagic risk the therapy entails. This study aims to determine the standard clinical practice in the treatment for preventing stroke in patients with nonvalvular atrial fibrillation (NVAF) in Spain. PATIENTS AND METHOD: The Real Evidence of Anti Coagulation Treatment in AF is a European, multicenter, multinational, observational, retrospectively monitored cohort of patients with NVAF. This study included patients recruited in Spain with at least one visit during the period of inclusion (May 2010/April 2012). The study evaluated the following: a) persistence of oral anticoagulant treatment (time to discontinuation); b) persistence rate (% of patients in treatment) at 6, 12 and 24 months and at 5 years; c) therapeutic compliance (medication possession ratio); d) the correlation between the treatment followed and that recommended by the European Society of Cardiology; and the incidence of stroke and hemorrhagic events. RESULTS: The patients treated with oral anticoagulants (n=7,526) had a median time to discontinuation of treatment of 1.99 years and a persistence rate at 5 years of 26% (discontinuation ≥3 months). The compliance (mean MPR) was 0.54±0.36. The incidence of stroke was 0.3/100 person-years, and the incidence of hemorrhagic events was 2.4/100 person-years. Fifty-eight percent of the patients with NVAF (n=12,514) followed the recommendations of the European Society of Cardiology. CONCLUSION: Forty-two percent of the patients with NVAF did not follow the recommendations of the European Society of Cardiology. We detected low persistence and treatment compliance rates for oral anticoagulants.","fulltextAvailable":false,"journal":"Revista clinica espanola","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Atrial Fibrillation","uri":{"id":"D001281","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patient Selection","uri":{"id":"D018579","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Medication Adherence","uri":{"id":"D055118","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Time-to-Treatment","uri":{"id":"D061665","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Compliance","uri":{"id":"D003187","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Evaluation Studies as Topic","uri":{"id":"D005069","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hemorrhage","uri":{"id":"D006470","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Societies","uri":{"id":"D012952","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Therapeutics","uri":{"id":"D013812","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Incidence","uri":{"id":"D015994","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Medicalization","uri":{"id":"D062528","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anticoagulants","uri":{"id":"D000925","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cardiology","uri":{"id":"D002309","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Spain","uri":{"id":"D013030","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"25288530","title":"Status of oral anticoagulant treatment in patients with nonvalvular atrial fibrillation in Spain. REACT-AF Study.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"To compare the pharmacokinetics of syringin, eleutheroside E and isofraxidin after intravenous administration of each monomer and Ciwujia injection. Twenty-four Sprague-Dawley rats were randomly divided into four groups and intravenously administrated with syringin, eleutheroside E, isofraxidin, and Ciwujia injection, respectively. The concentrations of the three components in rat plasma were determined by LC-MS/MS. DAS 2.0 software was applied to calculate the pharmacokinetic parameters while the SPSS 17.0 software was used for statistical analysis. Significant difference (P < 0.05) was found between each monomer and the injection on the main pharmacokinetic parameters such as AUC, CL and t1,/2. Compared with the injection, the group treated with the syringin has obvious decrease in AUC, and increase in CL while the group treated with eleutheroside E has obvious increase in AUC, and decrease in CL The t1/2 of isofraxidin was prolonged in Ciwujia injection. Pharmacokinetic characters of the ingredients in the injection varied greatly from the monomer. Other constituents in the injection may have an impact on the pharmacokinetic profiles of these three components.","fulltextAvailable":false,"journal":"Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Rats, Sprague-Dawley","uri":{"id":"D017207","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Administration, Intravenous","uri":{"id":"D061605","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Character","uri":{"id":"D002605","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Constitution and Bylaws","uri":{"id":"D003249","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pharmacokinetics","uri":{"id":"D010599","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Software","uri":{"id":"D012984","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Area Under Curve","uri":{"id":"D019540","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Acanthopanax","uri":{"id":"D031065","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Animals","uri":{"id":"D000818","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Drugs, Chinese Herbal","uri":{"id":"D004365","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Male","uri":{"id":"D008297","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Rats, Sprague-Dawley","uri":{"id":"D017207","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Lignans","uri":{"id":"D017705","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Rats","uri":{"id":"D051381","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Coumarins","uri":{"id":"D003374","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Glucosides","uri":{"id":"D005960","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Phenylpropionates","uri":{"id":"D010666","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Administration, Intravenous","uri":{"id":"D061605","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Administration, Intravenous","Animals","Coumarins","Drugs, Chinese Herbal","Glucosides","Lignans","Male","Phenylpropionates","Rats","Rats, Sprague-Dawley"]},"pmid":"25282907","title":"[Comparative pharmacokinetics of syringin, eleutheroside E and isofraxidin in rat plasma after intravenous administration of each monomer and Ciwujia injection].","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"UNLABELLED: As limited amounts of data are available regarding thrombolytic therapy for patients taking novel oral anticoagulants, thrombolytic therapy is not recommended in such cases. Here, we report an acute stroke patient taking rivaroxaban who received intravenous thrombolysis with recombinant tissue plasminogen activator (rt-PA). An 80-year-old man with a history of nonvalvular atrial fibrillation, who had been receiving 10 mg of rivaroxaban showed abrupt onset of aphasia and right hemiparesis. National Institutes of Health Stroke Scale score was 10. Onset of neurologic deficits occurred 4 hours after the last dose of rivaroxaban. Clinical data on admission were as follows: blood pressure, 170/90 mm Hg; prothrombin time (PT), 22.6 seconds (control, 12.9 seconds); international normalized ratio, 2.03; activated partial thromboplastin time, 46 seconds (normal, 23-32 seconds); and creatinine level, 1.11 mg/dL. Magnetic resonance angiography revealed occlusion of the superior trunk of the left middle cerebral artery. Intravenous infusion of .6 mg/kg of rt-PA (total dose, 36 mg) was performed 6 hours after the last rivaroxaban administration with informed consent. The neurologic deficit improved during infusion of rt-PA. Repeat brain computed tomography showed left frontal cortical infarction without hemorrhagic changes. In the case of rivaroxaban, it is difficult to accurately determine the drug activity. As the anticoagulant activity of rivaroxaban can be estimated from its pharmacokinetics and PT, it is clinically important to obtain accurate information about the timing of medication and blood sampling.","fulltextAvailable":false,"journal":"Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Atrial Fibrillation","uri":{"id":"D001281","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Blood Pressure","uri":{"id":"D001794","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Magnetic Resonance Spectroscopy","uri":{"id":"D009682","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Stroke","uri":{"id":"D020521","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cerebral Arteries","uri":{"id":"D002536","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Informed Consent","uri":{"id":"D007258","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Infusions, Intravenous","uri":{"id":"D007262","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"National Institutes of Health (U.S.)","uri":{"id":"D009316","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neurologic Manifestations","uri":{"id":"D009461","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Partial Thromboplastin Time","uri":{"id":"D010314","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Tissue Plasminogen Activator","uri":{"id":"D010959","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Plasminogen Activators","uri":{"id":"D010960","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prothrombin Time","uri":{"id":"D011517","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Thrombolytic Therapy","uri":{"id":"D015912","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Magnetic Resonance Angiography","uri":{"id":"D018810","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"International Normalized Ratio","uri":{"id":"D019934","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Middle Cerebral Artery","uri":{"id":"D020768","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Academies and Institutes","uri":{"id":"D000047","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Angiography","uri":{"id":"D000792","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Aphasia","uri":{"id":"D001037","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arteries","uri":{"id":"D001158","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Computers","uri":{"id":"D003201","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Creatinine","uri":{"id":"D003404","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pharmaceutical Preparations","uri":{"id":"D004364","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hemorrhage","uri":{"id":"D006470","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"History","uri":{"id":"D006664","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pharmacokinetics","uri":{"id":"D010599","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Plasminogen","uri":{"id":"D010958","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pressure","uri":{"id":"D011312","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Tissues","uri":{"id":"D014024","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Tomography","uri":{"id":"D014054","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Research Report","uri":{"id":"D058028","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Medicalization","uri":{"id":"D062528","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anticoagulants","uri":{"id":"D000925","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Infarction","uri":{"id":"D007238","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Paresis","uri":{"id":"D010291","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prothrombin","uri":{"id":"D011516","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Thromboplastin","uri":{"id":"D013925","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"25280819","title":"Intravenous Thrombolysis with Recombinant Tissue Plasminogen Activator in a Stroke Patient Treated with Rivaroxaban.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"To establish a method for the determination of astilbin, peoniflorin, rasmarinci acid, isofraxidin and liquiritin contained in Shaolin Xiaoyin tablets, in order to lay a foundation for designing late-stage dosage forms and clinical medication schemes. In this paper, efforts were made to establish a method for the determination of the blood concentration of the five components and study the in vivo pharmacokinetics in rats. The blood concentration was determined by HPLC. Phenomenex C18 column (4.6 mm x 250 mm, 5 microm) was adopted and eluted with methanol-acetonitrile-0.05% formic acid, the flow rate was 0.8 mL x min(-1), and the wavelength was 275 nm. The samples were processed by the solid phase extraction method. After oral administration of Shaoling Xiaoyin tablets, the rat bloods were collected at different time points to determine the blood concentrations. The experimental results showed that the baseline separation could be adopted for the five components, and astilbin, peoniflorin, rasmarinci acid, isofraxidin and liquiritin showed good linear relations within ranges of 2.48-248, 0.213 6-21.36, 0.531-53.1, 0.704-70.4, 0.253-25.3 mg x L(-1). All the five components could be absorbed in blood and excreted quickly. The method established in this paper is rapid and accurate, and could be used for in vivo analysis on preparations containing similar components. The main components in Shaoling Xiaoyin tablets could be absorbed and excreted quickly, and thus suitable to be made into sustained release tablets. Common preparations are required to be taken for 4-6 times a day.","fulltextAvailable":false,"journal":"Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Administration, Oral","uri":{"id":"D000284","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Dosage Forms","uri":{"id":"D004304","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Formates","uri":{"id":"D005561","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Solid Phase Extraction","uri":{"id":"D052616","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Foundations","uri":{"id":"D005582","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pharmacokinetics","uri":{"id":"D010599","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Medicalization","uri":{"id":"D062528","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Chromatography, High Pressure Liquid","uri":{"id":"D002851","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Paresthesia","uri":{"id":"D010292","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Administration, Oral","uri":{"id":"D000284","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Animals","uri":{"id":"D000818","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Chromatography, High Pressure Liquid","uri":{"id":"D002851","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Drugs, Chinese Herbal","uri":{"id":"D004365","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Male","uri":{"id":"D008297","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Rats, Sprague-Dawley","uri":{"id":"D017207","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Rats","uri":{"id":"D051381","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cinnamates","uri":{"id":"D002934","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Coumarins","uri":{"id":"D003374","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Glucosides","uri":{"id":"D005960","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Monoterpenes","uri":{"id":"D039821","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Flavonols","uri":{"id":"D044948","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Flavanones","uri":{"id":"D044950","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Depsides","uri":{"id":"D053630","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Administration, Oral","Animals","Chromatography, High Pressure Liquid","Cinnamates","Coumarins","Depsides","Drugs, Chinese Herbal","Flavanones","Flavonols","Glucosides","Male","Monoterpenes","Rats","Rats, Sprague-Dawley"]},"pmid":"25276982","title":"[Pharmacokinetic study on peoniflorin, astilbin, rosmarinic acid, isofraxidin and liquiritin in rat blood after oral administration of shaolin xiaoyin tablets].","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"AF is associated with the risk of stroke, and this risk is exceedingly high in elderly patients (> or = 75 years) and in patients after a stroke. DOACs are appropriate anticoagulants for AF patients without mechanical heart valves or mitral stenosis. Patients on DOACs do not require routine monitoring of coagulation, but need regular follow-up visits including an assessment of therapy adherence, thromboembolic and bleeding events and measurements of hemoglobin and platelets values as well as renal and liver function.","fulltextAvailable":false,"journal":"Duodecim; lääketieteellinen aikakauskirja","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Mitral Valve","uri":{"id":"D008943","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Atrial Fibrillation","uri":{"id":"D001281","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Heart Valves","uri":{"id":"D006351","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Mitral Valve Stenosis","uri":{"id":"D008946","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Aged","uri":{"id":"D000368","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Blood Platelets","uri":{"id":"D001792","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Constriction, Pathologic","uri":{"id":"D003251","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hemoglobins","uri":{"id":"D006454","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hemorrhage","uri":{"id":"D006470","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Thromboembolism","uri":{"id":"D013923","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anticoagulants","uri":{"id":"D000925","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Administration, Oral","uri":{"id":"D000284","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Humans","uri":{"id":"D006801","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Platelet Count","uri":{"id":"D010976","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Risk","uri":{"id":"D012306","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Risk Factors","uri":{"id":"D012307","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anticoagulants","uri":{"id":"D000925","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Atrial Fibrillation","uri":{"id":"D001281","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hemoglobins","uri":{"id":"D006454","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Kidney Function Tests","uri":{"id":"D007677","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Liver Function Tests","uri":{"id":"D008111","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Stroke","uri":{"id":"D020521","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Medication Adherence","uri":{"id":"D055118","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Administration, Oral","Anticoagulants","Atrial Fibrillation","Hemoglobins","Humans","Kidney Function Tests","Liver Function Tests","Medication Adherence","Platelet Count","Risk","Risk Factors","Stroke"]},"pmid":"25272782","title":"[The use of direct oral anticoagulants (DOAC) in the treatment atrial fibrillation (AF) patients].","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"The purpose of the study was to prepare and evaluate clarithromycin (CLA) floating tablets using experimental mixture design for treatment of Helicobacter pylori provided by prolonged gastric residence time and controlled plasma level. Ten different formulations were generated based on different molecular weight of hypromellose (HPMC K100, K4M, K15M) by using simplex lattice design (a sub-class of mixture design) with Minitab 16 software. Sodium bicarbonate and anhydrous citric acid were used as gas generating agents. Tablets were prepared by wet granulation technique. All of the process variables were fixed. Results of cumulative drug release at 8th h (CDR 8th) were statistically analyzed to get optimized formulation (OF). Optimized formulation, which gave floating lag time lower than 15 s and total floating time more than 10 h, was analyzed and compared with target for CDR 8th (80%). A good agreement was shown between predicted and actual values of CDR 8th with a variation lower than 1%. The activity of clarithromycin contained optimizedformula against H. pylori were quantified using well diffusion agar assay. Diameters of inhibition zones vs. log10 clarithromycin concentrations were plotted in order to obtain a standard curve and clarithromycin activity.","fulltextAvailable":false,"journal":"Acta poloniae pharmaceutica","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Research Design","uri":{"id":"D012107","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Molecular Weight","uri":{"id":"D008970","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Helicobacter pylori","uri":{"id":"D016480","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Sodium Bicarbonate","uri":{"id":"D017693","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Citric Acid","uri":{"id":"D019343","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Bicarbonates","uri":{"id":"D001639","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Diffusion","uri":{"id":"D004058","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pharmaceutical Preparations","uri":{"id":"D004364","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Evaluation Studies as Topic","uri":{"id":"D005069","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Internship and Residency","uri":{"id":"D007396","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Sodium","uri":{"id":"D012964","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Software","uri":{"id":"D012984","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Helicobacter","uri":{"id":"D016998","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Clarithromycin","uri":{"id":"D017291","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anti-Bacterial Agents","uri":{"id":"D000900","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Chemistry, Pharmaceutical","uri":{"id":"D002626","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Delayed-Action Preparations","uri":{"id":"D003692","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Microbial Sensitivity Tests","uri":{"id":"D008826","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Time Factors","uri":{"id":"D013997","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Citric Acid","uri":{"id":"D019343","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Excipients","uri":{"id":"D005079","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Methylcellulose","uri":{"id":"D008747","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Molecular Weight","uri":{"id":"D008970","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Tablets","uri":{"id":"D013607","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Helicobacter pylori","uri":{"id":"D016480","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Clarithromycin","uri":{"id":"D017291","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Sodium Bicarbonate","uri":{"id":"D017693","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Anti-Bacterial Agents","Chemistry, Pharmaceutical","Citric Acid","Clarithromycin","Delayed-Action Preparations","Excipients","Helicobacter pylori","Methylcellulose","Microbial Sensitivity Tests","Molecular Weight","Sodium Bicarbonate","Tablets","Time Factors"]},"pmid":"25272652","title":"Optimization and evaluation of clarithromycin floating tablets using experimental mixture design.","year":"2014 Mar-Apr"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"PURPOSE: The genetic polymorphism was one of the major considerations for adjusting doses of warfarin in Thai individuals. As a result, new oral anticoagulants (NOACs) were introduced to achieve therapeutic goals in stroke prevention in atrial fibrillation (SPAF) patients. However, a cost-utility analysis in a population-specific model was lacking in Thailand. This study was performed to determine which NOACs yielded population-specific, cost-effective results for SPAF compared with warfarin from both governmental and societal perspectives in Thailand. METHODS: A simplified Markov health state model was constructed to calculate the lifetime cost, life-years saved, and quality-adjusted life-years (QALYs) gained. Asia-specific clinical event parameters were defined from systematic searches of PubMed. Cost and utility input was obtained from hospital based data collection. FINDINGS: Although NOACs produced more life-years saved and QALYs gained resulting from the base-case versus warfarin, the lifetime costs of new alternatives increased to >1.4 times the comparative cost of warfarin. This caused an incremental cost-effective ratio that exceeded Thailand's cost-effectiveness threshold. The probabilistic sensitivity analysis denoted the robustness of our model and revealed that dose-adjusted warfarin was the most cost-effective option in >99% of iterations. NOACs produced cost-effective results when the medication unit cost was decreased by at least 85%. IMPLICATIONS: According to the results of this first cost-utility analysis in Thailand, warfarin is still the most cost-effective medication for SPAF from any perspective in Thailand at the threshold recommended by our health technology assessment guidelines.","fulltextAvailable":false,"journal":"Clinical therapeutics","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cost Savings","uri":{"id":"D017046","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Atrial Fibrillation","uri":{"id":"D001281","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Data Collection","uri":{"id":"D003625","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Polymorphism, Genetic","uri":{"id":"D011110","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Technology Assessment, Biomedical","uri":{"id":"D013673","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hospitals, General","uri":{"id":"D006769","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Biomedical Technology","uri":{"id":"D020811","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Classification","uri":{"id":"D002965","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hospitalization","uri":{"id":"D006760","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hospitals","uri":{"id":"D006761","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Technology","uri":{"id":"D013672","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Therapeutics","uri":{"id":"D013812","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"PubMed","uri":{"id":"D039781","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Asian Continental Ancestry Group","uri":{"id":"D044466","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Medicalization","uri":{"id":"D062528","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anticoagulants","uri":{"id":"D000925","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Thailand","uri":{"id":"D013785","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Warfarin","uri":{"id":"D014859","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Police","uri":{"id":"D016495","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"25267360","title":"Cost-Utility Analysis of Oral Anticoagulants for Nonvalvular Atrial Fibrillation Patients at the Police General Hospital, Bangkok, Thailand.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"Antiplatelet and anticoagulant medication increases the risk of intracranial hemorrhage (ICH) after a fall in geriatric patients. We sought to determine whether there were differences in ICH rates and outcomes based on type of anticoagulant or antiplatelet agent after a ground-level fall (GLF). Our institutional trauma registry was used to identify patients 65 years old or older after a GLF while taking warfarin, clopidogrel, or aspirin over a 2-year period. Rates and types of ICH and patient outcomes were evaluated. Of 562 patients who met inclusion and exclusion criteria, 218 (38.8%) were on warfarin, 95 (16.9%) were on clopidogrel, and 249 (44.3%) were on aspirin. Overall ICH frequency was 15 per cent with no difference in ICH rate, type of ICH, need for craniotomy, mortality, or intensive care unit or hospital length of stay between groups. Patients with ICH were more likely to present with abnormal Glasgow Coma Score, history of hypertension, and/or loss of consciousness.","fulltextAvailable":false,"journal":"The American surgeon","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"25264642","title":"Incidence of intracranial hemorrhage and outcomes after ground-level falls in geriatric trauma patients taking preinjury anticoagulants and antiplatelet agents.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"UNLABELLED: Renal impairment (RI) is an important factor in the selection of anticoagulant therapy in venous thromboembolic event (VTE) patients. In particular, the risk of bleeding events is higher for VTE patients with a glomerular filtration rate (GFR) below 30mL/min. The aim of this study was to collect data on the prevalence of RI in hospitalised VTE patients in Germany. Furthermore, we investigated how renal function changed during inpatient treatment. We conducted a retrospective chart review in six German hospitals. All patients with a VTE diagnosis who were treated as inpatients from 2007-2011 were included. Patients were categorised according to their renal function. RI was estimated from serum creatinine values. Persistent RI was defined as an estimated glomerular filtration rate (eGFR) of <30mL/min over at least 72hours. Renal function could be determined for 5,710 VTE patients. Of these 21.4% had an eGFR>90mL/min, 38.1% had an eGFR of 60-89mL/min, 17.3% had an eGFR of 45-59mL/min, 12.5% had an eGFR of 30-44mL/min, 7.2% had an eGFR of 15-29mL/min and 3.6% of the VTE patients had end-stage renal disease. Persistent severe RI was observed in 74.8% of patients with an eGFR <30mL/min. Overall, 40.6% of the VTE patients investigated had an eGFR <60mL/min; 10.8% had an eGFR <30mL/min. Almost three quarters of RI-VTE patients suffered from persistent severe RI. These results suggest that more than one in ten VTE patients is exposed to a high risk of accumulating anticoagulants; most of these RI patients also face an increased risk of mortality.","fulltextAvailable":false,"journal":"Thrombosis research","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Glomerular Filtration Rate","uri":{"id":"D005919","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Kidney Failure, Chronic","uri":{"id":"D007676","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Renal Insufficiency","uri":{"id":"D051437","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Venous Thromboembolism","uri":{"id":"D054556","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Creatinine","uri":{"id":"D003404","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Diagnosis","uri":{"id":"D003933","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Filtration","uri":{"id":"D005374","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hemorrhage","uri":{"id":"D006470","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hospitalization","uri":{"id":"D006760","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hospitals","uri":{"id":"D006761","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Inpatients","uri":{"id":"D007297","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Mortality","uri":{"id":"D009026","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Thromboembolism","uri":{"id":"D013923","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prevalence","uri":{"id":"D015995","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Serum","uri":{"id":"D044967","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anticoagulants","uri":{"id":"D000925","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Germany","uri":{"id":"D005858","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"25263017","title":"Prevalence of renal insufficiency in hospitalised patients with venous thromboembolic events: A retrospective analysis based on 6,725 VTE patients.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"WHAT IS KNOWN AND OBJECTIVE: Patients with non-valvular atrial fibrillation (NVAF) are at risk for stroke and systemic embolism (SSE), and this risk can be decreased with adjusted-dose warfarin. Warfarin, however, is cumbersome to use and requires at least monthly laboratory monitoring. Three new oral anticoagulants (NOACs) that are less cumbersome have been approved as alternatives to warfarin for SSE prevention in NVAF. Selecting a patient-specific alternative to warfarin can be confusing for pharmacists and clinicians. This review details clinical parameters to consider when choosing an alternative to warfarin for a specific patient and summarizes them in a Comparison Table. METHODS: Using available clinical evidence from pivotal trials, US FDA- and Health Canada-approved prescribing information and post-marketing observations, this review provides a summary of important clinical variables for clinicians to consider when choosing patient-centred anticoagulant alternatives to warfarin for prevention of SSE in NVAF. RESULTS AND DISCUSSION: Dabigatran, rivaroxaban and apixaban are approved alternatives to warfarin for primary and secondary prevention of SSE in patients with NVAF. Additionally, apixaban has also been compared to aspirin in patients with NVAF that were considered unsuitable for vitamin K antagonist therapy. Prospective consideration of age, weight, hepatic function, renal function and drug interactions are important clinical parameters to consider when selecting patient-centred alternatives to adjusted-dose warfarin. WHAT IS NEW AND CONCLUSION: Several NOACs are now alternatives to warfarin for SSE prevention in NVAF but require providers to make a shift in strategy from tailoring anticoagulant dose based on anticoagulant effect to selection of the anticoagulant based on clinical variables that affect anticoagulant exposure. These variables and their interactions should be considered in choosing an alternative to warfarin and are summarized in a simple table comparing the new anticoagulants.","fulltextAvailable":false,"journal":"Journal of clinical pharmacy and therapeutics","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Atrial Fibrillation","uri":{"id":"D001281","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Drug Interactions","uri":{"id":"D004347","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Vitamin K","uri":{"id":"D014812","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Secondary Prevention","uri":{"id":"D055502","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pharmaceutical Preparations","uri":{"id":"D004364","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hepatitis","uri":{"id":"D006505","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Laboratories","uri":{"id":"D007753","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pharmacists","uri":{"id":"D010595","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Vitamins","uri":{"id":"D014815","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anticoagulants","uri":{"id":"D000925","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Aspirin","uri":{"id":"D001241","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Warfarin","uri":{"id":"D014859","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"25252149","title":"Consideration of clinical variables for choosing new anticoagulant alternatives to warfarin for the management of non-valvular atrial fibrillation.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"Importance. The anticoagulant warfarin has been shown to interact with other medications, vitamin K containing foods, and over-the-counter products. These interactions may inhibit or potentiate the effect of warfarin, resulting in serious clotting or bleeding events. Observations. We report the case of an 84-year-old woman with atrial fibrillation, prescribed warfarin in May 2010 for stroke prevention. Her international normalized ratio (INR) was stable until April 2013, when she was prescribed AREDS (Age Related Eye Disease Study) formula pills, an eye vitamin compound, to slow the progression of age-related macular degeneration. This change was not reported to the Anticoagulation Service. Eighteen days later, she presented to the ED with groin and back pain and an INR of 10.4. An abdominal CT revealed a retroperitoneal hemorrhage with extension in multiple muscles. Both warfarin and AREDS were discontinued and the patient was discharged to subacute rehabilitation. This case was reviewed by the Anticoagulation Service and actions were taken to prevent similar adverse events. Conclusions. This report provides an example of the potential danger of supplement use, in this case, AREDS formula, in patients prescribed warfarin, and the importance of communicating medication changes to the providers responsible for warfarin management.","fulltextAvailable":false,"journal":"Case reports in medicine","meshAnnotations":{"@type":"java.util.ArrayList"},"meshHeading":null,"pmid":"25250052","title":"AREDS Formula, Warfarin, and Bleeding: A Case Report from the Michigan Anticoagulation Quality Improvement Initiative.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"Recognition of the adverse effects of medicinal herbs is not routine and the reports on such effects are even less frequent in clinical practice. Potential herb-drug interactions are of a major safety concern, especially for drugs with narrow therapeutic indices like warfarin, which can lead to severe adverse reactions that are sometimes life-threatening. The interactions between warfarin and medicinal herbs described in the literature have been summarized in this paper relying on Medline database (via PubMed) using the key words: warfarin, herbal supplements and interactions. The references on the analyzed literature have been investigated in order to collect the existing data. The case reports with severe adverse effects such as spontaneous postoperative bleeding, formation of hematomas, hematemesis, melena, thrombosis, subarachnoid hemorrhage and/or subdural hematomas after concomitant use of warfarin and the medicinal herbs: Panax ginseng, Hypericum perforatum, Salvia milthiorizza, Gingko biloba, Serenoa repens, Angelica sinensis, Vaccinium species, Allium sativum, Zingiber officinale, Tanacetum parthenium, Lucium barbarum, Matricaria chamomilla, Boswellia serrata and Camellia sinensis have been estimated. Some of the interactions between warfarin and medicinal herbs have been well assessed proving that they are closely-dependent. The interactions between warfarin and medicinal herbs, not generally reported in previous reviews, are presented in our review. The health professionals who are involved in treating the patients are expected to be fully informed about the interactions between warfarin and medicinal herbs in order to minimize the health risks of the patients.","fulltextAvailable":false,"journal":"Natural product communications","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Garlic","uri":{"id":"D005737","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Panax","uri":{"id":"D005894","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hematoma, Subdural","uri":{"id":"D006408","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Plants, Medicinal","uri":{"id":"D010946","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Subarachnoid Hemorrhage","uri":{"id":"D013345","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Ginkgo biloba","uri":{"id":"D020441","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hypericum","uri":{"id":"D020902","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Tanacetum parthenium","uri":{"id":"D020903","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Ginger","uri":{"id":"D020939","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Serenoa","uri":{"id":"D028024","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Camellia sinensis","uri":{"id":"D028241","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Boswellia","uri":{"id":"D029743","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Angelica sinensis","uri":{"id":"D029971","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Matricaria","uri":{"id":"D031168","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Herb-Drug Interactions","uri":{"id":"D041743","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pharmaceutical Preparations","uri":{"id":"D004364","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hemorrhage","uri":{"id":"D006470","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Literature","uri":{"id":"D008091","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Medicine","uri":{"id":"D008511","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Safety","uri":{"id":"D012449","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Therapeutics","uri":{"id":"D013812","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Thrombosis","uri":{"id":"D013927","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Herbal Medicine","uri":{"id":"D029001","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"PubMed","uri":{"id":"D039781","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Research Report","uri":{"id":"D058028","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Allium","uri":{"id":"D000490","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Panax","uri":{"id":"D005894","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hematemesis","uri":{"id":"D006396","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hematoma","uri":{"id":"D006406","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Melena","uri":{"id":"D008551","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Warfarin","uri":{"id":"D014859","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Ginkgo biloba","uri":{"id":"D020441","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hypericum","uri":{"id":"D020902","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Salvia","uri":{"id":"D027544","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Serenoa","uri":{"id":"D028024","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Camellia","uri":{"id":"D028244","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Boswellia","uri":{"id":"D029743","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Vaccinium","uri":{"id":"D029796","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Matricaria","uri":{"id":"D031168","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Tanacetum","uri":{"id":"D031203","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Animals","uri":{"id":"D000818","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Humans","uri":{"id":"D006801","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Plant Extracts","uri":{"id":"D010936","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Plants, Medicinal","uri":{"id":"D010946","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Warfarin","uri":{"id":"D014859","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Herb-Drug Interactions","uri":{"id":"D041743","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Animals","Herb-Drug Interactions","Humans","Plant Extracts","Plants, Medicinal","Warfarin"]},"pmid":"25233607","title":"Warfarin interactions with medicinal herbs.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"Synthetic coumarins were prepared in high yields using ionic liquids as an environmental friendly alternative. 3,4-Dimethyl-7-hydroxycoumarin (3ab) and 3-isopropyl-4-methyl-5,7-dihydroxycoumarin (3bc) showed interesting activity against Taq DNA polymerase with IC50 values of 115.7 microM and 82.2 microM, respectively. Also, 4-methyl-7-hydroxycoumarin (3aa) and 4-methyl-5,7-dihydroxycoumarin (3ba) exhibited inhibitory activity against MMLV-RT with IC50 values of 23.5 microM and 18.3 microM, respectively. These inhibitors could have importance as antiretroviral chemotherapeutic agents and also for the development of antitumor drugs.","fulltextAvailable":false,"journal":"Natural product communications","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Taq Polymerase","uri":{"id":"D019914","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anti-Retroviral Agents","uri":{"id":"D044966","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Antineoplastic Agents","uri":{"id":"D000970","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"DNA-Directed DNA Polymerase","uri":{"id":"D004259","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Taq Polymerase","uri":{"id":"D019914","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Ionic Liquids","uri":{"id":"D052578","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Chemistry","uri":{"id":"D002621","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"DNA","uri":{"id":"D004247","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pharmaceutical Preparations","uri":{"id":"D004364","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Coumarins","uri":{"id":"D003374","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Inhibitory Concentration 50","uri":{"id":"D020128","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Enzyme Inhibitors","uri":{"id":"D004791","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Plant Extracts","uri":{"id":"D010936","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Molecular Structure","uri":{"id":"D015394","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Coumarins","uri":{"id":"D003374","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Taq Polymerase","uri":{"id":"D019914","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Coumarins","Enzyme Inhibitors","Molecular Structure","Plant Extracts","Taq Polymerase"]},"pmid":"25233580","title":"Chemistry and biological activity of coumarins at molecular level.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"INTRODUCTION: Elderly people with vitamin K antagonists (VKA) have a higher risk of potentially serious hemorrhagic complications. An education program for patients (EPP) aged > or = 75 years with VKA was set up in 2008 in a French geriatric hospital. It includes individual and group sessions conducted by a nurse and a geriatrician. OBJECTIVES: The aim of this study was to assess this EPP after 5 years. Strengths, weaknesses and difficulties of implementation were highlighted, and some improvements were proposed. METHODS: This study is an external audit conducted by a pharmacist trained in EPP. Files of consecutive patients included in the program between may 2008 and March 2013 were reviewed allowing the data collection of patients characteristics and results of the different sessions. The educational objectives were assessed by the rate of correct responses to the questionnaires during the program. The results are presented taking into account the changes made during the 5 years of the program. RESULTS: One hundred forty-three patients, mean age 83.3 +/- 6.5 years, were included in the EPP. 51 sessions were conducted (2.8 patients/session on average). 58% of selected patients were hospitalized. The mean time between the start of anticoagulant treatment and the incLusion in the program was 48.9 +/- 71 months. For 95 patients (66.4%) the medication management at home required a caregiver who was present for sessions in 82 cases (57.3%). The questionnaires form and the organisation of the sessions were gradually improved between 2008 and the end of 2010. Thus, the impact of the EPP has been estimated from November 2010 to March 2013. The correct responses rates before and after the sessions were respectively: 47.8% vs 91.3% for knowledge of INR target values, 25.4% vs 91.3% for knowledge of hemorrhagic signs, 14.9% vs 87.0% for knowledge of the situations or the medications that may disturb the INR equilibrium. Furthermore, the mean number of correct responses, for the 23 patients participating in the entire program, is statistically different between the educational diagnostic and immediate evaluation (3.7/7 vs 5.4/7 p = 0.023) and no significant difference is observed between immediate and distant evaluation (5.4/7 vs 5.8/7 p = 0.720). CONCLUSION: An improvement of patient knowledge was observed with regard to the main educational objectives. Some improvements are proposed: to disseminate information to general practitioners, to add the follow up of INR values to assess an impact on anticoagulant treatment stability. Furthermore, this program is now adapted to the new oral anticoagulants. It is the role of hospital or community pharmacists to initiate and/or assess this type of EPP.","fulltextAvailable":false,"journal":"Journal de pharmacie de Belgique","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hospitals, Community","uri":{"id":"D006764","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patient Education as Topic","uri":{"id":"D010353","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"General Practitioners","uri":{"id":"D058005","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Aged","uri":{"id":"D000368","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Education","uri":{"id":"D004493","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Evaluation Studies as Topic","uri":{"id":"D005069","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hemorrhage","uri":{"id":"D006470","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hospitalization","uri":{"id":"D006760","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hospitals","uri":{"id":"D006761","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Nurses","uri":{"id":"D009726","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Nursing","uri":{"id":"D009729","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pharmacists","uri":{"id":"D010595","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Questionnaires","uri":{"id":"D011795","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Therapeutics","uri":{"id":"D013812","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Vitamins","uri":{"id":"D014815","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Caregivers","uri":{"id":"D017028","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Knowledge","uri":{"id":"D019359","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Medicalization","uri":{"id":"D062528","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anticoagulants","uri":{"id":"D000925","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Filing","uri":{"id":"D005371","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"International Normalized Ratio","uri":{"id":"D019934","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Aged","uri":{"id":"D000368","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Aged, 80 and over","uri":{"id":"D000369","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Female","uri":{"id":"D005260","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Humans","uri":{"id":"D006801","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Male","uri":{"id":"D008297","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patient Education as Topic","uri":{"id":"D010353","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Questionnaires","uri":{"id":"D011795","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anticoagulants","uri":{"id":"D000925","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Vitamin K","uri":{"id":"D014812","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Aged","Aged, 80 and over","Anticoagulants","Female","Humans","Male","Patient Education as Topic","Questionnaires","Vitamin K"]},"pmid":"25226761","title":"[Therapeutic education of elderly patients under antivitamin - K treatment: evaluation of the program after 5 years].","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"Patients taking anticoagulant medication pose a challenge for the clinician. Dentists are often required to manage bleeding as part of routine oral surgery or dental procedures, and altered hemostasis can lead to complications. Nevertheless, use of these medications is generally important for the patient's health and any alteration in the anticoagulant regimen may have untoward sequelae. In addition, several medications can affect the clotting mechanism, potentially compromising hemostasis. This article will review a variety of anticoagulant medications and the medical conditions that necessitate their use.","fulltextAvailable":false,"journal":"The New York state dental journal","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Surgery, Oral","uri":{"id":"D013515","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Dentists","uri":{"id":"D003815","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hemorrhage","uri":{"id":"D006470","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Methods","uri":{"id":"D008722","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"General Surgery","uri":{"id":"D013502","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Complicity","uri":{"id":"D028661","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Medicalization","uri":{"id":"D062528","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anticoagulants","uri":{"id":"D000925","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hemostasis","uri":{"id":"D006487","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Humans","uri":{"id":"D006801","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Risk Assessment","uri":{"id":"D018570","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anticoagulants","uri":{"id":"D000925","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hemostasis","uri":{"id":"D006487","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Platelet Aggregation Inhibitors","uri":{"id":"D010975","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Thromboembolism","uri":{"id":"D013923","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Dental Care for Chronically Ill","uri":{"id":"D017742","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Postoperative Hemorrhage","uri":{"id":"D019106","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Anticoagulants","Dental Care for Chronically Ill","Hemostasis","Humans","Platelet Aggregation Inhibitors","Postoperative Hemorrhage","Risk Assessment","Thromboembolism"]},"pmid":"25219061","title":"Management of the dental patient on anticoagulant medication: a review.","year":"2014 Jun-Jul"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"In order to improve the dissolution in vitro of components by processing tanshinone with the pray drying method, the physical properties of tanshinone power was analyzed by BET, differential scanning calorimetry, scanning electron microscopy and X-ray powder diffraction, and its dissolution in vitro was also investigated. The results of characterization showed decreased power size and increased specific surface area of tanshinone powder, and its existence in an amorphous state. Within 4 h, the accumulated dissolutions of tanshinone I and tanshinone II(A) in components of tanshinone reached 78.3%, 81.9%, respectively. Therefore, the spray-drying method was conducive to enhance the dissolution of components of tanshinone.","fulltextAvailable":false,"journal":"Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"X-Ray Diffraction","uri":{"id":"D014961","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Physical Processes","uri":{"id":"D055586","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Microscopy, Electron","uri":{"id":"D008854","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Microscopy, Electron, Scanning","uri":{"id":"D008855","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Calorimetry, Differential Scanning","uri":{"id":"D002152","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Powder Diffraction","uri":{"id":"D033362","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Calorimetry","uri":{"id":"D002151","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Electronics","uri":{"id":"D004581","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Electrons","uri":{"id":"D004583","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Microscopy","uri":{"id":"D008853","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Physics","uri":{"id":"D010825","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"X-Rays","uri":{"id":"D014965","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Chemistry, Pharmaceutical","uri":{"id":"D002626","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Drugs, Chinese Herbal","uri":{"id":"D004365","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Particle Size","uri":{"id":"D010316","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Solubility","uri":{"id":"D012995","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Diterpenes, Abietane","uri":{"id":"D045784","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Chemistry, Pharmaceutical","Diterpenes, Abietane","Drugs, Chinese Herbal","Particle Size","Solubility"]},"pmid":"25204171","title":"[Effect of spray drying process on physical properties and dissolution of tanshinone].","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"BACKGROUND: The incidence of adverse drug events (ADEs) in surgical and non-surgical patients may differ. This IPDMA identifies patient characteristics and types of medication most associated with patients experiencing ADEs and suggests target areas for reducing harm and implement focused interventions. METHODS: Authors of eligible studies on preventable ADEs (pADEs) were approached for collaboration. For assessment of differences among (non-)surgical patients and identification of associated factors descriptive statistics, Pearson Chi-Square, Poisson and logistic regression analyses were performed. For identification of high risk drugs (HRDs), a model was developed based on frequency, severity and preventability of medication related to ADEs. RESULTS: Included were 5,367 patients from four studies. Patients aged ≥ 77 years experienced more ADEs and pADEs compared to patients aged ≤ 52 years (odds ratios (OR) 2.12 (95%CI 1.70-2.65) and 2.55 (95%CI 1.70-3.84) respectively, both p<0.05). Polypharmacy on admission also increased the risk of ADEs (OR 1.21 (95%CI 1.03-1.44), p<0.05) and pADEs (OR 1.85 (95%CI 1.34-2.56), p < 0.05). pADEs were associated with more severe harm than non-preventable ADEs (54% versus 32%, p < 0.05). The top five HRDs were: antibiotics, sedatives, anticoagulants, diuretics and antihypertensives. Events associated with HRDs included diarrhoea or constipation, abnormal liver function test and central nervous system events. Most pADEs resulted from prescribing errors (90%). CONCLUSION: Elderly patients with polypharmacy on admission and receiving antibiotics, sedatives, anticoagulants, diuretics or antihypertensives were more prone to experiencing ADEs. Efficiency in prevention of ADEs may be improved by targeted vigilance systems for alertness of physicians and pharmacists.","fulltextAvailable":false,"journal":"British journal of clinical pharmacology","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Antigens, Bacterial","uri":{"id":"D000942","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Urogenital System","uri":{"id":"D014566","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis, Psoriatic","uri":{"id":"D015535","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis, Reactive","uri":{"id":"D016918","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Antigens","uri":{"id":"D000941","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arthritis","uri":{"id":"D001168","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Conjunctivitis","uri":{"id":"D003231","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Psoriasis","uri":{"id":"D011565","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Urethritis","uri":{"id":"D014526","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"HLA-B27 Antigen","uri":{"id":"D015796","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Spondylarthropathies","uri":{"id":"D025242","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"25199645","title":"An Individual Patient Data Meta-Analysis on Factors Associated with Adverse Drug Events in Surgical and Nonsurgical Inpatients.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"OBJECTIVES: We compared three methods for identifying drug overdose cases in inpatient hospital discharge data on their ability to classify drug overdoses by intent and drug type(s) involved. METHODS: We compared three International Classification of Diseases, Ninth Revision, Clinical Modification code-based case definitions using Kentucky hospital discharge data for 2000-2011. The first definition (Definition 1) was based on the external-cause-of-injury (E-code) matrix. The other two definitions were based on the Injury Surveillance Workgroup on Poisoning (ISW7) consensus recommendations for national and state poisoning surveillance using the principal diagnosis or first E-code (Definition 2) or any diagnosis/E-code (Definition 3). RESULTS: Definition 3 identified almost 50% more drug overdose cases than did Definition 1. The increase was largely due to cases with a first-listed E-code describing a drug overdose but a principal diagnosis that was different from drug overdose (e.g., mental disorders, or respiratory or circulatory system failure). Regardless of the definition, more than 53% of the hospitalizations were self-inflicted drug overdoses; benzodiazepines were involved in about 30% of the hospitalizations. The 2011 age-adjusted drug overdose hospitalization rate in Kentucky was 146/100,000 population using Definition 3 and 107/100,000 population using Definition 1. CONCLUSION: The ISW7 drug overdose definition using any drug poisoning diagnosis/E-code (Definition 3) is potentially the highest sensitivity definition for counting drug overdose hospitalizations, including by intent and drug type(s) involved. As the states enact policies and plan for adequate treatment resources, standardized drug overdose definitions are critical for accurate reporting, trend analysis, policy evaluation, and state-to-state comparison.","fulltextAvailable":false,"journal":"Public health reports (Washington, D.C. : 1974)","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Shock","uri":{"id":"D012769","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Mental Disorders","uri":{"id":"D001523","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Policy Making","uri":{"id":"D011050","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"International Classification of Diseases","uri":{"id":"D038801","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Drug Overdose","uri":{"id":"D062787","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Classification","uri":{"id":"D002965","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Diagnosis","uri":{"id":"D003933","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pharmaceutical Preparations","uri":{"id":"D004364","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Evaluation Studies as Topic","uri":{"id":"D005069","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hospitalization","uri":{"id":"D006760","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hospitals","uri":{"id":"D006761","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Inpatients","uri":{"id":"D007297","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Wounds and Injuries","uri":{"id":"D014947","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Consensus","uri":{"id":"D032921","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Theory of Mind","uri":{"id":"D056345","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Research Report","uri":{"id":"D058028","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Benzodiazepines","uri":{"id":"D001569","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Kentucky","uri":{"id":"D007629","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Analgesics","uri":{"id":"D000700","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Humans","uri":{"id":"D006801","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Population Surveillance","uri":{"id":"D011159","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Intention","uri":{"id":"D033182","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anticoagulants","uri":{"id":"D000925","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pharmaceutical Preparations","uri":{"id":"D004364","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Kentucky","uri":{"id":"D007629","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patient Discharge","uri":{"id":"D010351","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Poisoning","uri":{"id":"D011041","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Psychotropic Drugs","uri":{"id":"D011619","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Street Drugs","uri":{"id":"D013287","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"International Classification of Diseases","uri":{"id":"D038801","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Clinical Coding","uri":{"id":"D059019","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Drug Overdose","uri":{"id":"D062787","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Analgesics","Anticoagulants","Clinical Coding","Drug Overdose","Humans","Intention","International Classification of Diseases","Kentucky","Patient Discharge","Pharmaceutical Preparations","Poisoning","Population Surveillance","Psychotropic Drugs","Street Drugs"]},"pmid":"25177055","title":"Drug overdose surveillance using hospital discharge data.","year":"2014 Sep-Oct"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"OBJECTIVES: The long-term prognosis of individuals fulfilling the laboratory criteria, but not clinical criteria, of antiphospholipid syndrome (APS) has not been widely investigated. The primary aim of this study was to evaluate the incidence of first thrombotic event (deep venous thrombosis (DVT), pulmonary embolism (PE), myocardial infarction (MI), stroke or transient ischaemic attack (TIA) in a nationwide antiphospholipid antibody (aPL) carrier cohort. DESIGN: We conducted a prospective nationwide cohort study. SETTING: The aPL profile of participants was recorded from the laboratory database. Information was collected about thrombotic and pregnancy complications, subsequent medical history, other risk factors for thrombosis, use of prophylactic antithrombotic medication and general health. PARTICIPANTS: Participants included adult asymptomatic aPL carriers recognized in Finland during 1971-2009. MAIN OUTCOME MEASURE: The main outcome measure was incidence of first thrombotic event. RESULTS: A total of 119 (89% female) aPL carriers were followed for mean (SD) of 9.1 (7.5) years (range 3-41 years). Sixty-one per cent of the study participants had autoimmune disease, most often systemic lupus erythematosus (SLE). Thirty-six of 119 (30%) were either double or triple positive, 56% single lupus anticoagulant (LA) positive, and 8% and 5% single anticardiolipin antibodies (aCL) and anti-β2glycoprotein I antibodies (aβ2GPI) positive, respectively. Nine (7.6%) study patients experienced a first thrombotic event (five DVT, one PE, two MI, one TIA) mean (SD) 7.2 (8.3) years (range 1-26 years) after aPL detection (annual incidence rate 0.8%). All individuals who developed thrombotic complications had autoimmune disease. Annual rate of first thrombotic event in carriers of single positivity (0.65%) was equal to the known risk of thrombosis in the healthy Caucasian population, whereas the rate was two times higher in carriers of double or triple positivity (1.27%). Sixteen of 79 (20%) women experienced pregnancy complications. CONCLUSIONS: Double or triple positivity for aPL is a risk factor for future thrombotic events, especially in individuals with an underlying autoimmune disease, whereas single positivity does not seem to carry an elevated risk of thrombosis.","fulltextAvailable":false,"journal":"Lupus","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pregnancy Complications","uri":{"id":"D011248","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Risk Factors","uri":{"id":"D012307","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Autoimmune Diseases","uri":{"id":"D001327","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Antibodies, Antiphospholipid","uri":{"id":"D017152","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Laboratories","uri":{"id":"D007753","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Thrombosis","uri":{"id":"D013927","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Autoimmunity","uri":{"id":"D015551","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Incidence","uri":{"id":"D015994","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"25164304","title":"Persistent antiphospholipid antibody (aPL) in asymptomatic carriers as a risk factor for future thrombotic events: a nationwide prospective study.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"PURPOSE: This study examined the prevalence of risk factors for urological stone surgery and their possible influence on outcome and complications following ureteroscopy (URS). METHODS: The Clinical Research Office of the Endourological Society Ureteroscopy Global Study collected prospective data on consecutive patients with urinary stones treated with URS at centers around the world for 1 year. The prevalence of common comorbidities and anticoagulation therapy and their relationship with complications and age were examined. RESULTS: Of 11,719 patients, 2,989 patients (25.8 %) had cardiovascular disease, including 22.6 % with hypertension, and 1,266 patients (10.9 %) had diabetes mellitus. Approximately six percent of patients were receiving oral anticoagulation therapy, including aspirin (3.7 %) and clopidogrel (0.8 %). The prevalence of hypertension and diabetes mellitus and the proportion of patients receiving anticoagulant medication and/or antidiabetes treatment increased with age. Elderly were more likely to develop a postoperative complication when they had diabetes, a cardiovascular disease or received anticoagulation therapy. Post-operative bleeding was higher in patients receiving anticoagulants than those not receiving them (1.1 vs. 0.4 %; p < 0.01). Patients with risk factors for stone formation had more complications than those without (4.9 vs. 3.0 %, p < 0.001). CONCLUSIONS: This is the first study confirming in a global population that URS can effectively and safely be performed in a population with high comorbidity. The risk of a complication was highest among elderly patients presenting with comorbidities.","fulltextAvailable":false,"journal":"World journal of urology","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prospective Studies","uri":{"id":"D011446","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cardiovascular Diseases","uri":{"id":"D002318","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Diabetes Mellitus","uri":{"id":"D003920","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Postoperative Complications","uri":{"id":"D011183","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Risk Factors","uri":{"id":"D012307","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Urinary Calculi","uri":{"id":"D014545","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Biomedical Research","uri":{"id":"D035843","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Aged","uri":{"id":"D000368","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hemorrhage","uri":{"id":"D006470","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hypertension","uri":{"id":"D006973","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hypoglycemic Agents","uri":{"id":"D007004","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Societies","uri":{"id":"D012952","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"General Surgery","uri":{"id":"D013502","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Comorbidity","uri":{"id":"D015897","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prevalence","uri":{"id":"D015995","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Complicity","uri":{"id":"D028661","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Internationality","uri":{"id":"D038622","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Medicalization","uri":{"id":"D062528","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anticoagulants","uri":{"id":"D000925","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Aspirin","uri":{"id":"D001241","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Ureteroscopy","uri":{"id":"D018666","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Urolithiasis","uri":{"id":"D052878","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"25155035","title":"Age-related prevalence of diabetes mellitus, cardiovascular disease and anticoagulation therapy use in a urolithiasis population and their effect on outcomes: the Clinical Research Office of the Endourological Society Ureteroscopy Global Study.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"OBJECTIVE: To explore the correlative factors and clinical characteristics of digestive system injury during the treatment of anticoagulant and (or) antiplatelet-agents. METHODS: A total of 1 443 hospitalized patients on anticoagulant and (or) antiplatelet-agents from January 2010 to December 2013 at Renmin Hospital of Wuhan University were analyzed retrospectively. RESULTS: Their length of hospital stay was from 5 to 27 days. Most of them were elderly males (n = 880, 61.0%) with an average age of (62 ± 6) years. 1 138 patients (78.9%) were farmers, workers or someone without a specific occupation. During the treatment of anticoagulant/antiplatelet-agents, statistical difference existed (P = 0.01) between positively and negatively previous digestive disease groups for actively newly occurring digestive system injury (16.0% (41/256) vs 15.9% (189/1 187)). After the dosing of anticoagulant and (or) antiplatelet-agents, 57 (66.3%, 57/86) patients were complicated by hemorrhage of digestive tract, taking 62.9% (61/97) of all positive result patients for Helicobacter pylori test. Comparing preventive PPI group with no PPI group, there was no marked statistical differences (P = 2.67) for digestive system complication (including hemorrhage of digestive tract) while receiving anticoagulant and (or) antiplatelet-agents (13.9% (74/533) vs 17.1% (156/910)). During anticoagulant and/or antiplatelet-agent therapy, 185 patients (12.8%) were complicated by peptic ulcer or peptic ulcer with bleeding, 40 patients (2.8%) had erosive gastritis and 5 (0.3%) developed acute gastric mucosal lesions. And 42 of 76 patients complicated by hemorrhage of digestive tract underwent endoscopic hemostasis while 2 patients were operated. Ninety-seven patients (6.7%) died, including 61 (62.9%, 61/97) from hemorrhage of digestive tract. The remainder became cured, improved and discharged. Moreover, no significant statistical differences existed (P = 2.29) among three combination group (aspirin, clopidogrel, warfarin), two combination group (aspirin, clopidogrel), exclusive aspirin group and exclusive warfarin group in short-term (<27 d) mortality. CONCLUSIONS: It is necessary to clearly dictate the details of medication to the patients not highly educated. Elder, male, history of digestive system disease and Helicobacter pylori infection are possibly highly risk correlative factors for digestive system complications during anticoagulant/antiplatelet-agent therapy. The short-term protective effect of routine dose of PPI is inconspicuous. No significant correlation exists between short-term mortality and the dosage (or type) of anticoagulant/antiplatelet-agents.","fulltextAvailable":false,"journal":"Zhonghua yi xue za zhi","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Length of Stay","uri":{"id":"D007902","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Helicobacter Infections","uri":{"id":"D016481","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Peptic Ulcer","uri":{"id":"D010437","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Risk Factors","uri":{"id":"D012307","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Length of Stay","uri":{"id":"D007902","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Peptic Ulcer","uri":{"id":"D010437","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Helicobacter pylori","uri":{"id":"D016480","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Digestive System","uri":{"id":"D004064","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Digestive System Diseases","uri":{"id":"D004066","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hemostasis, Endoscopic","uri":{"id":"D016558","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Gastrointestinal Tract","uri":{"id":"D041981","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Aged","uri":{"id":"D000368","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Education","uri":{"id":"D004493","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hemorrhage","uri":{"id":"D006470","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"History","uri":{"id":"D006664","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hospitalization","uri":{"id":"D006760","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hospitals","uri":{"id":"D006761","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Male","uri":{"id":"D008297","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Mortality","uri":{"id":"D009026","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Occupations","uri":{"id":"D009790","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Ulcer","uri":{"id":"D014456","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Universities","uri":{"id":"D014495","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Wounds and Injuries","uri":{"id":"D014947","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Helicobacter","uri":{"id":"D016998","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Endoscopes","uri":{"id":"D019723","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Complicity","uri":{"id":"D028661","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Mucositis","uri":{"id":"D052016","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Medicalization","uri":{"id":"D062528","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anticoagulants","uri":{"id":"D000925","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Aspirin","uri":{"id":"D001241","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Gastritis","uri":{"id":"D005756","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hemostasis","uri":{"id":"D006487","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Warfarin","uri":{"id":"D014859","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"25146743","title":"[Retrospective analysis of correlative factors between digestive system injury and anticoagulant or antiplatelet-agents].","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"AIMS: As part of the Health Quality and Safety Commission's Atlas of Healthcare Variation in New Zealand, sociodemographic and regional differences in drug management for people with cardiovascular disease (CVD) were mapped. The aim of stakeholder engagement was to obtain feedback regarding interpretation, presentation and use of the Atlas data. METHODS: Feedback was obtained through surveys, one-on-one interviews and presentations at various meetings of clinicians, managers and researchers with an interest in CVD. Presentation and utility of the Atlas data for frontline quality improvement was explored. RESULTS: 28 stakeholders completed one-on-one feedback and over 100 attended meetings where the Atlas data were presented. Differences in dispensing by medication type, age, gender and ethnicity were thought to be related to diagnostic accuracy or the behaviour of prescribers or patients. Stakeholders found a funnel plot of the variation in triple therapy dispensing among general practices to be the most useful method of presentation, as it enabled practitioners to benchmark against peers, highlight areas for improvement, and monitor their progress over time. CONCLUSION: Stakeholder engagement has informed the interpretation of findings and the formatting of the Atlas data in a way that would potentially lead to improvements in the quality of patient care.","fulltextAvailable":false,"journal":"The New Zealand medical journal","meshAnnotations":{"@type":"java.util.ArrayList"},"meshHeading":{"@type":"java.util.ArrayList","@items":["Adult","Age Distribution","Aged","Anticoagulants","Antihypertensive Agents","Atlases as Topic","Benchmarking","Cardiovascular Diseases","Databases, Factual","Drug Prescriptions","Drug Therapy, Combination","Ethnic Groups","Feedback","Female","Health Status Disparities","Humans","Hydroxymethylglutaryl-CoA Reductase Inhibitors","Male","Middle Aged","New Zealand","Outcome Assessment (Health Care)","Platelet Aggregation Inhibitors","Quality Improvement","Secondary Prevention","Sex Distribution","Software"]},"pmid":"25145368","title":"Stakeholder engagement for the New Zealand Atlas of Healthcare Variation: cardiovascular disease secondary prevention: VIEW-3.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"BACKGROUND: The Health Quality and Safety Commission (HQSC) is developing Atlases of Healthcare Variation in New Zealand. We were invited to create and map the sociogeographic distribution of medication dispensing patterns among people with atherosclerotic cardiovascular disease (CVD). METHODS: We developed two interactive online atlas 'templates' demonstrating geographical variations in CVD medication dispensing using InstantAtlas. Each template provides stratified results in tabular, graphical and map format. In the 'Standard' template proportions were mapped according to standard deviations from the mean, while the 'Advanced' template used a 'heat-map' classification to show DHB-level variations. Furthermore, we added commentaries describing the variations present and provided questions of potential interest for users. RESULTS: The Standard template was best suited for DHB-level variations relative to a specific age, gender, or ethnic group but less effective for showing comparisons between two groups (e.g. Maori and Pacific). By contrast, the fixed legend and 'radar plot' in the Advanced template highlighted variations in medication dispensing rates geographically and sociodemographically more effectively. CONCLUSIONS: Geographical mapping of unwarranted variations in effective care requires careful consideration. Our experience from developing this CVD atlas is documented here for developers of other components of the Atlas of Healthcare Variation in New Zealand.","fulltextAvailable":false,"journal":"The New Zealand medical journal","meshAnnotations":{"@type":"java.util.ArrayList"},"meshHeading":{"@type":"java.util.ArrayList","@items":["Adult","Aged","Anticoagulants","Antihypertensive Agents","Atlases as Topic","Coronary Artery Disease","Databases, Factual","Drug Prescriptions","Drug Therapy, Combination","Ethnic Groups","Female","Humans","Hydroxymethylglutaryl-CoA Reductase Inhibitors","Male","Middle Aged","New Zealand","Platelet Aggregation Inhibitors","Secondary Prevention","Software"]},"pmid":"25145367","title":"Construction and use of mapping techniques to describe the geographical distribution of medication dispensing for the secondary prevention of atherosclerotic CVD in New Zealand: VIEW-2.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"BACKGROUND: Triple therapy with anti-platelet/anti-coagulant, blood pressure (BP)-lowering, and statin medications improves outcomes in atherosclerotic cardiovascular disease (CVD). However, in practice there is often a substantial evidence-practice gap, with sub-optimal initiation and longer-term adherence. Our aim was to enumerate a contemporary national cohort of people with significant CVD and report the variation in CVD secondary prevention dispensing by demographic variables. METHODS: Using anonymised linkage of national data sets, we identified 86,256 individuals, alive and residing in New Zealand at the end of 2010, aged 30-79 years who were hospitalised for an atherosclerotic CVD event or procedure in the previous10 years. This cohort was linked to the national pharmaceutical dispensing dataset to assess dispensing of CVD prevention medications during the 2011 calendar year. Adequate dispensing was defined as being dispensed a drug in at least 3 of the 4 quarters of the year. Multivariate regression was used to identify independent predictors of adequate dispensing. RESULTS: 59% were maintained on triple therapy, 77% on BP-lowering medication, 75% on anti-platelet/anti-coagulants and 70% on statins. From multivariate analysis, patients less than 50 years were about 20% less likely than older patients and women were 10% less likely than men to be maintained on triple therapy. Indian patients were about 10% more likely to be maintained on triple therapy than NZ European/Others. Those living in the Southern Cardiac Network region of New Zealand had slightly higher rates of triple therapy than National Cardiac Regions further north. CONCLUSIONS: The significant under-utilisation of safe and inexpensive secondary prevention medication, particularly in younger people and women, provides an opportunity to improve CVD outcomes in this easily identifiable high-risk population.","fulltextAvailable":false,"journal":"The New Zealand medical journal","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cardiovascular Diseases","uri":{"id":"D002318","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Ethnic Groups","uri":{"id":"D005006","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"New Zealand","uri":{"id":"D009520","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Secondary Prevention","uri":{"id":"D055502","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Classification","uri":{"id":"D002965","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Delivery of Health Care","uri":{"id":"D003695","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Safety","uri":{"id":"D012449","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Medicalization","uri":{"id":"D062528","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Radar","uri":{"id":"D011825","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Adult","uri":{"id":"D000328","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Aged","uri":{"id":"D000368","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Drug Therapy, Combination","uri":{"id":"D004359","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Ethnic Groups","uri":{"id":"D005006","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Female","uri":{"id":"D005260","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Humans","uri":{"id":"D006801","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Male","uri":{"id":"D008297","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Middle Aged","uri":{"id":"D008875","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Software","uri":{"id":"D012984","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Databases, Factual","uri":{"id":"D016208","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anticoagulants","uri":{"id":"D000925","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Antihypertensive Agents","uri":{"id":"D000959","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Atlases as Topic","uri":{"id":"D001271","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Coronary Artery Disease","uri":{"id":"D003324","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"New Zealand","uri":{"id":"D009520","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Platelet Aggregation Inhibitors","uri":{"id":"D010975","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Drug Prescriptions","uri":{"id":"D011307","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hydroxymethylglutaryl-CoA Reductase Inhibitors","uri":{"id":"D019161","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Secondary Prevention","uri":{"id":"D055502","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Adult","Age Factors","Aged","Anticoagulants","Antihypertensive Agents","Cohort Studies","Coronary Artery Disease","Drug Prescriptions","Drug Therapy, Combination","Ethnic Groups","Female","Humans","Hydroxymethylglutaryl-CoA Reductase Inhibitors","Male","Middle Aged","Multivariate Analysis","New Zealand","Platelet Aggregation Inhibitors","Secondary Prevention","Sex Factors","Socioeconomic Factors"]},"pmid":"25145366","title":"Effect of age, gender, ethnicity, socioeconomic status and region on dispensing of CVD secondary prevention medication in New Zealand: the Atlas of Health Care Variation CVD cohort (VIEW-1).","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"UNLABELLED: With the ever increasing number of patients on anticoagulant or antiplatelet medications presenting for a dermatological surgical procedure, dermatological surgeons are facing the challenge of managing these drugs in order to balance the bleeding complications against the risk of thromboembolic events. The difficulty results from the scarce available recommendations, the literature data that is in part contradictory and the rate of emergence of newer agents that have not been thoroughly studied and widely used. Although the common approach in the past was to stop any antithrombotic medications, including warfarin and aspirin, several days prior to cutaneous surgery, recent data suggest that this practice should be changed as the relatively low risk of bleeding does not justify the life-threatening nature of a likely thrombosis. For patients on warfarin surgery should be avoided if INR>3.5; aspirin should not be stopped prior to dermatological surgery and in most other circumstances patients taking long term antithrombotic medication should not stop this prior to dermatological surgery. In more complicated cases liaison with the prescriber is indispensable even when the therapy should be discontinued for a short period of time. This review studies the available data and presents the dermatological surgeon with a up-to-date information about all studies concerning the old and new antithrombotic agents in the setting of dermatological surgery procedures. Our aim was to propose our recommendations based on the most recent evidence and our experience and provide a comprehensive approach to the dermatological surgeon without excluding the need for individual assessment of each case. This article is protected by copyright. All rights reserved.","fulltextAvailable":false,"journal":"The British journal of dermatology","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Risk","uri":{"id":"D012306","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Fibrinolytic Agents","uri":{"id":"D005343","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Dermatologic Surgical Procedures","uri":{"id":"D062109","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pharmaceutical Preparations","uri":{"id":"D004364","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hemorrhage","uri":{"id":"D006470","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Literature","uri":{"id":"D008091","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Methods","uri":{"id":"D008722","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"General Surgery","uri":{"id":"D013502","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Thromboembolism","uri":{"id":"D013923","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Thrombosis","uri":{"id":"D013927","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Nature","uri":{"id":"D019368","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Complicity","uri":{"id":"D028661","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Medicalization","uri":{"id":"D062528","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anticoagulants","uri":{"id":"D000925","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Aspirin","uri":{"id":"D001241","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Warfarin","uri":{"id":"D014859","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"25142961","title":"Peri-operative management of and recommendations for antithrombotic medications in dermatological surgery.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"Interindividual variations in dose requirements of oral vitamin K antagonists (VKA) are attributed to several factors, including genetic variant alleles of vitamin K epoxide reductase complex subunit 1 (VKORC1) and cytochrome P450 2C9 (CYP2C9), but also interaction with co-medications. In this context, proton pump inhibitor (PPI)-related alterations of VKA maintenance dose requirements have been published. The present investigation aimed to test for an interaction profile of oral VKA-therapy and PPIs in relation to the CYP2C9 genotype. Median weekly stable VKA dose requirements over 1 year were recorded in 69 patients. Patients were genotyped for CYP2C9*2, CYP2C9*3, VKORC1c.-1639G>A and VKORC1c.174-136C>T and assessed for an association with PPI use and total VKA maintenance dose requirements. PPI users with CYP2C9 genetic variations required significantly lower weekly VKA maintenance doses than those with the wild-type genotype (t-test: P = 0·02). In contrast, in subjects without PPI use, the CYP2C9 genotype had no significant influence on oral VKA dose requirements. Further, the combined CYP2C9/VKORC1 genotype was a significant predictor for VKA dose requirements [linear regression: estimate: -1·47, standard error: 0·58 (P = 0·01)]. In conclusion, in carriers of CYP2C9 gene variations, the interference with the VKA metabolism is modified by PPI co-medication and the VCKORC1 genotype. Preceding knowledge of the genetic profile and the awareness for potentially occurring severe over-anticoagulation problems under PPI co-medication could contribute to a safer and personalized VKA pharmacotherapy.","fulltextAvailable":false,"journal":"British journal of haematology","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"NAD(P)H Dehydrogenase (Quinone)","uri":{"id":"D016660","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cytochrome P-450 Enzyme System","uri":{"id":"D003577","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pilot Projects","uri":{"id":"D010865","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Genetic Variation","uri":{"id":"D014644","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Vitamin K","uri":{"id":"D014812","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Proton Pumps","uri":{"id":"D017494","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Linear Models","uri":{"id":"D016014","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Proton Pump Inhibitors","uri":{"id":"D054328","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Vitamin K Epoxide Reductases","uri":{"id":"D064417","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Alleles","uri":{"id":"D000483","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Awareness","uri":{"id":"D001364","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cytochromes","uri":{"id":"D003580","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Drug Therapy","uri":{"id":"D004358","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Genes","uri":{"id":"D005796","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Genotype","uri":{"id":"D005838","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Maintenance","uri":{"id":"D008283","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Metabolism","uri":{"id":"D008660","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Mutation","uri":{"id":"D009154","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Oxidoreductases","uri":{"id":"D010088","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Protons","uri":{"id":"D011522","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Publishing","uri":{"id":"D011643","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Vitamins","uri":{"id":"D014815","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Knowledge","uri":{"id":"D019359","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Epoxy Compounds","uri":{"id":"D004852","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"25142093","title":"Influence of proton pump inhibitors and VKORC1 mutations on CYP2C9-mediated dose requirements of vitamin K antagonist therapy: a pilot study.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"BACKGROUND: Previous cross-sectional surveys in different European countries within the EUROASPIRE programme demonstrated a high prevalence of modifiable risk factors, unhealthy lifestyles and inadequate drug treatment in coronary heart disease patients. Comparable data for ischaemic stroke patients is lacking. METHODS: A stroke-specific study module was added to the EUROASPIRE III core survey. This cross-sectional multicentre survey included consecutive patients with first-ever ischaemic stroke from four European countries. Data were obtained from medical records, patient interviews and patient examinations within 6-36 months after the stroke event. Control of modifiable risk factors after stroke was evaluated against contemporary European guidelines. RESULTS: A total of 881 patients was recruited. Median age was 66 years, 37.5% were female; average time from the stroke event to interview was 550 days. At the time of the interview, 17.6% of stroke patients smoked cigarettes, 35.5% had a body mass index ≥30 kg/m(2), 62.4% showed elevated blood pressure and 75.7% exhibited elevated LDL cholesterol levels. Antiplatelet drugs or oral anticoagulants were used by 87.2%, antihypertensive medication by 84.4% and statins by 56.8% of stroke patients. Among patients using antihypertensive drugs and lipid-lowering medication at the time of the interview, 34.3% and 34.4%, respectively, achieved target blood pressure and total cholesterol values according to current European guidelines. CONCLUSION: The EUROASPIRE III stroke-specific module shows that secondary prevention and risk factor control in patients after ischaemic stroke need to be improved in four European centres at the time of the study since about half of patients are not achieving risk factor targets defined in European guidelines.","fulltextAvailable":false,"journal":"European journal of preventive cardiology","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Coronary Disease","uri":{"id":"D003327","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cross-Sectional Studies","uri":{"id":"D003430","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patient Selection","uri":{"id":"D018579","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hypercholesterolemia","uri":{"id":"D006937","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Blood Pressure","uri":{"id":"D001794","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Coronary Disease","uri":{"id":"D003327","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cross-Sectional Studies","uri":{"id":"D003430","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Heart Diseases","uri":{"id":"D006331","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cholesterol, LDL","uri":{"id":"D008078","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Medical Records","uri":{"id":"D008499","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Platelet Aggregation Inhibitors","uri":{"id":"D010975","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Risk Factors","uri":{"id":"D012307","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Body Mass Index","uri":{"id":"D015992","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Antihypertensive Agents","uri":{"id":"D000959","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Smoking","uri":{"id":"D012907","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Secondary Prevention","uri":{"id":"D055502","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Abstracting and Indexing as Topic","uri":{"id":"D000043","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cholesterol","uri":{"id":"D002784","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Data Collection","uri":{"id":"D003625","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pharmaceutical Preparations","uri":{"id":"D004364","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Europe","uri":{"id":"D005060","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Evaluation Studies as Topic","uri":{"id":"D005069","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Female","uri":{"id":"D005260","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Life Style","uri":{"id":"D008019","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pressure","uri":{"id":"D011312","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prevalence","uri":{"id":"D015995","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Medicalization","uri":{"id":"D062528","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anticoagulants","uri":{"id":"D000925","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Antihypertensive Agents","uri":{"id":"D000959","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Tobacco Products","uri":{"id":"D062789","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"25139770","title":"Control of main risk factors after ischaemic stroke across Europe: data from the stroke-specific module of the EUROASPIRE III survey.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"BACKGROUND: The perioperative use of anticoagulants (AC) and platelet aggregation inhibitors (PAI) in the field of spinal surgery suggests an increased rate of epidural bleeding. However, evidence is lacking and these medications are most often indispensable in the prevention of thromboembolic complications. Comprehensive recommendations for the correct use of AC and PAI are lacking. OBJECTIVE: The aim of this study was an analysis of the current situation with regards to the use of AC and PAI in spinal surgery and development of new recommendations. MATERIAL AND METHODS: Two independent surveys on the perioperative use of AC and PAI were obtained from centers for spinal surgery in Germany. The study obtained information on the perioperative use of AC and PAI, risk assessment of thromboembolic and hemorrhagic events as well as on the type and extent of the substance groups used. RESULTS: Almost the entire patient collective (98%) received perioperative low molecular weight heparin. In 64% the medical prophylaxis was started before surgery and in 36% after surgery. The period of prophylaxis was determined arbitrarily. Approximately 40% of interviewees employed paravertebral infiltration and 19% injected into the epidural space in patients on PAI medication. Open spinal canal surgery was performed in 30% of PAI medicated patients and closed spinal canal surgery was executed in 40%. The risk assessment of PAI differed significantly between aspirin and receptor blocker medication as well as dual administration of PAI. DISCUSSION: The use of AC and PAI in spinal surgery in Germany is very heterogeneous and large deviations from the guidelines frequently occurred. Therefore, there is a strong need for further studies to accurately assess the perioperative use of AC and PAI and to formulate precise recommendations.","fulltextAvailable":false,"journal":"Der Orthopäde","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Platelet Aggregation Inhibitors","uri":{"id":"D010975","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Molecular Weight","uri":{"id":"D008970","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Platelet Aggregation Inhibitors","uri":{"id":"D010975","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Risk Assessment","uri":{"id":"D018570","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Epidural Space","uri":{"id":"D004824","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Heparin, Low-Molecular-Weight","uri":{"id":"D006495","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Platelet Aggregation","uri":{"id":"D010974","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Spinal Canal","uri":{"id":"D013115","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Blood Platelets","uri":{"id":"D001792","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Data Collection","uri":{"id":"D003625","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hemorrhage","uri":{"id":"D006470","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Heparin","uri":{"id":"D006493","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Population Characteristics","uri":{"id":"D011154","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"General Surgery","uri":{"id":"D013502","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Thromboembolism","uri":{"id":"D013923","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Complicity","uri":{"id":"D028661","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Medicalization","uri":{"id":"D062528","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anticoagulants","uri":{"id":"D000925","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Aspirin","uri":{"id":"D001241","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Germany","uri":{"id":"D005858","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Injections","uri":{"id":"D007267","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"25116247","title":"[Thromboprophylaxis and platelet aggregation inhibitors in spinal surgery: perioperative management].","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"UNLABELLED: The objective is to identify practice patterns and attitudes of and barriers faced by US physicians assessing thromboembolism/stroke risk and managing anticoagulation in atrial fibrillation (AF) to determine educational needs. Case-based surveys were used to assess practice patterns, guideline use, barriers, and attitudes; 51 cardiologists and 50 primary care physicians (PCPs) were surveyed. Most cardiologists use validated risk scoring systems to assess thromboembolism/stroke risk, and more than half of PCPs use clinical experience. Assessment of bleeding risk varied; more than half of respondents rely on clinical judgment or patient bleeding history. The most commonly used prophylactic agents are warfarin/another vitamin K antagonist (PCPs) or antiplatelet agents (cardiologists). Newer anticoagulants are used less frequently. Bleeding risk, need for frequent monitoring (vitamin K antagonists), and medication costs were the most significant barriers. Cardiologists and PCPs could benefit from education on validated scoring systems to assess risk of thromboembolism/stroke and bleeding in AF, on newly released AF guidelines, and on newer anticoagulants.","fulltextAvailable":false,"journal":"American journal of medical quality : the official journal of the American College of Medical Quality","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Risk Management","uri":{"id":"D012308","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Atrial Fibrillation","uri":{"id":"D001281","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Platelet Aggregation Inhibitors","uri":{"id":"D010975","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Primary Health Care","uri":{"id":"D011320","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Vitamin K","uri":{"id":"D014812","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Risk Assessment","uri":{"id":"D018570","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Physicians, Primary Care","uri":{"id":"D058007","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Attitude","uri":{"id":"D001290","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Data Collection","uri":{"id":"D003625","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Education","uri":{"id":"D004493","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hemorrhage","uri":{"id":"D006470","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"History","uri":{"id":"D006664","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Judgment","uri":{"id":"D007600","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Physicians","uri":{"id":"D010820","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Thromboembolism","uri":{"id":"D013923","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Vitamins","uri":{"id":"D014815","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Medicalization","uri":{"id":"D062528","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anticoagulants","uri":{"id":"D000925","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Warfarin","uri":{"id":"D014859","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"25115364","title":"The Educational Needs of Clinicians Regarding Anticoagulation Therapy for Prevention of Thromboembolism and Stroke in Patients With Atrial Fibrillation.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"Fourteen compounds were isolated from Dalbergia odoriferae and purified by repeated column chromatography on silica and sephadex LH-20 gel and structurally identified by spectral analysis. These compounds were identified as 4, 9-dimethoxy-3-hydroxypterocarpan (1), medicarpin (2), 2', 4', 5-trihydroxy-7-methoxyisoflavone (3), 2', 3', 7-trihydroxy-4'-methoxyisoflavan (4), formononetin (5), 3, 8-dihydroxy-9-methoxypterocarpan (6), koparin (7), 3-hydroxy-9-methoxypterocarp-6a-ene (8), 2'-hydroxyformononetin (9), stevenin (10), 2', 7-dihydroxy-4', 5'-dimethoxyisoflavone (11), lyoniresinol (12), 2, 4-dihydroxy-5-methoxy-benzophenone (13) and neokhriol A (14). Compounds 1, 3, 4, 6, 8, 12 and 14 were isolated from this plant for the first time. Antibacterial activity assay showed that compound 4 had inhibitory effect on Ralstonia solanacearum.","fulltextAvailable":false,"journal":"Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Ralstonia solanacearum","uri":{"id":"D043368","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Chromatography","uri":{"id":"D002845","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Constitution and Bylaws","uri":{"id":"D003249","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Ralstonia","uri":{"id":"D043367","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Silicon Dioxide","uri":{"id":"D012822","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Dalbergia","uri":{"id":"D035782","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anti-Bacterial Agents","uri":{"id":"D000900","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Gels","uri":{"id":"D005782","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Microbial Sensitivity Tests","uri":{"id":"D008826","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Plant Extracts","uri":{"id":"D010936","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anisoles","uri":{"id":"D000840","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Benzophenones","uri":{"id":"D001577","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Chromatography","uri":{"id":"D002845","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Dextrans","uri":{"id":"D003911","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Isoflavones","uri":{"id":"D007529","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Naphthalenes","uri":{"id":"D009281","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Dalbergia","uri":{"id":"D035782","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pterocarpans","uri":{"id":"D036343","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Ralstonia solanacearum","uri":{"id":"D043368","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Silica Gel","uri":{"id":"D058428","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Anisoles","Anti-Bacterial Agents","Benzophenones","Chromatography","Dalbergia","Dextrans","Gels","Isoflavones","Microbial Sensitivity Tests","Naphthalenes","Plant Extracts","Pterocarpans","Ralstonia solanacearum","Silica Gel"]},"pmid":"25095373","title":"[Chemical constituents of Dalbergia odorifera].","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"Clinical guidelines advocate stroke prevention therapy in atrial fibrillation (AF) patients, specifically anticoagulation. However, the decision to initiate treatment is based on the risk (bleeding) versus benefit (prevention of stroke) of therapy, which is often difficult to assess. This review identifies available risk assessment tools to facilitate the safe and optimal use of antithrombotic therapy for stroke prevention in AF. Using key databases and online clinical resources to search the literature (1992-2012), 19 tools have been identified and published to date: 11 addressing stroke risk, 7 addressing bleeding risk and 1 integrating both risk assessments. The stroke risk assessment tools (e.g. CHADS2, CHA2DS2-VASc) share common risk factors: age, hypertension, previous cerebrovascular attack. The bleeding risk assessment tools (e.g. HEMORR2HAGES, HAS-BLED) share common risk factors: age, previous bleeding, renal and liver impairment. In terms of their development, six of the stroke risk assessment tools have been derived from clinical studies, whilst five are based on refinement of existing tools or expert consensus. Many have been evaluated by prospective application to data from real patient cohorts. Bleeding risk assessment tools have been derived from trials, or generated from patient data and then validated via further studies. One identified tool (i.e. Computerised Antithrombotic Risk Assessment Tool [CARAT]) integrates both stroke and bleeding, and specifically considers other key factors in decision-making regarding antithrombotic therapy, particularly those increasing the risk of medication misadventure with treatment (e.g. function, drug interactions, medication adherence). This highlights that whilst separate tools are available to assess stroke and bleeding risk, they do not estimate the relative risk versus benefit of treatment in an individual patient nor consider key medication safety aspects. More effort is needed to synthesize these separate risk assessments and integrate key medication safety issues, particularly since the introduction of new anticoagulants into practice.","fulltextAvailable":false,"journal":"Therapeutic advances in drug safety","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Risk Assessment","uri":{"id":"D018570","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Atrial Fibrillation","uri":{"id":"D001281","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Drug Interactions","uri":{"id":"D004347","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Risk","uri":{"id":"D012306","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Risk Factors","uri":{"id":"D012307","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Risk Assessment","uri":{"id":"D018570","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Medication Adherence","uri":{"id":"D055118","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Age Factors","uri":{"id":"D000367","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pharmaceutical Preparations","uri":{"id":"D004364","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Evaluation Studies as Topic","uri":{"id":"D005069","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hemorrhage","uri":{"id":"D006470","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hypertension","uri":{"id":"D006973","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Literature","uri":{"id":"D008091","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Publishing","uri":{"id":"D011643","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Safety","uri":{"id":"D012449","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Consensus","uri":{"id":"D032921","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Medicalization","uri":{"id":"D062528","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anticoagulants","uri":{"id":"D000925","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"25083260","title":"Safe use of antithrombotics for stroke prevention in atrial fibrillation: consideration of risk assessment tools to support decision-making.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"Anticoagulation therapy is used in several conditions to prevent or treat thromboembolism. Over the last 40 years, warfarin has been the oral anticoagulant of choice and has been considered the mainstay of treatment. However, its use is limited by a narrow therapeutic index and complex pharmacodynamics, necessitating regular monitoring and dose adjustments. Recently, two new oral anticoagulants--dabigatran etexilate (a direct thrombin inhibitor) and rivaroxiban (a factor Xa inhibitor)--have been approved for use in North America and Europe. Unlike warfarin, dabigatran and rivaroxiban are relatively small molecules that work as anticoagulants by targeting specific single steps of the coagulation cascade. Their advantages, relative to warfarin, include: predictable pharmacokinetics; limited food and drug interactions; rapid onset of action; and, short half-life. They require no monitoring. However, they lack a specific reversal agent. The number of patients taking dabigatran and rivaroxaban is increasing. Therefore, it is inevitable that dentists will be required to perform invasive procedures on this cohort of patients. This paper outlines the various properties of the new oral anticoagulants and the most recent guidelines regarding the management of these dental patients taking these medications.","fulltextAvailable":false,"journal":"Journal of the Irish Dental Association","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Food-Drug Interactions","uri":{"id":"D018565","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Drug Interactions","uri":{"id":"D004347","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"North America","uri":{"id":"D009656","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Antithrombins","uri":{"id":"D000991","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Factor Xa","uri":{"id":"D015951","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Abstracting and Indexing as Topic","uri":{"id":"D000043","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Americas","uri":{"id":"D000569","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Dentists","uri":{"id":"D003815","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pharmaceutical Preparations","uri":{"id":"D004364","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Europe","uri":{"id":"D005060","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Methods","uri":{"id":"D008722","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pharmacokinetics","uri":{"id":"D010599","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Therapeutics","uri":{"id":"D013812","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Thrombin","uri":{"id":"D013917","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Thromboembolism","uri":{"id":"D013923","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Work","uri":{"id":"D014937","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Medicalization","uri":{"id":"D062528","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anticoagulants","uri":{"id":"D000925","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Half-Life","uri":{"id":"D006207","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Warfarin","uri":{"id":"D014859","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Humans","uri":{"id":"D006801","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Thiophenes","uri":{"id":"D013876","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anticoagulants","uri":{"id":"D000925","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Benzimidazoles","uri":{"id":"D001562","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Morpholines","uri":{"id":"D009025","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prodrugs","uri":{"id":"D011355","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pyridines","uri":{"id":"D011725","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Thromboembolism","uri":{"id":"D013923","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Factor Xa","uri":{"id":"D015951","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Dental Care for Chronically Ill","uri":{"id":"D017742","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Antithrombin Proteins","uri":{"id":"D058833","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Anticoagulants","Antithrombin Proteins","Benzimidazoles","Dental Care for Chronically Ill","Factor Xa","Humans","Morpholines","Prodrugs","Pyridines","Thiophenes","Thromboembolism"]},"pmid":"25080640","title":"New oral anticoagulants and their implications for dental patients.","year":"2014 Jun-Jul"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"PURPOSE: A growing number of patients today receive anticoagulants. These drugs can cause serious adverse reactions leading to patients' hospitalization. The present study aimed to assess the number of hospital admissions as a result of anticoagulant adverse reactions in Alsace, a French region of 1.8 million inhabitants, and to estimate the economic burden associated with their management. METHODS: A retrospective analysis was performed using data extracted from the regional and anonymous hospital Programme de Médicalisation des Systèmes d'Information (PMSI) database to assess the number of hospital admissions and the associated costs. Stays from public and private hospitals were extracted from the database using two International Classification of Diseases, 10th revision, codes referring to anticoagulant drugs: 'T45.5-Poisoning by anticoagulants' and 'Y44.2-Anticoagulants' adverse effect in therapeutic use'. Costs were calculated from official French tariffs. RESULTS: Within a 2-year period from 1 Januray 2010 to 31 December 2011, 462 anticoagulant-related hospital admissions, predominantly in elderly patients, were identified in Alsace. These stays, as a result of anticoagulant adverse reactions, represented a cost of 2 050 127.86 euros (including hospitalization and expensive drugs). CONCLUSION: Regional PMSI database constitutes an effective tool to explore anticoagulant-related hospital admissions. Based on our study, one can state that the cost of anticoagulation therapies lies not only in the price of the drugs but also in the cost of adverse reaction management. Policy makers should be aware of this reality and should focus on better medication supervision in order to improve patient safety and reduce expenses. Copyright © 2014 John Wiley & Sons, Ltd.","fulltextAvailable":false,"journal":"Pharmacoepidemiology and drug safety","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patient Safety","uri":{"id":"D061214","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Administrative Personnel","uri":{"id":"D000288","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anticoagulants","uri":{"id":"D000925","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hospitals, Private","uri":{"id":"D016304","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"International Classification of Diseases","uri":{"id":"D038801","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Therapeutic Uses","uri":{"id":"D045506","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Aged","uri":{"id":"D000368","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anonyms and Pseudonyms","uri":{"id":"D000851","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Awareness","uri":{"id":"D001364","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Classification","uri":{"id":"D002965","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pharmaceutical Preparations","uri":{"id":"D004364","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hospitalization","uri":{"id":"D006760","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hospitals","uri":{"id":"D006761","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Organization and Administration","uri":{"id":"D009934","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Publications","uri":{"id":"D011642","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Safety","uri":{"id":"D012449","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Therapeutics","uri":{"id":"D013812","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Medicalization","uri":{"id":"D062528","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anticoagulants","uri":{"id":"D000925","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"25079654","title":"Anticoagulant-related hospital admissions: serious adverse reactions identified through hospital databases.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"UNLABELLED: In the present study we aimed to evaluate side effects of antiplatelet therapy in order to establish correlations with medication type, doses and association with other therapies. MATERIAL AND METHODS: In the study we prospectively evaluated a cohort of patients who received antiplatelet therapy for different pathologies. We included patients with acute coronary syndromes, valvular disease complicated with supraventricular arrhythmias (especially atrial fibrillation), carotidal critical stenosis, neurologic disease (ischemic or thrombotic), and peripheral artery disease. RESULTS AND DISCUSSIONS: The study included 125 patients (85 males and 40 females), aged between 45 and 85, and admitted in the 1st Cardiology Department, St Spiridon Hospital, between January 2012 and December 2013, who received antiplatelet therapy for different pathologies. All the patients included in the study received platelet antiaggregant therapy with Clopidogrel in association or not with Aspirin or low weight molecular heparin. Side effects reported (possibly correlated with antiplatelet therapy) were: macroscopic hematuria (7 cases), cutaneous ecchymosis (7 cases), purpuric lesions (9 cases), gingival bleeding (12 cases), upper gastrointestinal bleeding (6 cases), and hemoptysis (2 cases). CONCLUSIONS: Hemorrhagic events under the treatment with antiplatelet agents are rare in comparison with the large number of patients treated. Clinical manifestations are very different depending on the drug and also on the drug-associations used. Hemorrhagic accidents may sometimes be very serious, determining the specific therapeutic measures.","fulltextAvailable":false,"journal":"Revista medico-chirurgicală̆ a Societă̆ţ̜ii de Medici ş̧i Naturaliş̧ti din Iaş̧i","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prospective Studies","uri":{"id":"D011446","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Carotid Stenosis","uri":{"id":"D016893","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Atrial Fibrillation","uri":{"id":"D001281","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Molecular Weight","uri":{"id":"D008970","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Platelet Aggregation Inhibitors","uri":{"id":"D010975","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Peripheral Arterial Disease","uri":{"id":"D058729","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Acute Coronary Syndrome","uri":{"id":"D054058","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arrhythmias, Cardiac","uri":{"id":"D001145","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arteries","uri":{"id":"D001158","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Blood Platelets","uri":{"id":"D001792","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Constriction, Pathologic","uri":{"id":"D003251","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pharmaceutical Preparations","uri":{"id":"D004364","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Ecchymosis","uri":{"id":"D004438","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Evaluation Studies as Topic","uri":{"id":"D005069","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Female","uri":{"id":"D005260","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hematuria","uri":{"id":"D006417","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hemorrhage","uri":{"id":"D006470","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Heparin","uri":{"id":"D006493","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hospitalization","uri":{"id":"D006760","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hospitals","uri":{"id":"D006761","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Male","uri":{"id":"D008297","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pathology","uri":{"id":"D010336","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Syndrome","uri":{"id":"D013577","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Therapeutics","uri":{"id":"D013812","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Complicity","uri":{"id":"D028661","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Research Report","uri":{"id":"D058028","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Medicalization","uri":{"id":"D062528","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Aspirin","uri":{"id":"D001241","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cardiology","uri":{"id":"D002309","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Gingivitis","uri":{"id":"D005891","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hemoptysis","uri":{"id":"D006469","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Aged","uri":{"id":"D000368","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Aged, 80 and over","uri":{"id":"D000369","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Drug Therapy, Combination","uri":{"id":"D004359","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Female","uri":{"id":"D005260","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Humans","uri":{"id":"D006801","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Male","uri":{"id":"D008297","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Middle Aged","uri":{"id":"D008875","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prospective Studies","uri":{"id":"D011446","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Risk Factors","uri":{"id":"D012307","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Time Factors","uri":{"id":"D013997","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cohort Studies","uri":{"id":"D015331","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Risk Assessment","uri":{"id":"D018570","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anticoagulants","uri":{"id":"D000925","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Aspirin","uri":{"id":"D001241","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Heart Diseases","uri":{"id":"D006331","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hemorrhage","uri":{"id":"D006470","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Heparin","uri":{"id":"D006493","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Nervous System Diseases","uri":{"id":"D009422","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Platelet Aggregation Inhibitors","uri":{"id":"D010975","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Ticlopidine","uri":{"id":"D013988","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Peripheral Arterial Disease","uri":{"id":"D058729","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Aged","Aged, 80 and over","Anticoagulants","Aspirin","Cohort Studies","Drug Therapy, Combination","Female","Heart Diseases","Hemorrhage","Heparin","Humans","Male","Middle Aged","Nervous System Diseases","Peripheral Arterial Disease","Platelet Aggregation Inhibitors","Prospective Studies","Risk Assessment","Risk Factors","Ticlopidine","Time Factors"]},"pmid":"25076696","title":"Barriers of antiaggregant treatment.","year":"2014 Apr-Jun"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"BACKGROUND: Oral anticoagulation is recommended for stroke prevention in intermediate/high stroke risk atrial fibrillation (AF) patients. The objective of this study was to demonstrate the usefulness of analytic software tools for descriptive analyses of disease management in atrial AF; a secondary objective is to demonstrate patterns of potential anticoagulant undertreatment in AF. METHODS: Retrospective data analyses were performed using the Anticoagulant Quality Improvement Analyzer (AQuIA), a software tool designed to analyze health plan data. Two-year data from five databases were analyzed: IMS LifeLink (IMS), MarketScan Commercial (MarketScanCommercial), MarketScan Medicare Supplemental (MarketScanMedicare), Clinformatics™ DataMart, a product of OptumInsight Life Sciences (Optum), and a Medicaid Database (Medicaid). Included patients were ≥ 18 years old with a new or existing diagnosis of AF. The first observed AF diagnosis constituted the index date, with patient outcomes assessed over a one year period. Key study measures included stroke risk level, anticoagulant use, and frequency of International Normalized Ratio (INR) monitoring. RESULTS: High stroke risk (CHADS2 ≥ 2 points) was estimated in 54% (IMS), 22% (MarketScanCommercial), 64% (MarketscanMedicare), 42% (Optum) and 62% (Medicaid) of the total eligible population. Overall, 35%, 29%, 38%, 39% and 16% of all AF patients received an anticoagulant medication in IMS, MarketScanCommercial, MarketScanMedicare, Optum and Medicaid, respectively. Among patients at high risk for stroke, 19% to 51% received any anticoagulant. CONCLUSIONS: The AQuIA provided a consistent platform for analysis across multiple AF populations with varying baseline characteristics. Analyzer results show that many high-risk AF patients in selected commercial, Medicare-eligible, and Medicaid populations do not receive appropriate thromboprophylaxis, as recommended by treatment guidelines.","fulltextAvailable":false,"journal":"BMC health services research","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Software Design","uri":{"id":"D012985","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Atrial Fibrillation","uri":{"id":"D001281","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Health Planning","uri":{"id":"D006285","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Statistics as Topic","uri":{"id":"D013223","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Outcome Assessment (Health Care)","uri":{"id":"D017063","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Quality Improvement","uri":{"id":"D058996","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Biological Science Disciplines","uri":{"id":"D001690","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Software","uri":{"id":"D012984","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Disease Management","uri":{"id":"D019468","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"International Normalized Ratio","uri":{"id":"D019934","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patient Outcome Assessment","uri":{"id":"D063868","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Abstracting and Indexing as Topic","uri":{"id":"D000043","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Diagnosis","uri":{"id":"D003933","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Medicare","uri":{"id":"D006278","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Medicaid","uri":{"id":"D008484","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Science","uri":{"id":"D012586","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Software","uri":{"id":"D012984","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Life","uri":{"id":"D019369","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Medicalization","uri":{"id":"D062528","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anticoagulants","uri":{"id":"D000925","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"International Normalized Ratio","uri":{"id":"D019934","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"25069459","title":"Anticoagulant use for the prevention of stroke in patients with atrial fibrillation: findings from a multi-payer analysis.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":null,"fulltextAvailable":false,"journal":"BMJ (Clinical research ed.)","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Lasers","uri":{"id":"D007834","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Fluorescence","uri":{"id":"D005453","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Lasers","uri":{"id":"D007834","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Licensure","uri":{"id":"D008004","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Lighting","uri":{"id":"D008029","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pulse","uri":{"id":"D011674","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Principle-Based Ethics","uri":{"id":"D028662","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Nanostructures","uri":{"id":"D049329","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Nanoparticles","uri":{"id":"D053758","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Carbazoles","uri":{"id":"D002227","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Oxazines","uri":{"id":"D010078","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Antithrombins","Benzimidazoles","Clinical Trials as Topic","Dose-Response Relationship, Drug","Drug Approval","Drug Monitoring","Europe","Hemorrhage","Humans","Product Surveillance, Postmarketing","United States","United States Food and Drug Administration","Warfarin","beta-Alanine"]},"pmid":"25056265","title":"Dabigatran, bleeding, and the regulators.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"UNLABELLED: This review intends to provide guidance regarding perioperative management of anticoagulation and antiplatelet drug therapy as they relate to foot and ankle surgery. Venous and arterial thromboembolism are conditions in which the blood clots inappropriately, causing considerable morbidity and mortality. With an increase in awareness of thromboembolic risk factors and expansion of therapeutic options, more patients are routinely taking antithrombotic medication. When these patients require invasive procedures, a decision needs to be made if antithrombotic medication should be held perioperatively and if additional precautions are needed in the interim. Understanding the factors affecting the management of thromboembolism during the perioperative period can reduce the potential for complications. LEVELS OF EVIDENCE: Therapeutic, Level V - expert opinion.","fulltextAvailable":false,"journal":"Foot & ankle specialist","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Drug Therapy","uri":{"id":"D004358","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Expert Testimony","uri":{"id":"D005104","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Platelet Aggregation Inhibitors","uri":{"id":"D010975","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Risk Factors","uri":{"id":"D012307","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Blood Coagulation","uri":{"id":"D001777","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Perioperative Period","uri":{"id":"D059035","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Ankle","uri":{"id":"D000842","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arteries","uri":{"id":"D001158","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Awareness","uri":{"id":"D001364","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pharmaceutical Preparations","uri":{"id":"D004364","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Methods","uri":{"id":"D008722","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Morbidity","uri":{"id":"D009017","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Mortality","uri":{"id":"D009026","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"General Surgery","uri":{"id":"D013502","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Therapeutics","uri":{"id":"D013812","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Thromboembolism","uri":{"id":"D013923","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Complicity","uri":{"id":"D028661","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Medicalization","uri":{"id":"D062528","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"25053792","title":"Balancing the Risk of Complications in Foot and Ankle Surgical Patients Taking Antithrombotic Medication.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"BACKGROUND: Laparoscopic cholecystectomy has been widely used in clinical practice during the recent decades; however, the effects of pneumoperitoneum and the surgery on the coagulation system are largely unknown. This clinical study aimed to observe any possible effects of pneumoperitoneum and the surgery on the coagulation system of patients. METHODS: This was a prospective observational study. The inclusion criteria included (1) patients with chronic cholecystitis and/or cholecystic polyps and (2) patients in the relief stage of acute cholecystitis. The exclusion criteria included (1) patients in the episodic stage of acute cholecystitis and those complicated with cholangiolithiasis; (2) patients with concomitant hematologic diseases, damages to the liver function, malignant tumors or immune system diseases, or patients complicated with thrombotic or hemorrhagic disorders; and (3) patients who had taken anticoagulant medication within a week before surgery. Fifty patients who were hospitalized into our department for elective laparoscopic cholecystectomy between November 2011 and February 2013 were eligible and enrolled into this study. Of the 50 patients, 22 were male and 28 female. The age of the patients ranged from 29 to 78 (mean 56.7±11.5) years. The surgery for each of the 50 patients was performed with the same equipment and conditions. The surgeries for all the patients were performed under general anesthesia with the patients in a 30-degree head-up tilted posture, and the pressure of pneumoperitoneum was maintained at 13 mmHg. Venous blood specimens were taken from each patient before and at the end of pneumoperitoneum (i.e., 0 hour after surgery) and at 8 hours after surgery for determination of prothrombin time (PT), activated partial thromboplastin time (APTT), fibrinogen (Fib), thrombin time (TT), and D-dimer (DD). The results of the determinations of these parameters were compared. RESULTS: (1) All the patients recovered well without any complications. (2) The pre-pneumoperitoneum values of the parameters of coagulation had normalized. (3) The PT values slightly increased (P > 0.05) at the end of pneumoperitoneum (i.e., 0 hour after surgery) and decreased by 0.5 seconds at 8 hours after surgery as compared to the pre-pneumoperitoneum values (P < 0.05). (4) APTT at 0 and 8 hours decreased by 1.4 seconds (P > 0.05) and 3.7 seconds (P < 0.05) respectively as compared to pre-pneumoperitoneum values, while the difference between the APTT values at 0 and 8 hours after surgery was not statistically significant (P > 0.05). (5) FIB determined at 0 hour post-operation increased by 0.1 g/L as compared to pre-pneumoperitoneum values (P > 0.05); however, the FIB values at 8 hours after operation increased by 1.2 g/L as compared to the pre-pneumoperitoneum values (P < 0.05), and increased by 1.1 g/L as compared to 0 hour post-operation (P < 0.05). (6) The TT values obtained at 0 and 8 hours post-operation were not significantly different as compared to the pre-pneumoperitoneum values (P > 0.05). (7) The DD values gradually increased after operation; as compared to pre-pneumoperitoneum values, DD at 0 and 8 hours after operation increased by 210.8 ng/ml and 525.9 ng/ml respectively (P < 0.05) and DD at 8 hours after operation increased by 315.1 ng/ml as compared to 0 hour post-operation (P < 0.05). CONCLUSIONS: The pneumoperitoneum for laparoscopic cholecycstectomy may lead to postoperative hypercoagulation in the patients, and thereby may increase the risks for development of postoperative thrombosis; Patients may have risks for occurrence of thrombosis within 8 hours after the operation, to which attention should be paid in favor of preventing thrombosis.","fulltextAvailable":false,"journal":"Chinese medical journal","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prospective Studies","uri":{"id":"D011446","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Immune System Diseases","uri":{"id":"D007154","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anesthesia, General","uri":{"id":"D000768","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Immune System","uri":{"id":"D007107","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hematologic Diseases","uri":{"id":"D006402","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hemorrhagic Disorders","uri":{"id":"D006474","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Immune System Diseases","uri":{"id":"D007154","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Partial Thromboplastin Time","uri":{"id":"D010314","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prothrombin Time","uri":{"id":"D011517","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Thrombin Time","uri":{"id":"D013918","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cholecystectomy, Laparoscopic","uri":{"id":"D017081","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cholecystitis, Acute","uri":{"id":"D041881","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anesthesia","uri":{"id":"D000758","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Equipment and Supplies","uri":{"id":"D004864","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Female","uri":{"id":"D005260","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hemorrhage","uri":{"id":"D006470","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hospitalization","uri":{"id":"D006760","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hospitals","uri":{"id":"D006761","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Immunity","uri":{"id":"D007109","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Immunization","uri":{"id":"D007114","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Male","uri":{"id":"D008297","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neoplasms","uri":{"id":"D009369","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Posture","uri":{"id":"D011187","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pressure","uri":{"id":"D011312","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"General Surgery","uri":{"id":"D013502","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Thrombin","uri":{"id":"D013917","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Thrombosis","uri":{"id":"D013927","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Laparoscopes","uri":{"id":"D020706","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Complicity","uri":{"id":"D028661","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Medicalization","uri":{"id":"D062528","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anticoagulants","uri":{"id":"D000925","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cholecystectomy","uri":{"id":"D002763","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cholecystitis","uri":{"id":"D002764","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Fibrinogen","uri":{"id":"D005340","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pneumoperitoneum","uri":{"id":"D011027","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prothrombin","uri":{"id":"D011516","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Thromboplastin","uri":{"id":"D013925","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Thrombophilia","uri":{"id":"D019851","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"25043074","title":"Effects of pneumoperitoneum of laparoscopic cholecystectomy on the coagulation system of patients: a prospective observational study.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"Candidates for onabotulinumtoxinA are generally patients with overactive bladder (OAB) or neurogenic detrusor overactivity (NDO) whose disease is inadequately controlled with behavioral therapy and oral medication. All patients must be willing and able to perform clean intermittent catheterization (CIC). Before the decision to administer onabotulinumtoxinA is made, the clinician should provide counseling to the patient regarding the agent's indications, proposed benefits, risks, and mode of administration. The patient should be aware that onabotulinumtoxinA takes effect after approximately 1-2 weeks and usually lasts for 4-10 months, after which repeat injections will be necessary to maintain effect. Patient preparation may include pre-treatment antibiotics and withdrawal of antiplatelet therapy or anticoagulants. Preparation of the product involves reconstitution in sterile saline and dilution according to the planned dose. Local anesthesia (e.g., bladder instillation of lidocaine) is usually administered, although general anesthesia may be used in certain cases. The injections are performed using a flexible or rigid cystoscope, and the procedure takes approximately 15 min. The initial follow-up visit occurs within 7-14 days, when evidence of adverse effects, including urinary retention, can be evaluated. Repeat injections can be scheduled as needed, but not sooner than 3 months. Currently, the total dose of onabotulinumtoxinA should not exceed 360 U in a 3-month period for all indications, including those outside the urinary tract (i.e., cosmetic, ophthalmologic, etc.). Overall, onabotulinumtoxinA is effective, generally well tolerated, safe, and is relatively simple to provide.","fulltextAvailable":false,"journal":"Neurourology and urodynamics","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Risk Assessment","uri":{"id":"D018570","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anesthesia, General","uri":{"id":"D000768","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Administration, Intravesical","uri":{"id":"D000283","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anesthesia, Local","uri":{"id":"D000772","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Behavior Therapy","uri":{"id":"D001521","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Urinary Tract","uri":{"id":"D014551","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Urinary Retention","uri":{"id":"D016055","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Urinary Bladder, Overactive","uri":{"id":"D053201","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Intermittent Urethral Catheterization","uri":{"id":"D057928","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anesthesia","uri":{"id":"D000758","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anti-Bacterial Agents","uri":{"id":"D000900","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Appointments and Schedules","uri":{"id":"D001071","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Awareness","uri":{"id":"D001364","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cosmetics","uri":{"id":"D003358","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Evaluation Studies as Topic","uri":{"id":"D005069","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Infertility","uri":{"id":"D007246","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Methods","uri":{"id":"D008722","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Sterilization","uri":{"id":"D013242","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Salinity","uri":{"id":"D054712","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Medicalization","uri":{"id":"D062528","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anticoagulants","uri":{"id":"D000925","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Catheterization","uri":{"id":"D002404","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Lidocaine","uri":{"id":"D008012","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cystoscopes","uri":{"id":"D020684","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"25042141","title":"Chapter 6: Practical aspects of administration of onabotulinumtoxinA.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"OBJECTIVES: To evaluate the prevalence of polypharmacy and potentially inappropriate medication (PIM) use and the association between these and chemotherapy-related adverse events in older adults with cancer undergoing chemotherapy. DESIGN: Secondary analysis of prospectively collected data. SETTING: Outpatient oncology clinics in seven academic medical centers. PARTICIPANTS: Adults aged 65 and older with cancer undergoing chemotherapy. MEASUREMENTS: Measures included number of daily medications (polypharmacy); PIM use based on three indices (Beers, Zhan, and Drugs to Avoid in the Elderly criteria), and use of six \"high risk\" medication classes for adverse drug events (anticoagulants, antiplatelet agents, opioids, insulin, oral hypoglycemics, antiarrhythmics). Using multivariate logistic regression, the relations were evaluated between these criteria and Grade 3 to 5 chemotherapy-related toxicity and between these criteria and hospitalization during chemotherapy. RESULTS: Participants (N=500; mean age 73, 61% Stage IV disease) took a mean of 5±4 daily medications (range 0-23). PIM use was common (up to 29% according to Beers criteria). No association was found between number of daily medications (reference 0-3 medications) and toxicity (4-9 medications, odds ratio (OR)=1.34, 95% confidence interval (CI)=0.92-1.97; ≥10 medications, OR=0.82, 95% CI=0.45-1.49) or hospitalization (≥4 medications, OR=1.34, 95% CI=0.82-2.18, P=.24). There was also no association between PIM use and toxicity (P=.93) or hospitalization (P=.98). No medication class was associated with either outcome. CONCLUSIONS: Polypharmacy and PIM use were common but were not associated with chemotherapy-related toxicity or hospitalization in older adults with cancer.","fulltextAvailable":false,"journal":"Journal of the American Geriatrics Society","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Ambulatory Care Facilities","uri":{"id":"D000554","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anticoagulants","uri":{"id":"D000925","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Platelet Aggregation Inhibitors","uri":{"id":"D010975","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Confidence Intervals","uri":{"id":"D016001","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Logistic Models","uri":{"id":"D016015","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Odds Ratio","uri":{"id":"D016017","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Drug-Related Side Effects and Adverse Reactions","uri":{"id":"D064420","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Academic Medical Centers","uri":{"id":"D000046","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Medical Oncology","uri":{"id":"D008495","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Adult","uri":{"id":"D000328","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Aged","uri":{"id":"D000368","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Analgesics, Opioid","uri":{"id":"D000701","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anti-Arrhythmia Agents","uri":{"id":"D000889","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Drug Therapy","uri":{"id":"D004358","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pharmaceutical Preparations","uri":{"id":"D004364","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Evaluation Studies as Topic","uri":{"id":"D005069","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hospitalization","uri":{"id":"D006760","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hospitals","uri":{"id":"D006761","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hypoglycemic Agents","uri":{"id":"D007004","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Insulin","uri":{"id":"D007328","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Organization and Administration","uri":{"id":"D009934","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Outpatients","uri":{"id":"D010045","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prevalence","uri":{"id":"D015995","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Insulins","uri":{"id":"D061385","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Medicalization","uri":{"id":"D062528","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anticoagulants","uri":{"id":"D000925","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Beer","uri":{"id":"D001515","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Polypharmacy","uri":{"id":"D019338","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Aged","uri":{"id":"D000368","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Aged, 80 and over","uri":{"id":"D000369","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Antineoplastic Agents","uri":{"id":"D000970","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Female","uri":{"id":"D005260","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hospitalization","uri":{"id":"D006760","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Humans","uri":{"id":"D006801","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Longitudinal Studies","uri":{"id":"D008137","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Male","uri":{"id":"D008297","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neoplasms","uri":{"id":"D009369","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prospective Studies","uri":{"id":"D011446","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Inappropriate Prescribing","uri":{"id":"D057970","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Polypharmacy","uri":{"id":"D019338","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Aged","Aged, 80 and over","Antineoplastic Agents","Female","Hospitalization","Humans","Inappropriate Prescribing","Longitudinal Studies","Male","Neoplasms","Polypharmacy","Prospective Studies"]},"pmid":"25041361","title":"Polypharmacy and potentially inappropriate medication use in older adults with cancer undergoing chemotherapy: effect on chemotherapy-related toxicity and hospitalization during treatment.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"BACKGROUND: Heparin is an anticoagulant medication that is normally injected subcutaneously. Subcutaneous administration of heparin may result in complications such as bruising, haematoma and pain at the injection site. One of the factors that may affect pain, haematoma and bruising is injection speed. OBJECTIVES: To assess the effects of the duration (speed) of subcutaneous heparin injection on pain, haematoma and bruising at the injection site in people admitted to hospitals or clinics who require treatment with unfractionated heparin or low molecular weight heparin. SEARCH METHODS: The Cochrane Peripheral Vascular Diseases Group Trials Search Co-ordinator searched the Specialised Register (last searched August 2013) and CENTRAL (2013, Issue 7). We searched MEDLINE, EMBASE, CINAHL and two Persian databases Iranmedex and SID (August 2013). SELECTION CRITERIA: We sought randomised controlled trials (RCTs) comparing the effects of different durations of subcutaneous injections of heparin on pain, bruising and haematoma at the injection site. DATA COLLECTION AND ANALYSIS: Two review authors, working independently, extracted data onto a structured form and assessed study quality. We used the criteria recommended by the Cochrane Handbook to assess the quality of included studies. The study outcomes were summarised using quantitative and qualitative methods. MAIN RESULTS: One RCT was identified which met the inclusion criteria, involving 50 participants with a mean age of 55.25 (± 12.37) years. In this trial it was not possible to blind the participants and care givers. The method of sequence generation and allocation concealment was not described. The overall quality of the evidence was moderate due to the single small included study. Each participant had two injections, one in the left side and one in right side of the abdomen. One of these was injected slowly (intervention) and the other was injected fast (control). The second injection was 12 hours after the first injection. The duration of fast injection was 10 seconds and the duration of slow injection was 30 seconds. The study reported a significantly lower pain intensity for slow versus fast injection. The mean pain intensity was 13.9 ± 17.1 mm with the slow injection and 20.6 ± 22.3 mm with the fast injection (P < 0.001). In addition the bruising sizes were smaller with slow injections compared to fast injections at 48 hours follow-up (mean bruising size 18.76 ± 9.32 mm(2) with the slow injection and 109.2 ± 468.66 mm(2) with the fast injection, P = 0.033) and 72 hours follow-up (mean bruising size 21.72 ± 76.16 mm(2) with the slow injection and 110.12 ± 472.86 mm(2) with the fast injection, P = 0.025). The incidence of haematoma was not measured as an outcome. AUTHORS' CONCLUSIONS: There is only limited evidence of any difference in pain intensity and bruising sizes following slow versus fast injections due to the inclusion of only one small unblinded trial. The single included study suggests that slow injection might have slightly lower pain intensity and bruising size at the heparin injection site, but the results should be considered with caution. Until more reliable evidence emerges, slow injection might be the preferred approach.","fulltextAvailable":false,"journal":"The Cochrane database of systematic reviews","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Heparin, Low-Molecular-Weight","uri":{"id":"D006495","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Injections, Subcutaneous","uri":{"id":"D007279","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Molecular Weight","uri":{"id":"D008970","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Outcome Assessment (Health Care)","uri":{"id":"D017063","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Heparin","uri":{"id":"D006493","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Heparin, Low-Molecular-Weight","uri":{"id":"D006495","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Injections, Subcutaneous","uri":{"id":"D007279","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Vascular Diseases","uri":{"id":"D014652","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Peripheral Vascular Diseases","uri":{"id":"D016491","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Caregivers","uri":{"id":"D017028","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Heparin","uri":{"id":"D006493","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hospitalization","uri":{"id":"D006760","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hospitals","uri":{"id":"D006761","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Work","uri":{"id":"D014937","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Incidence","uri":{"id":"D015994","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Complicity","uri":{"id":"D028661","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Research Report","uri":{"id":"D058028","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Medicalization","uri":{"id":"D062528","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anticoagulants","uri":{"id":"D000925","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Contusions","uri":{"id":"D003288","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Injections","uri":{"id":"D007267","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Sudden Infant Death","uri":{"id":"D013398","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"MEDLINE","uri":{"id":"D016239","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"25036897","title":"Slow versus fast subcutaneous heparin injections for prevention of bruising and site-pain intensity.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"Burning Mouth Syndrome (BMS) is defined as a chronic orofacial pain syndrome, without evidence of mucosal lesions and other clinical signs of disease or laboratory abnormalities. Patients with BMS complain of burning pain in the mouth, xerostomia and taste disturbances. It is more common among women and the median age of occurrence is about 60 years. BMS may be primary or secondary to other diseases. The mainstay in the treatment of BMS includes antidepressants, benzodiazepines, and anticonvulsants. A few cases of BMS caused due to medication have been reported. The causative drugs include angiotensin-converting enzyme inhibitors, anticoagulants, antipsychotics, antiretrovirals, and benzodiazepines. This is a case report of a patient on antidepressants who developed symptoms of BMS thereby causing a dilemma in management.","fulltextAvailable":false,"journal":"The Korean journal of pain","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Chronic Pain","uri":{"id":"D059350","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Angiotensin-Converting Enzyme Inhibitors","uri":{"id":"D000806","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Burning Mouth Syndrome","uri":{"id":"D002054","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Enzyme Inhibitors","uri":{"id":"D004791","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Facial Pain","uri":{"id":"D005157","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pain","uri":{"id":"D010146","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anticonvulsants","uri":{"id":"D000927","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pharmaceutical Preparations","uri":{"id":"D004364","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Enzymes","uri":{"id":"D004798","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Laboratories","uri":{"id":"D007753","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Syndrome","uri":{"id":"D013577","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Antipsychotic Agents","uri":{"id":"D014150","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Women","uri":{"id":"D014930","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Mucositis","uri":{"id":"D052016","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Research Report","uri":{"id":"D058028","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Medicalization","uri":{"id":"D062528","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anticoagulants","uri":{"id":"D000925","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Antidepressive Agents","uri":{"id":"D000928","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Benzodiazepines","uri":{"id":"D001569","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Xerostomia","uri":{"id":"D014987","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"25031818","title":"Antidepressant-induced Burning Mouth Syndrome: A Unique Case.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"In the present investigation, the effective root compound of plumbagin of Plumbago zeylanica (Plumbaginaceae) was evaluated for chemical constituent and antimalarial effect against the fourth instar larvae of Anopheles stephensi Liston (Diptera). In the chromatographic analyses of root compound with Rf value of 0.788 and NMR analyses also revealed that the effective compound contain naphthoquinone plumbagin were identified as the major chemical constituent. Larval mortality was observed after 3 h of exposure period. The plumbagin compound showed remarkable larvicidal activity against A. stephensi (LC50 32.65 and LC9072.27 ppm). Histopathological effects of compound was observed in the treated larvae. Based on the results, the plumbagin compound of P. zeylanica can be considered as a new source of natural larvicide for the control of malarial vector.","fulltextAvailable":false,"journal":"Parasitology research","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Constitution and Bylaws","uri":{"id":"D003249","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Diptera","uri":{"id":"D004175","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Evaluation Studies as Topic","uri":{"id":"D005069","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Larva","uri":{"id":"D007814","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Mortality","uri":{"id":"D009026","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Culicidae","uri":{"id":"D009033","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Nature","uri":{"id":"D019368","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anopheles","uri":{"id":"D000852","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Antimalarials","uri":{"id":"D000962","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Naphthoquinones","uri":{"id":"D009285","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Plumbaginaceae","uri":{"id":"D029606","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Animals","uri":{"id":"D000818","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Insecticides","uri":{"id":"D007306","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Naphthoquinones","uri":{"id":"D009285","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Plant Extracts","uri":{"id":"D010936","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Plant Roots","uri":{"id":"D018517","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anopheles","uri":{"id":"D000852","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Larva","uri":{"id":"D007814","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Plumbaginaceae","uri":{"id":"D029606","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Animals","Anopheles","Insecticides","Larva","Naphthoquinones","Plant Extracts","Plant Roots","Plumbaginaceae"]},"pmid":"25028206","title":"Antimalarial efficacy of dynamic compound of plumbagin chemical constituent from Plumbago zeylanica Linn (Plumbaginaceae) against the malarial vector Anopheles stephensi Liston (Diptera: Culicidae).","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"A simple, convenient, rapid and accurate high-performance liquid chromatographic (HPLC) method was established for the simultaneous determination about three ingredients of a traditional herbal prescription, Guibi-tang (GBT): liquiritin (1), nodakenin (2) and glycyrrhizin (3). Chromatographic analysis on the three components was separated within 35 min on a Gemini C18 column and maintained at 40°C. The mobile phase consisted of water with 1.0% (v/v) acetic acid (solvent A) and acetonitrile with 1.0% (v/v) acetic acid (solvent B) in gradient mode at a flow-rate of 1.0 mL/min. Chromatograms were acquired at 254, 280 and 330 nm in a photodiode array (PDA) detector. The calibration curves showed excellent linearity (R(2)=1.0000). The average recovery of three compounds was >93.5%, with a relative standard deviation (RSD) of <2.0%. The intra-day and inter-day precision (RSD) of the three components were 0.04%-3.04% and 0.11%-2.48%, respectively. The contents of compounds 1-3 in GBT were 1.09-1.10, 2.35-2.37 and 0.81-0.82 mg/g, respectively.","fulltextAvailable":false,"journal":"Pakistan journal of pharmaceutical sciences","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Acetates","uri":{"id":"D000085","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Acetic Acid","uri":{"id":"D019342","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Acetals","uri":{"id":"D000080","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Acetates","uri":{"id":"D000085","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Calibration","uri":{"id":"D002138","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Herbal Medicine","uri":{"id":"D029001","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prescriptions","uri":{"id":"D055656","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Acetonitriles","uri":{"id":"D000097","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Chromatography, High Pressure Liquid","uri":{"id":"D002851","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Glycyrrhizic Acid","uri":{"id":"D019695","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Calibration","uri":{"id":"D002138","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Chromatography, High Pressure Liquid","uri":{"id":"D002851","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Drugs, Chinese Herbal","uri":{"id":"D004365","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Limit of Detection","uri":{"id":"D057230","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Coumarins","uri":{"id":"D003374","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Glucosides","uri":{"id":"D005960","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Glycyrrhizic Acid","uri":{"id":"D019695","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Flavanones","uri":{"id":"D044950","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Calibration","Chromatography, High Pressure Liquid","Coumarins","Drugs, Chinese Herbal","Flavanones","Glucosides","Glycyrrhizic Acid","Limit of Detection"]},"pmid":"25015446","title":"Simultaneous determination of liquiritin, nodakenin and glycyrrhizinin Guibi-tang, a traditional herbal prescription by HPLC-PDA.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"PURPOSE: To evaluate the safety of uninterrupted rivaroxaban, a novel oral anticoagulant that directly inhibits factor Xa, and a vitamin K antagonist (VKA) in eligible adult patients with nonvalvular AF (NVAF) who are scheduled for a catheter ablation. METHODS/DESIGN: This is a prospective, randomized, open-label, active-controlled, global multicenter safety study of up to 250 randomized patients. Eligible patients with paroxysmal or persistent NVAF, a left ventricular ejection fraction >40 %, and a creatinine clearance >50 mL/min will be randomized 1:1 to rivaroxaban 20 mg orally once daily or to dose-adjusted oral VKA (recommended international normalized ratio (INR) 2.0-3.0) and stabilized on anticoagulation therapy for 1-7 days (if no intracardiac thrombus on transesophageal echocardiogram (TEE) immediately prerandomization/post-randomization or if 3 weeks of sufficient anticoagulation is documented) or for 4-5 weeks (if no TEE, no documented 3 weeks of sufficient anticoagulation, or by patient choice). During catheter ablation, heparin will be administered (ACT-targeted range = 300-400 s) after catheter ablation, and VKA will be managed per usual care. The next dose of rivaroxaban will be provided at least 6 h after establishment of hemostasis. The primary endpoint will be the incidence of post-procedure major bleeding events observed during the first 30 ± 5 days post-ablation. Secondary endpoints will include post-procedure thromboembolic events, additional bleeding, time-to-event, and medication adherence. RELEVANCE: This study is intended to provide information about the safety characteristics of rivaroxaban in patients with NVAF undergoing catheter ablation.","fulltextAvailable":false,"journal":"Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Atrial Fibrillation","uri":{"id":"D001281","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Stroke Volume","uri":{"id":"D013318","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Vitamin K","uri":{"id":"D014812","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Medication Adherence","uri":{"id":"D055118","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Factor Xa","uri":{"id":"D015951","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Catheter Ablation","uri":{"id":"D017115","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"International Normalized Ratio","uri":{"id":"D019934","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Adult","uri":{"id":"D000328","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Appointments and Schedules","uri":{"id":"D001071","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Creatinine","uri":{"id":"D003404","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Evaluation Studies as Topic","uri":{"id":"D005069","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hemorrhage","uri":{"id":"D006470","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Heparin","uri":{"id":"D006493","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Safety","uri":{"id":"D012449","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Thromboembolism","uri":{"id":"D013923","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Thrombosis","uri":{"id":"D013927","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Vitamins","uri":{"id":"D014815","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Incidence","uri":{"id":"D015994","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Internationality","uri":{"id":"D038622","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Catheters","uri":{"id":"D057785","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Medicalization","uri":{"id":"D062528","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anticoagulants","uri":{"id":"D000925","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hemostasis","uri":{"id":"D006487","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"International Normalized Ratio","uri":{"id":"D019934","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"25005452","title":"Rationale and design of VENTURE-AF: a randomized, open-label, active-controlled multicenter study to evaluate the safety of rivaroxaban and vitamin K antagonists in subjects undergoing catheter ablation for atrial fibrillation.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"OBJECTIVE: To systematically examine discontinuation rates with new US Food and Drug Administration-approved oral anticoagulants (NOACs) in patients with various indications for long-term anticoagulation. PATIENTS AND METHODS: Poor adherence to medications is considered a potential and frequent cause of treatment failure. We searched the PubMed, Cochrane Central Register of Controlled Trials, EMBASE, EBSCO, Web of Science, and CINAHL databases for articles published from January 1, 2001, through September 15, 2013. The following Medical Subject Heading terms and/or keywords were used for our database searches: rivaroxaban, dabigatran, apixaban, new oral anticoagulants, oral thrombin inhibitors, and oral factor Xa inhibitors. Articles in English that focused on randomized controlled trials (RCTs) comparing NOACs (apixaban, dabigatran, and rivaroxaban) with conventional therapy or placebo were abstracted. Independent extraction of relevant data was performed by 2 authors. The primary end point of interest was discontinuation due to all causes. Other end points of interest were discontinuation due to adverse events, consent withdrawal, and nonadherence. RESULTS: Eighteen RCTs including a total of 101,801 patients were included for analysis. Total study drug discontinuation rates were not statistically different with NOACs in comparison to pharmacologically active comparators for treatment of venous thromboembolism/pulmonary embolism (risk ratio [RR], 0.91; 95% CI, 0.74-1.13; P=.40) and for NOACs in comparison to warfarin and aspirin for prevention of stroke in patients with atrial fibrillation (RR, 1.01; 95% CI, 0.87-1.17; P=.92). In contrast, in acute coronary syndromes, total study drug discontinuation with NOACs was significantly higher than with placebo (RR, 1.40; 95% CI, 1.07-1.83; P=.01). Overall discontinuations were comparable to those with active comparators. CONCLUSION: Study drug discontinuations with NOACs were not significantly different from those with conventional drugs in treatment of venous thromboembolism/pulmonary embolism and prevention of stroke in patients with atrial fibrillation but were worse in acute coronary syndromes as noted in evidence from contemporary RCTs.","fulltextAvailable":false,"journal":"Mayo Clinic proceedings","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Medication Adherence","uri":{"id":"D055118","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Atrial Fibrillation","uri":{"id":"D001281","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Odds Ratio","uri":{"id":"D016017","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pulmonary Embolism","uri":{"id":"D011655","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Subject Headings","uri":{"id":"D013358","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Factor Xa","uri":{"id":"D015951","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Treatment Failure","uri":{"id":"D017211","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Medical Subject Headings","uri":{"id":"D046650","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Acute Coronary Syndrome","uri":{"id":"D054058","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Venous Thromboembolism","uri":{"id":"D054556","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Abstracting and Indexing as Topic","uri":{"id":"D000043","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Classification","uri":{"id":"D002965","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pharmaceutical Preparations","uri":{"id":"D004364","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Publishing","uri":{"id":"D011643","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Science","uri":{"id":"D012586","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Syndrome","uri":{"id":"D013577","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Thrombin","uri":{"id":"D013917","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Thromboembolism","uri":{"id":"D013923","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"PubMed","uri":{"id":"D039781","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Medicalization","uri":{"id":"D062528","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anticoagulants","uri":{"id":"D000925","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Aspirin","uri":{"id":"D001241","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Warfarin","uri":{"id":"D014859","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Administration, Oral","uri":{"id":"D000284","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Humans","uri":{"id":"D006801","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Thiophenes","uri":{"id":"D013876","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Randomized Controlled Trials as Topic","uri":{"id":"D016032","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anticoagulants","uri":{"id":"D000925","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Benzimidazoles","uri":{"id":"D001562","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Morpholines","uri":{"id":"D009025","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pulmonary Embolism","uri":{"id":"D011655","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pyrazoles","uri":{"id":"D011720","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pyridones","uri":{"id":"D011728","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"beta-Alanine","uri":{"id":"D015091","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Stroke","uri":{"id":"D020521","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Acute Coronary Syndrome","uri":{"id":"D054058","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Venous Thromboembolism","uri":{"id":"D054556","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Medication Adherence","uri":{"id":"D055118","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Acute Coronary Syndrome","Administration, Oral","Anticoagulants","Benzimidazoles","Humans","Medication Adherence","Morpholines","Pulmonary Embolism","Pyrazoles","Pyridones","Randomized Controlled Trials as Topic","Stroke","Thiophenes","Venous Thromboembolism","beta-Alanine"]},"pmid":"24996233","title":"Treatment discontinuations with new oral agents for long-term anticoagulation: insights from a meta-analysis of 18 randomized trials including 101,801 patients.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"OBJECTIVE: Emergency departments (EDs) are characterized by simultaneous care of multiple patients with various medical conditions. Due to a large number of patients with complex diseases, speed and complexity of medication use, working in under-staffing and crowded environment, medication errors are commonly perpetrated by emergency care providers. This study was designed to evaluate the incidence of medication errors among patients attending to an ED in a teaching hospital in Iran. METHODS: In this cross-sectional study, a total of 500 patients attending to ED were randomly assessed for incidence and types of medication errors. Some factors related to medication errors such as working shift, weekdays and schedule of the educational program of trainee were also evaluated. FINDINGS: Nearly, 22% of patients experienced at least one medication error. The rate of medication errors were 0.41 errors per patient and 0.16 errors per ordered medication. The frequency of medication errors was higher in men, middle age patients, first weekdays, night-time work schedules and the first semester of educational year of new junior emergency medicine residents. More than 60% of errors were prescription errors by physicians and the remaining were transcription or administration errors by nurses. More than 35% of the prescribing errors happened during the selection of drug dose and frequency. The most common medication errors by nurses during the administration were omission error (16.2%) followed by unauthorized drug (6.4%). Most of the medication errors happened for anticoagulants and thrombolytics (41.2%) followed by antimicrobial agents (37.7%) and insulin (7.4%). CONCLUSION: In this study, at least one-fifth of the patients attending to ED experienced medication errors resulting from multiple factors. More common prescription errors happened during ordering drug dose and frequency. More common administration errors included dug omission or unauthorized drug.","fulltextAvailable":false,"journal":"Journal of research in pharmacy practice","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cross-Sectional Studies","uri":{"id":"D003430","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Emergency Medicine","uri":{"id":"D004635","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Emergency Service, Hospital","uri":{"id":"D004636","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anti-Infective Agents","uri":{"id":"D000890","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Emergency Medical Services","uri":{"id":"D004632","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hospitals, Teaching","uri":{"id":"D006784","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Medication Errors","uri":{"id":"D008508","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pharmaceutical Services","uri":{"id":"D010593","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pharmacy Service, Hospital","uri":{"id":"D010607","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Medical Errors","uri":{"id":"D019300","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Appointments and Schedules","uri":{"id":"D001071","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pharmaceutical Preparations","uri":{"id":"D004364","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Education","uri":{"id":"D004493","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Emergencies","uri":{"id":"D004630","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Environment","uri":{"id":"D004777","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Evaluation Studies as Topic","uri":{"id":"D005069","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hospitalization","uri":{"id":"D006760","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hospitals","uri":{"id":"D006761","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Insulin","uri":{"id":"D007328","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Internship and Residency","uri":{"id":"D007396","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Iran","uri":{"id":"D007492","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Medicine","uri":{"id":"D008511","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Men","uri":{"id":"D008571","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Nurses","uri":{"id":"D009726","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Nursing","uri":{"id":"D009729","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Physicians","uri":{"id":"D010820","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Work","uri":{"id":"D014937","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Incidence","uri":{"id":"D015994","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prescriptions","uri":{"id":"D055656","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Insulins","uri":{"id":"D061385","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Medicalization","uri":{"id":"D062528","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anticoagulants","uri":{"id":"D000925","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pharmacies","uri":{"id":"D010594","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pharmacy","uri":{"id":"D010604","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Teaching","uri":{"id":"D013663","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"24991618","title":"Frequency and types of the medication errors in an academic emergency department in Iran: The emergent need for clinical pharmacy services in emergency departments.","year":"2013"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"Non-valvular atrial fibrillation (NVAF) represents a major health-care problem, needing an extensive and strict thrombosis prevention for stroke and cardiovascular (CV) disease risks. NVAF management guidelines recommend adequate antithrombotic and anti-atherosclerotic therapies. Medication adherence has been recognized as a pivotal element in health quality promotion and in the achievement of better clinical outcomes. We conducted a post-hoc analysis of the \"Atrial fibrillation Registry for Ankle-brachial index Prevalence Assessment-Collaborative Italian Study (ARAPACIS)\" with the aim of discerning differences in pharmacological management and medication adherence among NVAF Italian patients. Furthermore, data were analysed according to Italian geographical macro-regions (North, Center, South) to evaluate whether socioeconomic conditions might also influence medication adherence. Thus, we selected 1,366 NVAF patients that fulfilled the Morisky Medication Adherence Scale-4 items. Regional disparities in drug prescriptions were observed. In particular, in high-risk patients (CHA2DS2-VASc ≥2) oral anticoagulants were more prescribed in Northern and Center patients (61 and 60 %, respectively) compared to 53 % of high-risk Southern patients. Also, medication adherence showed a progressive decrease from North to South (78 vs. 60 %, p < 0.001). This disparity was independent of the number of drugs consumed for any reason, since prevalence of poly-therapy among the three macro-regions was similar. Our results show regional differences in NVAF patients' antithrombotic management and medication adherence, potentially reflecting well-known disparities in socioeconomic status among Italian regions. Future interventions promoting campaigns to global health-care education may be desirable to improve clinical outcomes in NVAF patients.","fulltextAvailable":false,"journal":"Internal and emergency medicine","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Statistics as Topic","uri":{"id":"D013223","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cardiovascular Diseases","uri":{"id":"D002318","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Health Promotion","uri":{"id":"D006293","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Atrial Fibrillation","uri":{"id":"D001281","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Drug Prescriptions","uri":{"id":"D011307","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Medication Adherence","uri":{"id":"D055118","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Social Class","uri":{"id":"D012923","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Ankle Brachial Index","uri":{"id":"D055109","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Abstracting and Indexing as Topic","uri":{"id":"D000043","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Delivery of Health Care","uri":{"id":"D003695","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pharmaceutical Preparations","uri":{"id":"D004364","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Education","uri":{"id":"D004493","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Evaluation Studies as Topic","uri":{"id":"D005069","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Forecasting","uri":{"id":"D005544","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Registries","uri":{"id":"D012042","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Thrombosis","uri":{"id":"D013927","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prevalence","uri":{"id":"D015995","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Internationality","uri":{"id":"D038622","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prescriptions","uri":{"id":"D055656","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Medicalization","uri":{"id":"D062528","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anticoagulants","uri":{"id":"D000925","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"24990547","title":"Medication prescription and adherence disparities in non valvular atrial fibrillation patients: an Italian portrait from the ARAPACIS study.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"INTRODUCTION/SIGNIFICANCE/POPULATION: Research has failed to demonstrate an optimal flushing solution or frequency for central catheters. In a 2002 study of 50 000 home care patients, catheter dysfunction with loss of patency was the most common complication and occurred in 29% of the peripherally inserted central catheters (PICCs) tracked. With the advent of the Affordable Care Act and the promise of expanded home care services, this study offers evidence as to a preferred flushing protocol to prevent catheter patency complications for home infusion patients with PICCs. METHODS: This prospective, randomized, 1-way, single-blinded posttest with control group study was performed to compare 3 commonly used flushing protocols in home infusion patients with PICCs. The independent variable was the flushing protocol, and dependent variables included the development of patency-related complications and other significant issues such as sluggishness, occlusion, missed medication doses, catheter replacement, additional nursing visits, and the use of alteplase (Cathflo Activase). DATA ANALYSIS/RESULTS: Each of the study groups had patients who experienced 1 or more patency-related complications. Additional factors that may affect catheter function, including patient age, gender, diagnosis, therapy type, frequency of catheter use, catheter brand/size/number of lumens, concomitant use of anticoagulant medications, and whether PICCs were used for routine lab testing, were analyzed, and no statistical significance was determined. Catheter dwell time (catheter days) was statistically significant (p = .003, confidence interval = 95%; assuming equal variance) and confirmed the assumption that the longer a home care patient's catheter was in place, the more complications occurred. There were no cases of heparin allergy, heparin-induced thrombocytopenia, or line infection. DISCUSSION/CONCLUSION/RECOMMENDATIONS FOR PRACTICE: The data provide some evidence to support the elimination of heparin flushing in home care patients with PICCs, although data in the saline-only group that related to additional registered nurse visits to assess PICC patency and the use of alteplase (Cathflo Activase) were trending toward significance because this group experienced a higher incidence of these complications than both the heparin groups. These findings should not be translated to home care patients with cancer or pregnancy diagnoses because these populations were excluded from this study. More studies of this topic area should be initiated. Please see video abstract, Supplemental Digital Content 1, for more information (http://links.lww.com/JIN/A3).","fulltextAvailable":false,"journal":"Journal of infusion nursing : the official publication of the Infusion Nurses Society","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Catheters, Indwelling","uri":{"id":"D002408","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patient Care","uri":{"id":"D005791","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Home Care Services","uri":{"id":"D006699","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Confidence Intervals","uri":{"id":"D016001","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Control Groups","uri":{"id":"D035061","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Nurses, Community Health","uri":{"id":"D064691","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patient Protection and Affordable Care Act","uri":{"id":"D058991","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Abstracting and Indexing as Topic","uri":{"id":"D000043","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Diagnosis","uri":{"id":"D003933","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Heparin","uri":{"id":"D006493","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hypersensitivity","uri":{"id":"D006967","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Nurses","uri":{"id":"D009726","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Nursing","uri":{"id":"D009729","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pregnancy","uri":{"id":"D011247","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Track and Field","uri":{"id":"D014142","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Incidence","uri":{"id":"D015994","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Complicity","uri":{"id":"D028661","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Catheters","uri":{"id":"D057785","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Medicalization","uri":{"id":"D062528","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anticoagulants","uri":{"id":"D000925","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Flushing","uri":{"id":"D005483","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Tissue Plasminogen Activator","uri":{"id":"D010959","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Thrombocytopenia","uri":{"id":"D013921","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"24983260","title":"A randomized controlled comparison of flushing protocols in home care patients with peripherally inserted central catheters.","year":"2014 Jul-Aug"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"BACKGROUND: Direct oral anticoagulants have been developed to address some of the drawbacks of vitamin-K antagonists. However, special attention should be given when using these drugs, especially in patients with renal insufficiency, questionable compliance, and those at high risk of bleeding. OBJECTIVE: To evaluate the appropriateness of prescribing dabigatran etexilate (DE) and rivaroxaban in patients with nonvalvular atrial fibrillation (NVAF) in real-life clinical practice. METHODS: This was a prospective study that included patients presenting to a teaching hospital from April to mid-October 2013, who were taking rivaroxaban or DE for NVAF. Appropriateness of prescribing was evaluated using 9 of the 10 criteria of the Medication Appropriateness Index. The primary outcome measure was the prevalence of inappropriate prescribing. Secondary outcome measures included (a) categories of inappropriateness, (b) prevalence of adverse drug events, and (c) interventions made by a clinical pharmacist to optimize prescribing. RESULTS: A total of 69 patients were evaluated; 16 patients (23%) had 1 inappropriate criterion, and an additional 18 (26%) had more than 1 inappropriate criterion. The most frequent inappropriate criteria were inappropriate choice (28% of patients), wrong dosage (26%), and impractical modalities of administration (26%). An adverse event (AE) was found in 51% of patients (including 8 patients with transient ischemic attack/stroke). The clinical pharmacists performed 48 interventions, and 94% were accepted by the physician. CONCLUSIONS: Inappropriate use of DE and rivaroxaban in patients with NVAF is frequent and possibly leads to AEs. Reinforcing education of health care professionals and patients is needed. Collaboration with clinical pharmacists can contribute to better use.","fulltextAvailable":false,"journal":"The Annals of pharmacotherapy","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Health Education","uri":{"id":"D006266","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Health Educators","uri":{"id":"D040441","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Health Care","uri":{"id":"health_care_category","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Atrial Fibrillation","uri":{"id":"D001281","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Delivery of Health Care","uri":{"id":"D003695","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prospective Studies","uri":{"id":"D011446","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Outcome Assessment (Health Care)","uri":{"id":"D017063","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Renal Insufficiency","uri":{"id":"D051437","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Inappropriate Prescribing","uri":{"id":"D057970","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Drug-Related Side Effects and Adverse Reactions","uri":{"id":"D064420","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Ischemic Attack, Transient","uri":{"id":"D002546","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hospitals, Teaching","uri":{"id":"D006784","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pharmacists","uri":{"id":"D010595","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Abstracting and Indexing as Topic","uri":{"id":"D000043","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Compliance","uri":{"id":"D003187","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cooperative Behavior","uri":{"id":"D003299","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pharmaceutical Preparations","uri":{"id":"D004364","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Education","uri":{"id":"D004493","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Evaluation Studies as Topic","uri":{"id":"D005069","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hemorrhage","uri":{"id":"D006470","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hospitalization","uri":{"id":"D006760","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hospitals","uri":{"id":"D006761","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pharmacists","uri":{"id":"D010595","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Physicians","uri":{"id":"D010820","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Specialization","uri":{"id":"D013038","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prevalence","uri":{"id":"D015995","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Medicalization","uri":{"id":"D062528","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anticoagulants","uri":{"id":"D000925","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Reinforcement (Psychology)","uri":{"id":"D012054","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Teaching","uri":{"id":"D013663","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"24982310","title":"Appropriateness of prescribing dabigatran etexilate and rivaroxaban in patients with nonvalvular atrial fibrillation: a prospective study.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"Dendritic cell-specific intercellular adhesion molecule 3-grabbing non-integrin-related (DC-SIGNR), also known as liver/lymph node-specific intercellular adhesion molecule 3-grabbing non-integrin, CLEC4M, CD209L, and CD299, is a Ca(2+) -dependent lectin that has been implicated in increasing the infection rates of several viruses, including HIV, but the physiological role of DC-SIGNR in healthy cells is currently not known with certainty. A close homologue of DC-SIGNR, dendritic-cell specific intercellular adhesion molecule 3-grabbing non-integrin, has been shown to act as a recycling endocytic receptor, which binds pathogens at the cell's surface and then releases them in the low pH environment of endosomal compartments. However, it is currently under debate in the literature as to whether DC-SIGNR plays a similar role. In this work, we used NMR to explore whether the DC-SIGNR carbohydrate recognition domain (CRD) shows any pH dependence in its ability to bind carbohydrates and Ca(2+) . We found clear evidence of reduced or abolished CRD-binding affinities for three different glycans at low pH (4.2) as compared to neutral pH (6.8). We also report the assignment of the DC-SIGNR CRD in the apo form, and use these new results to characterize the degree of structural rearrangement upon binding (or release) of Ca(2+) . Finally, we report a differential effect of pH on the affinities of glycans containing mannose exclusively versus glycans containing GlcNAc moieties. Our results lead us to propose that the DC-SIGNR CRD rapidly and reversibly releases glycan ligands and Ca(2+) at reduced pH (behaviour that would be expected for an endocytic receptor), and that the binding of mannose-containing oligosaccharides is more strongly affected by pH than the binding of GlcNAc-containing oligosaccharides.","fulltextAvailable":false,"journal":"The FEBS journal","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Dendrites","uri":{"id":"D003712","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Environment","uri":{"id":"D004777","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"HIV","uri":{"id":"D006678","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hydrogen-Ion Concentration","uri":{"id":"D006863","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Ligands","uri":{"id":"D008024","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Literature","uri":{"id":"D008091","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Lymph","uri":{"id":"D008196","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Oligosaccharides","uri":{"id":"D009844","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Polysaccharides","uri":{"id":"D011134","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Endosomes","uri":{"id":"D011992","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Virulence","uri":{"id":"D014774","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Work","uri":{"id":"D014937","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Research Report","uri":{"id":"D058028","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Apolipoproteins E","uri":{"id":"D001057","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Carbohydrates","uri":{"id":"D002241","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Mannose","uri":{"id":"D008358","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Lectins","uri":{"id":"D037102","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Calcium","uri":{"id":"D002118","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Humans","uri":{"id":"D006801","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hydrogen-Ion Concentration","uri":{"id":"D006863","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Receptors, Cell Surface","uri":{"id":"D011956","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cell Adhesion Molecules","uri":{"id":"D015815","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Protein Structure, Tertiary","uri":{"id":"D017434","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Binding Sites","uri":{"id":"D001665","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Chelating Agents","uri":{"id":"D002614","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Edetic Acid","uri":{"id":"D004492","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Oligosaccharides","uri":{"id":"D009844","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Solutions","uri":{"id":"D012996","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Protein Structure, Secondary","uri":{"id":"D017433","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Nuclear Magnetic Resonance, Biomolecular","uri":{"id":"D019906","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Lectins, C-Type","uri":{"id":"D037181","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Binding Sites","Calcium","Cell Adhesion Molecules","Chelating Agents","Edetic Acid","Humans","Hydrogen-Ion Concentration","Lectins, C-Type","Nuclear Magnetic Resonance, Biomolecular","Oligosaccharides","Protein Structure, Secondary","Protein Structure, Tertiary","Receptors, Cell Surface","Solutions"]},"pmid":"24976257","title":"NMR evidence for oligosaccharide release from the dendritic-cell specific intercellular adhesion molecule 3-grabbing non-integrin-related (CLEC4M) carbohydrate recognition domain at low pH.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"OBJECTIVE: The study was aimed at using ultrasound duplex scanning for determining the sequence and terms of formation of venous haemodynamics impairments in the affected lower extremity in patients after endured acute thrombosis of deep veins and assessing the effect of phlebotonic drugs on the course of these processes. MATERIAL AND METHODS: We examined and treated a total of 66 patients presenting with newly onset acute thrombosis of deep veins of lower limbs without concomitant varicose disease. Group I patients (n = 22) received the standard course of angiotropic and metabolic infusion therapy, direct and indirect anticoagulants, as well as used elastic compression. Group II patients (n = 22) in addition to the similar course of treatment received a phlebotonic drug (Venarus) according to the standard regimen: 1,000 mg daily for two months every half year. Group III patients (n = 22) additionally to the same standard treatment regimen were also given VenarusR at a dose of 1,000 mg daily but taken uninterruptedly and constantly during the whole period of follow up. All patients were subjected to ultrasound duplex scanning of deep veins of lower limbs initially at admission, then 3 weeks, 3, 6, 12 and 18 months after making the diagnosis of acute thrombosis. RESULTS: Group II and III patients additionally taking the phlebotonic were found to have acceleration of processes of recanalization averagely by 15-20% as compared with Group I patients. Group III patients taking the phlebotonic agent permanently demonstrated deceleration of the processes of formation of horizontal and vertical veno-venous refluxes on the background of more adequate recanalization by the end of the follow-up period. CONCLUSION: Permanent taking of phlebotonics increases the rate and scope of recanalization of the thrombosed deep veins of lower limbs, as well as dramatically decreases the development of the horizontal and vertical reflux, decreasing clinical manifestations of chronic venous insufficiency.","fulltextAvailable":false,"journal":"Angiologii͡a i sosudistai͡a khirurgii͡a = Angiology and vascular surgery","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Sequence Analysis","uri":{"id":"D017421","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Venous Thrombosis","uri":{"id":"D020246","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Venous Insufficiency","uri":{"id":"D014689","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Venous Thrombosis","uri":{"id":"D020246","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Lower Extremity","uri":{"id":"D035002","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Acceleration","uri":{"id":"D000054","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Diagnosis","uri":{"id":"D003933","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pharmaceutical Preparations","uri":{"id":"D004364","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Extremities","uri":{"id":"D005121","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Metabolism","uri":{"id":"D008660","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Thrombosis","uri":{"id":"D013927","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anticoagulants","uri":{"id":"D000925","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Deceleration","uri":{"id":"D003654","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Acute Disease","uri":{"id":"D000208","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Adult","uri":{"id":"D000328","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Female","uri":{"id":"D005260","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Follow-Up Studies","uri":{"id":"D005500","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hemodynamics","uri":{"id":"D006439","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Humans","uri":{"id":"D006801","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Male","uri":{"id":"D008297","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Middle Aged","uri":{"id":"D008875","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Vasoconstrictor Agents","uri":{"id":"D014662","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Treatment Outcome","uri":{"id":"D016896","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anticoagulants","uri":{"id":"D000925","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Combined Modality Therapy","uri":{"id":"D003131","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Diosmin","uri":{"id":"D004145","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Drug Combinations","uri":{"id":"D004338","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hesperidin","uri":{"id":"D006569","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Veins","uri":{"id":"D014680","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Venous Insufficiency","uri":{"id":"D014689","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Drug Monitoring","uri":{"id":"D016903","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Ultrasonography, Doppler, Duplex","uri":{"id":"D018616","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Venous Thrombosis","uri":{"id":"D020246","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Lower Extremity","uri":{"id":"D035002","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Compression Bandages","uri":{"id":"D058128","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Acute Disease","Adult","Anticoagulants","Combined Modality Therapy","Compression Bandages","Diosmin","Drug Combinations","Drug Monitoring","Female","Follow-Up Studies","Hemodynamics","Hesperidin","Humans","Lower Extremity","Male","Middle Aged","Treatment Outcome","Ultrasonography, Doppler, Duplex","Vasoconstrictor Agents","Veins","Venous Insufficiency","Venous Thrombosis"]},"pmid":"24961326","title":"[Ultrasound assessment of alterations in venous haemodynamics in patients with post-thrombotic disease permanently taking phlebotonics].","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"OBJECTIVE: To evaluate the effectiveness of a topically applied gel containing essential oils (menthol and thymol) and polyphenolic antioxidants (phloretin and ferulic acid) for reducing halitosis in dogs. ANIMALS: 20 dogs. PROCEDURES: A blinded crossover clinical trial was conducted. Dogs received a dental cleaning and examination (periodontal examination including periodontal probing and assessments of plaque, calculus, and gingivitis). Owners then applied a gel (active or placebo) to oral soft tissues twice daily for a 4-week period. Teeth of the dogs were cleaned again, and owners applied the other gel for a 4-week period. Clinicians scored halitosis immediately after the initial cleaning and at 4 and 8 weeks, and owners scored halitosis weekly. RESULTS: Halitosis assessment by clinicians revealed that both groups had improvement in halitosis scores. Two dogs were removed because of owner noncompliance. In the active-to-placebo group (n = 9), halitosis was significantly reduced during application of the active gel but increased during application of the placebo. Seven of 9 owners reported increased halitosis when treatment was changed from the active gel to the placebo. In the placebo-to-active group (n = 9), halitosis decreased during application of the placebo and continued to decrease during application of the active gel. Seven of 9 owners reported a decrease in halitosis with the active gel. CONCLUSIONS AND CLINICAL RELEVANCE: An oral topically applied gel with essential oils and polyphenolic antioxidants applied daily after an initial professional dental cleaning decreased oral malodor in dogs.","fulltextAvailable":false,"journal":"American journal of veterinary research","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cross-Over Studies","uri":{"id":"D018592","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Oils, Volatile","uri":{"id":"D009822","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Antioxidants","uri":{"id":"D000975","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Evaluation Studies as Topic","uri":{"id":"D005069","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Menthol","uri":{"id":"D008610","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Periodontics","uri":{"id":"D010517","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Periodontitis","uri":{"id":"D010518","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Tissues","uri":{"id":"D014024","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Research Report","uri":{"id":"D058028","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Polyphenols","uri":{"id":"D059808","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Calculi","uri":{"id":"D002137","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Gingivitis","uri":{"id":"D005891","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Halitosis","uri":{"id":"D006209","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Phloretin","uri":{"id":"D010693","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Thymol","uri":{"id":"D013943","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Tooth","uri":{"id":"D014070","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Tooth Eruption","uri":{"id":"D014078","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Animals","uri":{"id":"D000818","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anti-Inflammatory Agents","uri":{"id":"D000893","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Antioxidants","uri":{"id":"D000975","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Female","uri":{"id":"D005260","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Gels","uri":{"id":"D005782","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Male","uri":{"id":"D008297","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Administration, Topical","uri":{"id":"D000287","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Coumaric Acids","uri":{"id":"D003373","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Dental Plaque","uri":{"id":"D003773","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Dog Diseases","uri":{"id":"D004283","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Dogs","uri":{"id":"D004285","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Gingivitis","uri":{"id":"D005891","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Halitosis","uri":{"id":"D006209","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Menthol","uri":{"id":"D008610","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Oils, Volatile","uri":{"id":"D009822","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Phloretin","uri":{"id":"D010693","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Thymol","uri":{"id":"D013943","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cross-Over Studies","uri":{"id":"D018592","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Administration, Topical","Animals","Anti-Inflammatory Agents","Antioxidants","Coumaric Acids","Cross-Over Studies","Dental Plaque","Dog Diseases","Dogs","Female","Gels","Gingivitis","Halitosis","Male","Menthol","Oils, Volatile","Phloretin","Thymol"]},"pmid":"24959732","title":"Evaluation of a topical gel containing a novel combination of essential oils and antioxidants for reducing oral malodor in dogs.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"BACKGROUND: Our aim in this study was to investigate whether mean platelet volume (MPV) value could be used as an early marker to predict pelvic inflammatory disease (PID). METHODS: Overall, 44 patients with PID and 44 healthy women were included in the study. The control group consisted of 44 women who applied to the clinic for a routine gynaecological check-up, without chronic disease or a history of medication use. Owing to the fact that it would affect thrombocyte function, women who have the following conditions were excluded from the study: women who were taking anticoagulant therapy, oral contraceptives, nonsteroid anti-inflammatory medications and who had chronic diseases. The leukocyte count, platelet count, neutrophil ratio and MPV values were collected from PID and the control group. C reactive protein values of patients with PID were also noted. RESULTS: MPV values in patients with PID were lower than those in the control group. This reduction in MPV is statistically significant when the PID patient group is compared with the control group (p < 0.001). A negative correlation was discovered between platelet count and MPV values (p = 0.019, r = - 0.425). Receiver-operating curve analysis pointed out that MPV has greater area under curve value than neutrophil rate, leukocyte and platelet count (0.73, 0.64, 0.72 and 0.49 respectively). CONCLUSION: Since the MPV value was significantly decreased in patients with PID, it may serve as an additional and even more valuable marker than leukocyte count in the diagnosis of PID.","fulltextAvailable":false,"journal":"Wiener klinische Wochenschrift","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Chronic Disease","uri":{"id":"D002908","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Contraceptives, Oral","uri":{"id":"D003276","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Platelet Count","uri":{"id":"D010976","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Control Groups","uri":{"id":"D035061","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pelvic Inflammatory Disease","uri":{"id":"D000292","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"C-Reactive Protein","uri":{"id":"D002097","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Leukocyte Count","uri":{"id":"D007958","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Area Under Curve","uri":{"id":"D019540","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Mean Platelet Volume","uri":{"id":"D063847","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anti-Inflammatory Agents","uri":{"id":"D000893","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Blood Platelets","uri":{"id":"D001792","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Contraceptive Agents","uri":{"id":"D003270","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Diagnosis","uri":{"id":"D003933","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"History","uri":{"id":"D006664","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Leukocytes","uri":{"id":"D007962","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Proteins","uri":{"id":"D011506","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Women","uri":{"id":"D014930","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Medicalization","uri":{"id":"D062528","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anticoagulants","uri":{"id":"D000925","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neutrophils","uri":{"id":"D009504","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"24958650","title":"May mean platelet volume levels be a predictor in the diagnosis of pelvic inflammatory disease?","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"To establish a method for determination contents of schizandrin, tanshinone I, cryptotanshinone, tanshinone II (A) and schizandrin B in rongxin pills. The HPLC method was performed on an Agilent C18. The mobile phase was composed of methnol and water wish gradient elution. The flow rate was 1.0 mL x min(-1). The column temperature was 30 degrees C and the detection wavelength wash 240 nm. The linear of schizandrin, tanshinone I, cryptotanshinone, Tanshinone II (A) and schizandrin B were 3.000-48.00 (r = 1.000), 3.985-63.76 (r = 0.999 9), 6.370-101.9 (r = 1.000), 8.690-139.0 (r = 0.999 9), 1.700-27.20 mg x L(-1) (r = 0.999 9), respectively. The average recoveries were 98.44%, 100.3%, 99.29%, 99.07%, 98.42%, and RSDs were 0.61%, 1.1%, 0.52%, 0.72%, 0.97%. The method is convenient, accurate and has good precision. It can be used for determination of the preparation.","fulltextAvailable":false,"journal":"Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Temperature","uri":{"id":"D013696","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Chromatography, High Pressure Liquid","uri":{"id":"D002851","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Chromatography, High Pressure Liquid","uri":{"id":"D002851","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Drugs, Chinese Herbal","uri":{"id":"D004365","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Organic Chemicals","uri":{"id":"D009930","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Reproducibility of Results","uri":{"id":"D015203","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Linear Models","uri":{"id":"D016014","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Lignans","uri":{"id":"D017705","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Phenanthrenes","uri":{"id":"D010616","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Polycyclic Compounds","uri":{"id":"D011083","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Quality Control","uri":{"id":"D011786","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cyclooctanes","uri":{"id":"D034242","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Diterpenes, Abietane","uri":{"id":"D045784","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Chromatography, High Pressure Liquid","Cyclooctanes","Diterpenes, Abietane","Drugs, Chinese Herbal","Lignans","Linear Models","Organic Chemicals","Phenanthrenes","Polycyclic Compounds","Quality Control","Reproducibility of Results"]},"pmid":"24956842","title":"[Determination of five components in rongxin pills by HPLC].","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"OBJECTIVE: To optimize the extracting technology from Angelica sinensis by central composite design-response surface methodology. METHODS: On the basis of the single factor,independent variables were ethanol concentrations, solvent ratio and ultrasonic time, while dependent variable was the OD value of extraction rates of ferulic acid and liqustilide. A two-order polynomial equation was fitted to estimate the relationship between independent and dependent variables. Response surface method was used to optimize the extracting process. RESULTS: The optimum extraction conditions for Angelica sinesis were obtained as follows: the extracting solvent was methanol concentrations of 70%, 30 fold solvent, extracting for once and for 40 minutes. The deviation between observed and predicted values was 1.23%. CONCLUSION: The result indicates that the central composite design and response surface methodology is simple, convenient and reliable for optimizing the extraction process of Angelica sinesis with higher precision.","fulltextAvailable":false,"journal":"Zhong yao cai = Zhongyaocai = Journal of Chinese medicinal materials","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Angelica sinensis","uri":{"id":"D029971","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Methanol","uri":{"id":"D000432","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Technology","uri":{"id":"D013672","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Ethanol","uri":{"id":"D000431","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Ultrasonics","uri":{"id":"D014465","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Chromatography, High Pressure Liquid","uri":{"id":"D002851","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Drugs, Chinese Herbal","uri":{"id":"D004365","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Solvents","uri":{"id":"D012997","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Reproducibility of Results","uri":{"id":"D015203","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Models, Statistical","uri":{"id":"D015233","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Plant Roots","uri":{"id":"D018517","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Methanol","uri":{"id":"D000432","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Coumaric Acids","uri":{"id":"D003373","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Technology, Pharmaceutical","uri":{"id":"D013678","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"4-Butyrolactone","uri":{"id":"D015107","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Angelica sinensis","uri":{"id":"D029971","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["4-Butyrolactone","Angelica sinensis","Chromatography, High Pressure Liquid","Coumaric Acids","Drugs, Chinese Herbal","Methanol","Models, Statistical","Plant Roots","Reproducibility of Results","Solvents","Technology, Pharmaceutical"]},"pmid":"24956828","title":"[Optimation the extracting technology of Angelica sinensis by central composite design and response surface methodology].","year":"2013"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"Objective. Guidelines on antiplatelet medication use during endoscopy are based on limited evidence. We investigate the risk of bleeding and ischemic events in patients undergoing endoscopic mucosal resection (EMR) of esophageal lesions in the setting of scheduled cessation and prompt resumption of clopidogrel. Design. Single centre retrospective review. Patients. Patients undergoing EMR of esophageal lesions. Interventions. Use of clopidogrel before EMR and resumption after EMR. Patients cease antiplatelets and anticoagulants 7 days before EMR and resume clopidogrel 2 days after EMR in average risk patients. Main Outcomes. Gastrointestinal bleeding (GIB) and ischemic events (IE) within 30 days of EMR. Results. 798 patients underwent 1716 EMR. 776 EMR were performed on patients on at least 1 antiplatelet/anticoagulant (APAC). 17 EMR were performed following clopidogrel cessation. There were 14 GIB and 2 IE. GIB risk in the setting of recent clopidogrel alone (0%) was comparable to those not on APAC (1.1%) (P = 1.0). IE risk on clopidogrel (6.3%) was higher than those not on APAC (0.1%) (P = 0.03). Limitations. Retrospective study. Conclusions. Temporary cessation of clopidogrel before EMR and prompt resumption is not associated with an increased risk of gastrointestinal bleeding but may be associated with increased ischemic events.","fulltextAvailable":false,"journal":"ISRN gastroenterology","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Retrospective Studies","uri":{"id":"D012189","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Appointments and Schedules","uri":{"id":"D001071","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Esophagitis","uri":{"id":"D004941","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hemorrhage","uri":{"id":"D006470","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Endoscopes","uri":{"id":"D019723","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Mucositis","uri":{"id":"D052016","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Medicalization","uri":{"id":"D062528","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anticoagulants","uri":{"id":"D000925","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Endoscopy","uri":{"id":"D004724","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"24944824","title":"The risk of endoscopic mucosal resection in the setting of clopidogrel use.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"OBJECTIVES: Pharmacotherapy with vitamin K antagonists (VKA) and low-molecular-weight heparins (LMWH) is a major cost driver in the treatment of venous thromboembolism (VTE). Major representatives of anticoagulants in Europe include: acenocoumarol and warfarin (VKA), enoxaparin, dalteparin, nadroparin, reviparin, parnaparin and bemiparin (LMWH). Aim of this report is to measure and critically assess the utilization of anticoagulants and other resources used in the out-patient treatment of VTE in Poland. To confront the findings with available scientific evidence on pharmacological and clinical properties of anticoagulants. MATERIALS AND METHODS: The perspectives of the National Health Fund (NHF) and the patients were adopted, descriptive statistics methods were used. The data were gathered at the NHF and the clinic specialized in treatment of coagulation disorders. RESULTS: Non-pharmacological costs of treatment were for the NHF 1.6 times higher with VKA than with LMWH. Daily cost of pharmacotherapy with LMWH turned out higher than with VKA (234 times for the NHF, 42 times per patient). Within both LMWH and VKA the reimbursement due for the daily doses of a particular medication altered in the manner inversely proportional to the level of patient co-payment. Utilization of long-marketed and cheap VKA was dominated by LMWH, when assessed both through the monetary measures and by the actual volume of sales. Pharmaceutical reimbursement policy favored the more expensive equivalents among VKA and LMWH, whereas in the financial terms the patients were far better off when remaining on a more expensive alternative. CONCLUSIONS: The pharmaceutical pricing and reimbursement policy of the state should be more closely related to the pharmacological properties of anticoagulants.","fulltextAvailable":false,"journal":"European review for medical and pharmacological sciences","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Health Care Costs","uri":{"id":"D017048","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Drug and Narcotic Control","uri":{"id":"D004335","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Vitamin K","uri":{"id":"D014812","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Drug and Narcotic Control","uri":{"id":"D004335","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Heparin, Low-Molecular-Weight","uri":{"id":"D006495","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Venous Thromboembolism","uri":{"id":"D054556","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Drug Therapy","uri":{"id":"D004358","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Europe","uri":{"id":"D005060","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Heparin","uri":{"id":"D006493","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Outpatients","uri":{"id":"D010045","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Poland","uri":{"id":"D011044","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Specialization","uri":{"id":"D013038","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Thromboembolism","uri":{"id":"D013923","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Vitamins","uri":{"id":"D014815","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Research Report","uri":{"id":"D058028","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Medicalization","uri":{"id":"D062528","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Acenocoumarol","uri":{"id":"D000074","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anticoagulants","uri":{"id":"D000925","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Commerce","uri":{"id":"D003132","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Heparin, Low-Molecular-Weight","uri":{"id":"D006495","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Warfarin","uri":{"id":"D014859","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Nadroparin","uri":{"id":"D017762","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Enoxaparin","uri":{"id":"D017984","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Dalteparin","uri":{"id":"D017985","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"24943977","title":"Are pharmacological properties of anticoagulants reflected in pharmaceutical pricing and reimbursement policy? Out-patient treatment of venous thromboembolism and utilization of anticoagulants in Poland.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"PURPOSE: An overview of the responses to some of the most frequently asked questions regarding axitinib administration and dosage modifications used in clinical practice are presented. SUMMARY: Axitinib was approved for second-line treatment of advanced renal cell carcinoma by the Food and Drug Administration on January 27, 2012. Inquiries received over the first six months after the approval date were reviewed. A large number of questions were related to administration of axitinib in different patient populations or in patients with various comorbidities, such as its (1) use in patients unable to swallow oral medication or administration of axitinib via a nasogastric tube, (2) use in patients with renal or hepatic impairment, (3) central nervous system penetration and use in patients with brain metastases, (4) drug interactions, particularly with anticoagulants, and (5) dosage modifications. Responses to these inquiries were provided based on the published literature or from data on file from the manufacturer. The dosage of axitinib can be adjusted for use in patients with hepatic impairment or in patients who cannot otherwise tolerate the usual regimen. Patients taking concomitant warfarin can also take axitinib, and patients who cannot swallow oral medications can receive a liquid formulation of the drug, though its efficacy and comparability to the tablet formulation has not been tested. CONCLUSION: Based on the published literature and company data on file, the axitinib dosage may be modified to accommodate patients with renal or hepatic impairment, who cannot swallow oral medication, are receiving concomitant warfarin, or who cannot otherwise tolerate the standard dosage regimen. For patients who cannot swallow, an oral suspension can be prepared because crushing axitinib is not recommended.","fulltextAvailable":false,"journal":"American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Automatic Data Processing","uri":{"id":"D001330","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Central Nervous System","uri":{"id":"D002490","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Drug Interactions","uri":{"id":"D004347","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Nervous System","uri":{"id":"D009420","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Carcinoma, Renal Cell","uri":{"id":"D002292","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Carcinoma","uri":{"id":"D002277","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pharmaceutical Preparations","uri":{"id":"D004364","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hepatitis","uri":{"id":"D006505","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Literature","uri":{"id":"D008091","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neoplasm Metastasis","uri":{"id":"D009362","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Publishing","uri":{"id":"D011643","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Comorbidity","uri":{"id":"D015897","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Penetrance","uri":{"id":"D019683","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Medicalization","uri":{"id":"D062528","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anticoagulants","uri":{"id":"D000925","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Filing","uri":{"id":"D005371","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Suspensions","uri":{"id":"D013535","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Warfarin","uri":{"id":"D014859","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"24939498","title":"Common questions regarding clinical use of axitinib in advanced renal cell carcinoma.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"This study was aimed to evaluate the effectiveness of solution form of 17% ethylenediaminetetraacetic acid (EDTA) on removing smear layer of root canals at different exposure time periods and to provide scientific basis for EDTA as a choice of root canal irrigation in clinical practice. Twenty-five single-rooted teeth were randomly divided into 5 groups: control group (group A) was given 2.5% NaOCl, and 4 experimental groups were given 2.5% NaOCl and 17% EDTA, including groups B, C, D and E with exposure time of 1, 3, 5 and 7 min, respectively. After preparation of the root canals, the teeth were split along their longitudinal axis, and the root sections were examined under scanning electron microscope for evaluation of smear layer removal and erosion on the surface of the root canal walls. The specimens in group B showed presence of smear layer on the walls of the root canal with no statistical difference from that in group A (P>0.05). In groups C and D, partial removal of smear layer was obtained, and there was no significant difference between the two groups (P>0.05), but there was significant difference in removal of smear layer between group C and group B (P<0.05). Root canal walls in group E specimens showed almost complete removal of smear layer, and the removal of smear layer was significantly different from that in group D (P<0.01). There was no significant change in the structure of the surface of root canal for each sample. It was concluded that combined irrigation with 17% EDTA and 2.5% NaOCl could remove the smear layer with no significant alteration in dentinal structure when the chelating agent was applied for 7 min. At 3 and 5 min of application, partial removal of smear layer was observed and at 1 min negligible removal of smear layer was achieved.","fulltextAvailable":false,"journal":"Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Control Groups","uri":{"id":"D035061","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Chelating Agents","uri":{"id":"D002614","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Dental Pulp Cavity","uri":{"id":"D003786","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Edetic Acid","uri":{"id":"D004492","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Smear Layer","uri":{"id":"D016369","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Axis","uri":{"id":"D001368","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Edetic Acid","uri":{"id":"D004492","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Electronics","uri":{"id":"D004581","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Electrons","uri":{"id":"D004583","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Evaluation Studies as Topic","uri":{"id":"D005069","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Chelating Agents","uri":{"id":"D002614","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Malpractice","uri":{"id":"D008318","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Tooth","uri":{"id":"D014070","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Tooth Eruption","uri":{"id":"D014078","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Adolescent","uri":{"id":"D000293","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Humans","uri":{"id":"D006801","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Microscopy, Electron, Scanning","uri":{"id":"D008855","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Time Factors","uri":{"id":"D013997","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Treatment Outcome","uri":{"id":"D016896","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Young Adult","uri":{"id":"D055815","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Bicuspid","uri":{"id":"D001641","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Chelating Agents","uri":{"id":"D002614","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Edetic Acid","uri":{"id":"D004492","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Root Canal Irrigants","uri":{"id":"D012388","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Sodium Hypochlorite","uri":{"id":"D012973","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Solutions","uri":{"id":"D012996","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Smear Layer","uri":{"id":"D016369","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Root Canal Preparation","uri":{"id":"D018915","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Adolescent","Bicuspid","Chelating Agents","Edetic Acid","Humans","Microscopy, Electron, Scanning","Root Canal Irrigants","Root Canal Preparation","Smear Layer","Sodium Hypochlorite","Solutions","Time Factors","Treatment Outcome","Young Adult"]},"pmid":"24939310","title":"Efficacy of solution form of ethylenediaminetetraacetic acid on removing smear layer of root canal at different exposure time In Vitro.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"Heparin may cause hyperkalemia by blocking aldosterone biosynthesis in the adrenal gland. Dizygotic twin sisters were born by Cesarean section at 25 weeks' gestation. The younger sister developed acute hyperkalemia (7.4 mEq/L) at 10 days of age. At the time of the development of the hyperkalemia, there were no signs of systemic infection, cardiac or renal failure, adrenal insufficiency, or sudden anemia. She was receiving no medication other than heparin to maintain the vascular catheter. Heparin was changed to dalteparin at 12 days of age. The plasma potassium level normalized after 14 days of age. After this change, the urinary potassium concentration and the aldosterone and plasma renin activity increased. The urinary aldosterone levels before and after the changes were 31 and 183 pg/μg creatinine, respectively. When heparin-induced hyperkalemia is suspected, stopping the heparin administration facilitates diagnosis and treatment; if anticoagulant therapy is required; one treatment option is changing from unfractionated heparin to low-molecular-weight heparin.","fulltextAvailable":false,"journal":"Journal of clinical research in pediatric endocrinology","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Attention Deficit Disorder with Hyperactivity","uri":{"id":"D001289","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Abstracting and Indexing as Topic","uri":{"id":"D000043","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Child","uri":{"id":"D002648","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Feedback","uri":{"id":"D005246","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Gambling","uri":{"id":"D005715","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Reward","uri":{"id":"D012201","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Punishment","uri":{"id":"D011678","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"24932609","title":"Heparin-induced hyperkalemia in an extremely-low-birth-weight infant: a case report.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"OBJECT: Screening of blunt vertebral artery (VA) injuries has increased since research has shown that they occur at a higher incidence than originally reported. Grade 1 and 2 injuries are the most common form of blunt VA injury. Proper screening, management, and follow-up of these injuries remain controversial. In this report, imaging, progression, treatment, and outcomes of Grade 1 and 2 blunt VA injuries were analyzed to better define their natural history and to establish a rational management plan based upon their risk of progression and cerebral infarct. METHODS: A retrospective review of all blunt traumatic carotid artery and VA injuries from December 2003 to April 2013 was performed. For the purposes of this report, focus was given to Grade 1 and 2 VA injuries. Grade 1 injuries were defined as a vessel lumen stenosis of less than 25%, and Grade 2 injuries were defined as vessel lumen stenosis between 25% and 50%. Demographic information, radiological imaging, number of images performed per individual, length of radiological follow-up, radiological outcome at the end of follow-up, treatment provided, and documentation of stroke or transient ischemic attack were recorded. RESULTS: One hundred eighty-seven Grade 1 and 2 VA injuries in 143 patients were identified. Of these 143 patients, 120 with 152 Grade 1 or 2 blunt VA injuries were available for follow-up. The mean duration of follow-up was 40 days. Repeat imaging showed that 148 (97.4%) Grade 1 or 2 blunt VA injuries were stable, improved, or resolved on final follow-up imaging. Seventy-nine patients (66%) were treated with aspirin, whereas 35 patients (29%) received no treatment. The remaining patients were treated with other antiplatelet agents or anticoagulant medication. Neuroimaging demonstrated 2 cases (1.7%) with posterior circulation infarcts that were believed to be related to their blunt VA injuries, both of which occurred during the initial hospitalization and within the first 4 days after injury. CONCLUSIONS: Although follow-up imaging showed progressive worsening without radiological improvement in only a small number of patients with low-grade blunt VA injuries, these findings did not correlate with adverse clinical outcome. The posttraumatic cerebral infarction rate of 1.7% may be overestimated, and the use of acetylsalicylic acid or other antiplatelet or anticoagulant medication did not correlate with radiological changes or rate of cerebral infarction. While these data suggest the possibility that these low-grade VA injuries may not require treatment or follow-up, future prospective studies are needed to make conclusive changes related to management.","fulltextAvailable":false,"journal":"Journal of neurosurgery","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Treatment Outcome","uri":{"id":"D016896","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anticoagulants","uri":{"id":"D000925","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Wounds, Nonpenetrating","uri":{"id":"D014949","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Carotid Arteries","uri":{"id":"D002339","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Platelet Aggregation Inhibitors","uri":{"id":"D010975","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prospective Studies","uri":{"id":"D011446","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Aspirin","uri":{"id":"D001241","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cerebral Infarction","uri":{"id":"D002544","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Ischemic Attack, Transient","uri":{"id":"D002546","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Trauma Centers","uri":{"id":"D014193","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Vertebral Artery","uri":{"id":"D014711","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Natural History","uri":{"id":"D019021","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arteries","uri":{"id":"D001158","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Constriction, Pathologic","uri":{"id":"D003251","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Demography","uri":{"id":"D003710","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Forecasting","uri":{"id":"D005544","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"History","uri":{"id":"D006664","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hospitalization","uri":{"id":"D006760","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hospitals","uri":{"id":"D006761","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Vertebrates","uri":{"id":"D014714","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Wounds and Injuries","uri":{"id":"D014947","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Incidence","uri":{"id":"D015994","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Nature","uri":{"id":"D019368","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Research Report","uri":{"id":"D058028","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neuroimaging","uri":{"id":"D059906","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Medicalization","uri":{"id":"D062528","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anticoagulants","uri":{"id":"D000925","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Aspirin","uri":{"id":"D001241","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Documentation","uri":{"id":"D004282","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Infarction","uri":{"id":"D007238","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"24905561","title":"Clinical and radiological outcomes following traumatic Grade 1 and 2 vertebral artery injuries: a 10-year retrospective analysis from a Level 1 trauma center.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"BACKGROUND: Warfarin is an oral anticoagulant used in the long-term treatment/prevention of venothromboembolic disease. Patients undergoing elective surgical and non-surgical procedures may require temporary warfarin discontinuation followed by reinitiation after their procedure. Because little information is available regarding best methods for warfarin reinitiation, we investigated current practices to inform management decisions. METHODS: Subjects were required to have a known and stable warfarin dose prior to discontinuation, which was operationalized by requiring, within 7-days prior to discontinuation, that they have at least one INR in therapeutic range (2.0-3.5), no INR(s) out of range, and no more than a 15% change in warfarin dose. Stable dose prior to discontinuation was defined as the average daily dose received in the 7-days immediately prior to discontinuation. Reinitiation dose was defined as the average daily dose received in the first 3 days after warfarin was restarted. Subjects were divided into three groups based on whether they received approximately the same, higher, or lower dose at reinitiation and were also grouped by calendar time into three distinct periods that reflected differing levels of availability of electronic and patient care data that may impact reinitiation dose decisions. These groupings facilitated analyses and descriptions of trends in reinitiation dosing and supported other analyses, including tests for association between dose group and selected subject demographic, clinical, medication and hospitalization measures. All study data were abstracted from Marshfield Clinic electronic patient care and administrative databases and electronic patient care databases from Marshfield St Joseph Hospital. RESULTS: We identified 205 subjects with warfarin temporarily discontinued between 1994 and 2012: 99 subjects in same dose group, 32 subjects in the low group, and 74 subjects in the high group. Because relatively wide differences were observed in the proportion of same dose subjects during more recent years (2007-2012) compared to earlier years (54% vs 35%), we focused our analyses on this recent period, which included 140 subjects. Review of physician notes and other documents yielded virtually no information about reasons for reinitiation dose decisions. In addition, tests for association between reinitiation dose group and subject demographic, clinical, medication and hospital measures were uniformly uninformative. CONCLUSIONS: We observed varied dosing strategies for reinitiating patients on warfarin and an apparent trend toward reinitiating patients on same dose in more recent years. However we could not associate dosing strategy with specific patient demographic, clinical, medication or hospital factors. Many factors influence whether a physician reinitiates a patient at a different dose than his/her prior stable warfarin dose. However, in the absence of clinical indications for modification, we believe patients with a previously established effective dose should be reinitiated at that same dose following temporary warfarin discontinuation.","fulltextAvailable":false,"journal":"Clinical medicine & research","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patient Care","uri":{"id":"D005791","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Information Management","uri":{"id":"D019451","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Abstracting and Indexing as Topic","uri":{"id":"D000043","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Demography","uri":{"id":"D003710","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Electronics","uri":{"id":"D004581","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Electrons","uri":{"id":"D004583","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hospitalization","uri":{"id":"D006760","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hospitals","uri":{"id":"D006761","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Methods","uri":{"id":"D008722","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Physicians","uri":{"id":"D010820","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Therapeutics","uri":{"id":"D013812","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Medicalization","uri":{"id":"D062528","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anticoagulants","uri":{"id":"D000925","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Warfarin","uri":{"id":"D014859","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"International Normalized Ratio","uri":{"id":"D019934","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"24899695","title":"Reinitiating Warfarin: Relationships Between Dose and Selected Patient, Clinical and Hospital Measures.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"Thromboembolic diseases affect a significant proportion of older adults; however, due to the risks and associated adverse events with anticoagulation therapy, this population may be less likely to receive the best care. Among anticoagulant-related events within the nursing home, most involve oral anticoagulant agents and occur due to deficiencies in monitoring. With the recent approvals of new oral anticoagulant agents dabigatran, rivaroxaban, and apixaban, more options are now available for treating thrombotic disorders. Ensuring that all members of the health care team are aware of the risks and benefits of these agents is paramount to improving the monitoring as well as safety in older adults who are at greatest risk for adverse events.","fulltextAvailable":false,"journal":"Journal of gerontological nursing","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Health Care","uri":{"id":"health_care_category","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Delivery of Health Care","uri":{"id":"D003695","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Home Nursing","uri":{"id":"D006701","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Long-Term Care","uri":{"id":"D008134","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Nursing Homes","uri":{"id":"D009735","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Risk Assessment","uri":{"id":"D018570","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Nurses, Community Health","uri":{"id":"D064691","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anticoagulants","uri":{"id":"D000925","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patient Care Team","uri":{"id":"D010348","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Adult","uri":{"id":"D000328","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Awareness","uri":{"id":"D001364","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Nurses","uri":{"id":"D009726","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Nursing","uri":{"id":"D009729","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Safety","uri":{"id":"D012449","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Thromboembolism","uri":{"id":"D013923","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Medicalization","uri":{"id":"D062528","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anticoagulants","uri":{"id":"D000925","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Aged","uri":{"id":"D000368","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Humans","uri":{"id":"D006801","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anticoagulants","uri":{"id":"D000925","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Geriatric Nursing","uri":{"id":"D005851","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Long-Term Care","uri":{"id":"D008134","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Drug Monitoring","uri":{"id":"D016903","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Aged","Anticoagulants","Drug Monitoring","Geriatric Nursing","Humans","Long-Term Care"]},"pmid":"24892311","title":"Anticoagulation in long-term care: how can we improve medication monitoring?","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"PURPOSE: To evaluate the effect of QMix and other conventional endodontic irrigants on the micropush-out bond strength of Biodentine (BD) and white mineral trioxide aggregate (WMTA). MATERIALS AND METHODS: One hundred eighty midroot dentin slices with a thickness of 1.0 mm were prepared. BD and WMTA were placed inside the lumens of the root slices (n = 90). Then the specimens of each material were divided into 6 groups (n = 15) according to irrigation solution (saline, 5.25% NaOCl, 2% CHX, 17% EDTA, or QMix) immersed in the same for 30 min. For the control group, a wet cotton pellet was placed over the specimen. After that, the micropush-out bond strength was determined using a universal testing machine, and the bond failure mode was determined using a stereomicroscope. The morphological microstructures of specimens were evaluated with scanning electron microscopy (SEM). Data were analyzed using ANOVA and Tukey's post-hoc test. RESULTS: BD revealed higher bond strength than WMTA (p < 0.05). WMTA was significantly affected after exposure to 2% CHX solution. QMix irrigant did not compromise the bond strength of BD or WMTA. Most failures for BD were cohesive, while for WMTA, adhesive failures were the predominant type. A substantial change in the microstructure of BD and WMTA occurred after exposure to different irrigation solutions. CONCLUSIONS: QMix did not affect the bond strength of BD or WMTA. BD showed higher resistance than WMTA to dislodgement forces from root dentin.","fulltextAvailable":false,"journal":"The journal of adhesive dentistry","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Microscopy, Electron","uri":{"id":"D008854","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Microscopy, Electron, Scanning","uri":{"id":"D008855","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Control Groups","uri":{"id":"D035061","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Adhesiveness","uri":{"id":"D000268","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Adhesives","uri":{"id":"D000269","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Analysis of Variance","uri":{"id":"D000704","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Edetic Acid","uri":{"id":"D004492","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Electronics","uri":{"id":"D004581","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Electrons","uri":{"id":"D004583","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Evaluation Studies as Topic","uri":{"id":"D005069","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Microscopy","uri":{"id":"D008853","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Minerals","uri":{"id":"D008903","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Universities","uri":{"id":"D014495","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"European Continental Ancestry Group","uri":{"id":"D044465","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Salinity","uri":{"id":"D054712","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Endodontics","uri":{"id":"D004708","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Humans","uri":{"id":"D006801","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Microscopy, Electron, Scanning","uri":{"id":"D008855","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Polymers","uri":{"id":"D011108","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Sodium Chloride","uri":{"id":"D012965","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Stress, Mechanical","uri":{"id":"D013314","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Surface Properties","uri":{"id":"D013499","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Temperature","uri":{"id":"D013696","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Time Factors","uri":{"id":"D013997","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Adhesiveness","uri":{"id":"D000268","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Biguanides","uri":{"id":"D001645","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Dental Bonding","uri":{"id":"D001840","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Chlorhexidine","uri":{"id":"D002710","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Dental Pulp Cavity","uri":{"id":"D003786","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Dental Stress Analysis","uri":{"id":"D003799","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Dentin","uri":{"id":"D003804","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Drug Combinations","uri":{"id":"D004338","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Edetic Acid","uri":{"id":"D004492","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Humidity","uri":{"id":"D006813","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Materials Testing","uri":{"id":"D008422","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Oxides","uri":{"id":"D010087","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Root Canal Filling Materials","uri":{"id":"D012387","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Root Canal Irrigants","uri":{"id":"D012388","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Sodium Hypochlorite","uri":{"id":"D012973","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Aluminum Compounds","uri":{"id":"D017607","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Calcium Compounds","uri":{"id":"D017610","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Silicates","uri":{"id":"D017640","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Adhesiveness","Aluminum Compounds","Biguanides","Calcium Compounds","Chlorhexidine","Dental Bonding","Dental Pulp Cavity","Dental Stress Analysis","Dentin","Drug Combinations","Edetic Acid","Humans","Humidity","Materials Testing","Microscopy, Electron, Scanning","Oxides","Polymers","Root Canal Filling Materials","Root Canal Irrigants","Silicates","Sodium Chloride","Sodium Hypochlorite","Stress, Mechanical","Surface Properties","Temperature","Time Factors"]},"pmid":"24892122","title":"Influence of QMix irrigant on the micropush-out bond strength of biodentine and white mineral trioxide aggregate.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"BACKGROUND: Timely and appropriate use of antiplatelet and anticoagulant therapies has been shown to improve outcomes among ST-segment elevation myocardial infarction (STEMI) patients but has not been well described in patients transferred for primary percutaneous coronary intervention (PCI). METHODS: We examined 16,801 (26%) transfer and 47,329 direct-arrival STEMI patients treated with primary PCI at 441 Acute Coronary Treatment and Intervention Outcomes Network Registry-Get With The Guidelines hospitals. Medication use was compared between transfer and direct-arrival patients to determine if these therapies were delayed or dosed in excess. RESULTS: Although transfer patients were more likely to receive antiplatelet and anticoagulant therapies before catheterization, they had longer delays to initiation of heparin (35 vs. 25 minutes), clopidogrel (119 vs. 84 minutes), and glycoprotein IIb/IIIa inhibitor (107 vs. 60 minutes, P < .0001 for both). Administration of low-molecular-weight heparin and glycoprotein IIb/IIIa inhibitor at the STEMI-referring hospital was associated with longer delays to reperfusion compared with deferred administration at the STEMI-receiving hospital, whereas early use of unfractionated heparin was not. Among treated patients, those transferred were more likely to receive excess heparin dosing (adjusted odds ratio [OR] 1.28 [95% CI 1.04-1.58] for unfractionated heparin, adjusted OR 1.54 [95% CI 1.09-2.18] for low-molecular-weight heparin) and are associated with higher risks of major bleeding complications (adjusted OR 1.10, 95% CI 1.03-1.17). CONCLUSIONS: ST-segment elevation myocardial infarction patients transferred for primary PCI in community practice are at risk for delayed and excessively dosed antithrombotic therapy, highlighting the need for continued quality improvement to maximize the appropriate use of these important adjunctive therapies.","fulltextAvailable":false,"journal":"American heart journal","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patient Transfer","uri":{"id":"D010360","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Odds Ratio","uri":{"id":"D016017","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Quality Improvement","uri":{"id":"D058996","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Heparin","uri":{"id":"D006493","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Heparin, Low-Molecular-Weight","uri":{"id":"D006495","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Myocardial Infarction","uri":{"id":"D009203","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patient Transfer","uri":{"id":"D010360","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Platelet Glycoprotein GPIIb-IIIa Complex","uri":{"id":"D019039","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Percutaneous Coronary Intervention","uri":{"id":"D062645","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Glycoproteins","uri":{"id":"D006023","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hemorrhage","uri":{"id":"D006470","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Heparin","uri":{"id":"D006493","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hospitalization","uri":{"id":"D006760","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hospitals","uri":{"id":"D006761","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Residence Characteristics","uri":{"id":"D012111","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Reperfusion","uri":{"id":"D015424","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Complicity","uri":{"id":"D028661","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Medicalization","uri":{"id":"D062528","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anticoagulants","uri":{"id":"D000925","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Catheterization","uri":{"id":"D002404","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Infarction","uri":{"id":"D007238","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Aged","uri":{"id":"D000368","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Female","uri":{"id":"D005260","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Humans","uri":{"id":"D006801","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Male","uri":{"id":"D008297","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Middle Aged","uri":{"id":"D008875","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Myocardial Infarction","uri":{"id":"D009203","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Peptide Fragments","uri":{"id":"D010446","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Retrospective Studies","uri":{"id":"D012189","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cohort Studies","uri":{"id":"D015331","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anticoagulants","uri":{"id":"D000925","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Aspirin","uri":{"id":"D001241","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Heparin","uri":{"id":"D006493","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Heparin, Low-Molecular-Weight","uri":{"id":"D006495","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hirudins","uri":{"id":"D006629","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patient Transfer","uri":{"id":"D010360","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Platelet Aggregation Inhibitors","uri":{"id":"D010975","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pyridines","uri":{"id":"D011725","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Recombinant Proteins","uri":{"id":"D011994","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Ticlopidine","uri":{"id":"D013988","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Angioplasty, Balloon, Coronary","uri":{"id":"D015906","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Practice Guidelines as Topic","uri":{"id":"D017410","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Platelet Glycoprotein GPIIb-IIIa Complex","uri":{"id":"D019039","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Guideline Adherence","uri":{"id":"D019983","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Early Medical Intervention","uri":{"id":"D061345","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Time-to-Treatment","uri":{"id":"D061665","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Aged","Angioplasty, Balloon, Coronary","Anticoagulants","Aspirin","Cohort Studies","Early Medical Intervention","Female","Guideline Adherence","Heparin","Heparin, Low-Molecular-Weight","Hirudins","Humans","Male","Middle Aged","Myocardial Infarction","Patient Transfer","Peptide Fragments","Platelet Aggregation Inhibitors","Platelet Glycoprotein GPIIb-IIIa Complex","Practice Guidelines as Topic","Pyridines","Recombinant Proteins","Retrospective Studies","Ticlopidine","Time-to-Treatment"]},"pmid":"24890532","title":"The quality of antiplatelet and anticoagulant medication administration among ST-segment elevation myocardial infarction patients transferred for primary percutaneous coronary intervention.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"BACKGROUND: Dabigatran is a novel oral anti-coagulant (NOAC) that reduces risk of stroke in patients with non-valvular atrial fibrillation (NVAF). It does not require routine monitoring with laboratory testing which may have an adverse impact on adherence. We aimed to describe adherence to dabigatran in the first year after initiation and assess the association between non-adherence to dabigatran and clinical outcomes in a large integrated healthcare system. METHODS: We studied a national cohort of 5,376 patients with NVAF, initiated on dabigatran between October-2010 and September-2012 at all Veterans Affairs hospitals. Adherence to dabigatran was calculated as proportion of days covered (PDC) and association between PDC and outcomes was assessed using standard regression techniques. RESULTS: Mean age of the study cohort was 71.3 ± 9.7 years; 98.3% were men and mean CHADS2 score was 2.4 ± 1.2 (mean CHA2DS2VASc score 3.2 ± 1.4). Median PDC was 94% (IQR 76%-100%; mean PDC 84% ± 22%) over a median follow-up of 244 days (IQR 140-351). A total of 1,494 (27.8%) patients had a PDC <80% and were classified as non-adherent. After multivariable adjustment, lower adherence was associated with increased risk for combined all-cause mortality and stroke (HR 1.13, 95% CI 1.07-1.19 per 10% decrease in PDC). Adherence to dabigatran was not associated with non-fatal bleeding or myocardial infarction. CONCLUSIONS: In the year after initiation, adherence to dabigatran for a majority of patients is very good. However, 28% of patients in our cohort had poor adherence. Furthermore, lower adherence to dabigatran was associated with increased adverse outcomes. Concerted efforts are needed to optimize adherence to NOACs.","fulltextAvailable":false,"journal":"American heart journal","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"United States Department of Veterans Affairs","uri":{"id":"D014493","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Outcome Assessment (Health Care)","uri":{"id":"D017063","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hospitals, Veterans","uri":{"id":"D006787","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Systems Integration","uri":{"id":"D018511","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Atrial Fibrillation","uri":{"id":"D001281","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Delivery of Health Care","uri":{"id":"D003695","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cohort Studies","uri":{"id":"D015331","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Veterans Health","uri":{"id":"D058014","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Myocardial Infarction","uri":{"id":"D009203","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Delivery of Health Care","uri":{"id":"D003695","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hemorrhage","uri":{"id":"D006470","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hospitalization","uri":{"id":"D006760","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hospitals","uri":{"id":"D006761","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Laboratories","uri":{"id":"D007753","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Men","uri":{"id":"D008571","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Mortality","uri":{"id":"D009026","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Veterans","uri":{"id":"D014728","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anticoagulants","uri":{"id":"D000925","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Infarction","uri":{"id":"D007238","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Aged","uri":{"id":"D000368","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Aged, 80 and over","uri":{"id":"D000369","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Female","uri":{"id":"D005260","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Humans","uri":{"id":"D006801","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Longitudinal Studies","uri":{"id":"D008137","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Male","uri":{"id":"D008297","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Middle Aged","uri":{"id":"D008875","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Myocardial Infarction","uri":{"id":"D009203","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Retrospective Studies","uri":{"id":"D012189","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Risk Factors","uri":{"id":"D012307","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"United States","uri":{"id":"D014481","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cohort Studies","uri":{"id":"D015331","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Multivariate Analysis","uri":{"id":"D015999","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Treatment Outcome","uri":{"id":"D016896","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Antithrombins","uri":{"id":"D000991","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Atrial Fibrillation","uri":{"id":"D001281","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Benzimidazoles","uri":{"id":"D001562","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hemorrhage","uri":{"id":"D006470","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"United States Department of Veterans Affairs","uri":{"id":"D014493","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"beta-Alanine","uri":{"id":"D015091","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Stroke","uri":{"id":"D020521","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Medication Adherence","uri":{"id":"D055118","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Aged","Aged, 80 and over","Antithrombins","Atrial Fibrillation","Benzimidazoles","Cohort Studies","Female","Hemorrhage","Humans","Longitudinal Studies","Male","Medication Adherence","Middle Aged","Multivariate Analysis","Myocardial Infarction","Retrospective Studies","Risk Factors","Stroke","Treatment Outcome","United States","United States Department of Veterans Affairs","beta-Alanine"]},"pmid":"24890529","title":"Adherence to dabigatran therapy and longitudinal patient outcomes: insights from the veterans health administration.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"INTRODUCTION: Bearing in mind that many promising drug candidates have the problem of reaching their target site, the concept of advanced drug delivery can play a significant complementary role in shaping modern medicine. Among other nanoscale drug carriers, superparamagnetic iron oxide nanoparticles (SPIONs) have shown great potential in nanomedicine. The intrinsic properties of SPIONs, such as inherent magnetism, broad safety margin and the availability of methods for fabrication and surface engineering, pave the way for diverse biomedical applications. SPIONs can achieve the highest drug targeting efficiency among carriers, since an external magnetic field locally applied to the target organ enhances the accumulation of magnetic nanoparticles in the drug site of action. Moreover, theranostic multifunctional SPIONs make simultaneous delivery and imaging possible. In spite of these favorable qualities, there are some toxicological concerns, such as oxidative stress, unpredictable cellular responses and induction of signaling pathways, alteration in gene expression profiles and potential disturbance in iron homeostasis, that need to be carefully considered. Besides, the protein corona at the surface of the SPIONs may induce few shortcomings such as reduction of SPIONs targeting efficacy. AREAS COVERED: In this review, we will present recent developments of SPIONs as theranostic agents. The article will further address some barriers on drug delivery using SPIONs. EXPERT OPINION: One of the major success determinants in targeted in vivo drug delivery using SPIONs is the adequacy of magnetic gradient. This can be partially achieved by using superconducting magnets, local implantation of magnets and application of magnetic stents. Other issues that must be considered include the pharmacokinetics and in vivo fate of SPIONs, their biodegradability, biocompatibility, potential side effects and the crucial impact of protein corona on either drug release profile or mistargeting. Surface modification of SPIONs can open up the possibility of drug delivery to intracellular organelles, drug delivery across the blood-brain barrier, modifying metabolic diseases and a variety of other multimodal and/or theranostic applications.","fulltextAvailable":false,"journal":"Expert opinion on drug delivery","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Drug Carriers","uri":{"id":"D004337","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Gene Expression","uri":{"id":"D015870","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Drug Delivery Systems","uri":{"id":"D016503","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Oxidative Stress","uri":{"id":"D018384","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Gene Expression Profiling","uri":{"id":"D020869","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Transcriptome","uri":{"id":"D059467","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Magnetic Fields","uri":{"id":"D060526","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Blood-Brain Barrier","uri":{"id":"D001812","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Metabolic Diseases","uri":{"id":"D008659","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"History, Modern 1601-","uri":{"id":"D049711","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pharmaceutical Preparations","uri":{"id":"D004364","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Genes","uri":{"id":"D005796","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Homeostasis","uri":{"id":"D006706","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Medicine","uri":{"id":"D008511","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Metabolism","uri":{"id":"D008660","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Oxides","uri":{"id":"D010087","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pharmacokinetics","uri":{"id":"D010599","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Proteins","uri":{"id":"D011506","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Safety","uri":{"id":"D012449","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Therapeutics","uri":{"id":"D013812","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Stents","uri":{"id":"D015607","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Nanoparticles","uri":{"id":"D053758","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Organelles","uri":{"id":"D015388","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Nanomedicine","uri":{"id":"D050997","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Mindfulness","uri":{"id":"D064866","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Animals","uri":{"id":"D000818","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Humans","uri":{"id":"D006801","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Dextrans","uri":{"id":"D003911","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Diagnostic Imaging","uri":{"id":"D003952","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Drug Carriers","uri":{"id":"D004337","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Drug Delivery Systems","uri":{"id":"D016503","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Nanomedicine","uri":{"id":"D050997","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Magnetite Nanoparticles","uri":{"id":"D058185","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Magnetic Fields","uri":{"id":"D060526","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Animals","Dextrans","Diagnostic Imaging","Drug Carriers","Drug Delivery Systems","Humans","Magnetic Fields","Magnetite Nanoparticles","Nanomedicine"]},"pmid":"24870351","title":"Superparamagnetic iron oxide nanoparticles for delivery of therapeutic agents: opportunities and challenges.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"BACKGROUND: Patients in nursing homes are often treated with many drugs concurrently (polypharmacy), which increases the risk of drug-drug interactions. The purpose of this study was to assess the incidence of such interactions in nursing home patients. MATERIAL AND METHOD: The study was based on medication lists collected from all nursing home patients in Trondheim Municipality in the course of one day in 2010. Data from the medication lists was linked to the Norwegian interaction database, Druid. RESULTS: The study included 1241 nursing home patients. Patients used an average of 9.8 drugs regularly or as needed, with a variation of from 0 to 30. In all, 15 patients (1.2%) used drug combinations that are classified in Druid as «should not be combined», while 592 (47.7%) used combinations classified as «take precautions». There was a clear relationship between the number of drugs prescribed and the risk of interactions. The three most common drug combinations in the group «should not be combined» were warfarin and non-steroidal anti-inflammatory drugs, clopidogrel and proton pump inhibitors, and anti-Parkinson medication and dopamine antagonists. CONCLUSION: The incidence of serious drug-drug interactions among nursing home patients in Trondheim Municipality is low. Polypharmacy is widespread, and the incidence of drug interactions where precautions should be taken is high. As nursing home patients are a vulnerable group with respect to drug interactions, the risk of interactions should be carefully considered when treatment with a new drug is started.","fulltextAvailable":false,"journal":"Tidsskrift for den Norske lægeforening : tidsskrift for praktisk medicin, ny række","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Drug Interactions","uri":{"id":"D004347","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Home Nursing","uri":{"id":"D006701","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Nursing Homes","uri":{"id":"D009735","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Proton Pumps","uri":{"id":"D017494","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Nurses, Community Health","uri":{"id":"D064691","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Drug Combinations","uri":{"id":"D004338","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Dopamine Antagonists","uri":{"id":"D018492","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Proton Pump Inhibitors","uri":{"id":"D054328","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anti-Inflammatory Agents","uri":{"id":"D000893","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pharmaceutical Preparations","uri":{"id":"D004364","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Nurses","uri":{"id":"D009726","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Nursing","uri":{"id":"D009729","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Protons","uri":{"id":"D011522","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Incidence","uri":{"id":"D015994","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Medicalization","uri":{"id":"D062528","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Dopamine","uri":{"id":"D004298","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Warfarin","uri":{"id":"D014859","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Polypharmacy","uri":{"id":"D019338","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Humans","uri":{"id":"D006801","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Databases, Factual","uri":{"id":"D016208","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anti-Inflammatory Agents, Non-Steroidal","uri":{"id":"D000894","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Antiparkinson Agents","uri":{"id":"D000978","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Drug Interactions","uri":{"id":"D004347","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Nursing Homes","uri":{"id":"D009735","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Platelet Aggregation Inhibitors","uri":{"id":"D010975","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Drug Prescriptions","uri":{"id":"D011307","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Ticlopidine","uri":{"id":"D013988","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Warfarin","uri":{"id":"D014859","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Dopamine Antagonists","uri":{"id":"D018492","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Polypharmacy","uri":{"id":"D019338","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Proton Pump Inhibitors","uri":{"id":"D054328","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Drug-Related Side Effects and Adverse Reactions","uri":{"id":"D064420","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Anti-Inflammatory Agents, Non-Steroidal","Antiparkinson Agents","Databases, Factual","Dopamine Antagonists","Drug Interactions","Drug Prescriptions","Drug-Related Side Effects and Adverse Reactions","Humans","Nursing Homes","Platelet Aggregation Inhibitors","Polypharmacy","Proton Pump Inhibitors","Ticlopidine","Warfarin"]},"pmid":"24865728","title":"[Drug-drug interactions in nursing home patients].","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"BACKGROUND: Patients admitted to internal medicine services receive multiple drugs and thus are at risk of medication errors. Aim: To determine the frequency of medication errors (ME) among patients admitted to an internal medicine service of a high complexity hospital. MATERIAL AND METHODS: A prospective observational study conducted in 225 patients admitted to an internal medicine service. Each stage of drug utilization system (prescription, transcription, dispensing, preparation and administration) was directly observed by trained pharmacists not related to hospital staff during three months. ME were described and categorized according to the National Coordinating Council for Medication Error Reporting and Prevention. In each stage of medication use, the frequency of ME and their characteristics were determined. RESULTS: A total of 454 drugs were prescribed to the studied patients. In 138 (30,4%) indications, at least one ME occurred, involving 67 (29,8%) patients. Twenty four percent of detected ME occurred during administration, mainly due to wrong time schedules. Anticoagulants were the therapeutic group with the highest occurrence of ME. CONCLUSIONS: At least one ME occurred in approximately one third of patients studied, especially during the administration stage. These errors could affect the medication safety and avoid achieving therapeutic goals. Strategies to improve the quality and safe use of medications can be implemented using this information.","fulltextAvailable":false,"journal":"Revista médica de Chile","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prospective Studies","uri":{"id":"D011446","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Quality Improvement","uri":{"id":"D058996","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Drug Utilization","uri":{"id":"D004363","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Internal Medicine","uri":{"id":"D007388","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Medication Errors","uri":{"id":"D008508","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Medical Errors","uri":{"id":"D019300","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Appointments and Schedules","uri":{"id":"D001071","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pharmaceutical Preparations","uri":{"id":"D004364","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hospitalization","uri":{"id":"D006760","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hospitals","uri":{"id":"D006761","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Medicine","uri":{"id":"D008511","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pharmacists","uri":{"id":"D010595","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Safety","uri":{"id":"D012449","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Therapeutics","uri":{"id":"D013812","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prescriptions","uri":{"id":"D055656","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Research Report","uri":{"id":"D058028","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Medicalization","uri":{"id":"D062528","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anticoagulants","uri":{"id":"D000925","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"24861113","title":"[Monitoring medication errors in an internal medicine service].","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"BACKGROUND: Dabigatran, rivaroxaban, and apixaban have been approved for use in patients with atrial fibrillation based upon randomized trials demonstrating their comparable or superior efficacy and safety relative to warfarin. Little is known about their adoption into clinical practice, whether utilization is consistent with the controlled-trials on which their approval was based, and how their use has affected health spending for patients and insurers. STUDY DESIGN: We used medical and prescription claims data from a large insurer to identify patients with non-valvular atrial fibrillation who were prescribed an oral anticoagulant in 2010-2013. We plotted trends in medication initiation over time, assessed corresponding insurer and patient out-of-pocket spending, and evaluated the cumulative number and cost of anticoagulants. We identified predictors of novel anticoagulant initiation using multivariable logistic models. Finally, we estimated the difference in total drug expenditures over 6 months for patients initiating warfarin vs. a novel anticoagulant. RESULTS: 6,893 patients with atrial fibrillation initiated an oral anticoagulant during the study period. By the end of the study period, novel anticoagulants accounted for 62% of new prescriptions and 98% of anticoagulant-related drug costs. Female sex, lower household income and higher CHADS2, CHA2DS2-VASC, and HAS-BLED scores were significantly associated with lower odds of receiving a novel anticoagulant (p<0.001 for each). Average combined patient and insurer anticoagulant spending in the first 6 months after initiation was more than $900 greater for patients initiating a novel anticoagulant. CONCLUSIONS: This study demonstrates rapid adoption of novel anticoagulants into clinical practice, particularly among patients with lower CHADS2 and HAS-BLED scores, and high health care cost consequences. These findings provide important directions for future comparative and cost-effectiveness research.","fulltextAvailable":false,"journal":"The American journal of medicine","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Health Care Costs","uri":{"id":"D017048","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Health Care","uri":{"id":"health_care_category","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Atrial Fibrillation","uri":{"id":"D001281","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Delivery of Health Care","uri":{"id":"D003695","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Logistic Models","uri":{"id":"D016015","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Health Care Costs","uri":{"id":"D017048","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Drug Costs","uri":{"id":"D016527","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Adoption","uri":{"id":"D000300","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pharmaceutical Preparations","uri":{"id":"D004364","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Evaluation Studies as Topic","uri":{"id":"D005069","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Health Expenditures","uri":{"id":"D005102","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Family Characteristics","uri":{"id":"D005191","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Female","uri":{"id":"D005260","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Forecasting","uri":{"id":"D005544","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Income","uri":{"id":"D007182","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Organization and Administration","uri":{"id":"D009934","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Safety","uri":{"id":"D012449","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prescriptions","uri":{"id":"D055656","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Medicalization","uri":{"id":"D062528","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anticoagulants","uri":{"id":"D000925","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Insurance","uri":{"id":"D007341","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Insurance Carriers","uri":{"id":"D007343","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Warfarin","uri":{"id":"D014859","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"24859719","title":"Patterns of Initiation of Oral Anticoagulants in Patients with Atrial Fibrillation - Quality and Cost Implications.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"BACKGROUND AND PURPOSE: Shockwave lithotripsy (SWL) is the gold standard treatment of patients with most renal and proximal ureteral calculi. Severe bleeding complications in SWL are extremely rare. Uncorrected bleeding diathesis might increase the risk and is considered to be an absolute contraindication for SWL. Perioperative management of anticoagulative and antiplatelet therapy has changed in the recent past. In particular, low-dose acetylsalicylic acid (ASA) is no longer a contraindication for many surgical procedures. METHODS: A systematic Medline/PubMed literature search of peer-reviewed scientific articles in urology and cardiovascular medicine was performed concerning the management of anticoagulative and antiplatelet medication during SWL. RESULTS: The literature on medically acquired and pathological bleeding diathesis and SWL in general is rare, retrospective, nonstandardized, and of low quality. Routine cessation of obligatory indicated anticoagulative or antiplatelet medication implies a significant risk for cardiovascular adverse events (CAE). Ureterorenoscopy is recommended in patients with uncorrected bleeding diathesis, although this is not based on high-level evidence. CONCLUSION: In patients with obligatory intake of anticoagulative or antiplatelet medication, the risk for CAE must be balanced against the SWL-induced bleeding risk. In patients with low-dose ASA-intake, SWL should be considered as an option instead of being disregarded as an absolute contraindication. Prospective randomized trials designed to define the optimal management of anticoagulants and antiplatelets during SWL are warranted.","fulltextAvailable":false,"journal":"Journal of endourology / Endourological Society","meshAnnotations":{"@type":"java.util.ArrayList"},"meshHeading":null,"pmid":"24851726","title":"Antiplatelet and anticoagulative medication during shockwave lithotripsy.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"Antithrombotic medication is a cornerstone of acute ischemic stroke treatment and secondary prevention. The efficacy of thrombolysis with alteplase in acute stroke has been demonstrated in several clinical trials. This safe and costeffective therapy has transformed the practice of stroke care and has led to subsequent trials of other antithrombotic medications for treatment of ischemic stroke in the acute phase. These antithrombotics include thrombolytic, antiplatelet and anticoagulant agents. While, no other medication has yet demonstrated adequate efficacy, our current and evolving understanding of infarct expansion, ischemic penumbra, collateral circulation and the blood brain barrier is allowing testing of antithrombotic medications tailored to individual patient pathophysiology in clinical trials. This understanding accompanies developments in neuroimaging and organization of stroke care that allow for wide-spread recruitment in these trials. Alteplase remains the mainstay treatment of arterial acute ischemic stroke; however, anticoagulation is the standard therapy for cerebral venous sinus thrombosis. Antithrombotic use in acute stroke, arterial and venous, has demonstrated efficacy but leaves many questions unanswered. This patient population is a fertile ground for novel research, especially as it relates to; combination antithrombotic therapy, combination of pharmacological and mechanical thrombolysis, and the transition to secondary prevention. Here we review the current antithrombotics in the acute phase of ischemic stroke highlighting the evidence-base and areas of uncertainty.","fulltextAvailable":false,"journal":"Current vascular pharmacology","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Stroke","uri":{"id":"D020521","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Venous Thrombosis","uri":{"id":"D020246","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Stroke","uri":{"id":"D020521","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anticoagulants","uri":{"id":"D000925","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Blood-Brain Barrier","uri":{"id":"D001812","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Collateral Circulation","uri":{"id":"D003097","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Sinus Thrombosis, Intracranial","uri":{"id":"D012851","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Secondary Prevention","uri":{"id":"D055502","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Mechanical Thrombolysis","uri":{"id":"D061185","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arteries","uri":{"id":"D001158","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Fertility","uri":{"id":"D005298","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Fertilization","uri":{"id":"D005306","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Thrombosis","uri":{"id":"D013927","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Uncertainty","uri":{"id":"D035501","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Neuroimaging","uri":{"id":"D059906","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Medicalization","uri":{"id":"D062528","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anticoagulants","uri":{"id":"D000925","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Fertilizers","uri":{"id":"D005308","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Tissue Plasminogen Activator","uri":{"id":"D010959","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"24846224","title":"Acute antithrombotic treatment of ischemic stroke.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"OBJECTIVE: Rapid decision-making during acute stroke care can improve outcomes. We wished to assess whether crucial information to facilitate decisions is routinely collected by emergency practitioners before hospital admission. MATERIALS AND METHODS: We examined whether ambulance records contained information relevant to a thrombolysis treatment decision for consecutive stroke admissions to three emergency departments in England between 14 May 2012 and 10 June 2013. RESULTS: In all, 424 of 544 (78%) records included a paramedic diagnosis of stroke. Twice as many hospital records contained a symptom onset time/last known to be well time, but there was 82% agreement within 1 h when a prehospital time was also recorded. This was more likely for younger patients. Documentation of medication history was infrequent (12%), particularly for anticoagulant status (6%). When compared with hospital documentation, paramedics recorded a history of diabetes for 38/49 (78%), previous stroke 44/69 (64%), hypertension 71/140 (51%) and atrial fibrillation 19/64 (30%). CONCLUSION: In a retrospective cohort of stroke patients admitted by emergency ambulance, standard practice did not consistently result in prehospital documentation of information that could promote rapid treatment decisions. Training emergency practitioners and/or providing clinical protocols could facilitate early stroke treatment decisions, but prehospital information availability is likely to be a limiting factor.","fulltextAvailable":false,"journal":"European journal of emergency medicine : official journal of the European Society for Emergency Medicine","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Atrial Fibrillation","uri":{"id":"D001281","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Emergency Service, Hospital","uri":{"id":"D004636","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Stroke","uri":{"id":"D020521","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Clinical Protocols","uri":{"id":"D002985","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hospital Records","uri":{"id":"D006753","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Ambulances","uri":{"id":"D000552","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Diagnosis","uri":{"id":"D003933","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Emergencies","uri":{"id":"D004630","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"History","uri":{"id":"D006664","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hospitalization","uri":{"id":"D006760","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hospitals","uri":{"id":"D006761","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hypertension","uri":{"id":"D006973","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Medicalization","uri":{"id":"D062528","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Allied Health Personnel","uri":{"id":"D000488","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anticoagulants","uri":{"id":"D000925","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Documentation","uri":{"id":"D004282","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"England","uri":{"id":"D004739","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Walking","uri":{"id":"D016138","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"24841772","title":"Agreement between ambulance and hospital records for information promoting urgent stroke treatment decisions.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"The purpose of the study was to investigate whether early high-dose potent statin therapy in patients with ST elevation myocardial infarction undergoing primary percutaneous coronary intervention can reduce infarct size compared with conventional low-dose statin therapy. In a randomized placebo-controlled multicenter trial, 185 patients were assigned either to an early high-dose rosuvastatin group (n = 92, rosuvastatin 40 mg before treatment plus maintenance for 7 days) or to a conventional low-dose rosuvastatin group (n = 93, placebo before treatment plus rosuvastatin 10-mg maintenance for 7 days). Serial cardiac magnetic resonance imaging (MRI) was performed during the acute (3 to 7 days) and chronic (3 months) phases. The primary end point was relative infarct volume assessed by MRI at 3 months. Baseline characteristics were similar between the 2 groups, except hypertension, which was more prevalent in the high-dose group. Serial MRI data were available for 121 patients (high-dose group n = 54 and low-dose group n = 67). The relative infarct volumes in the acute (23.0 ± 9.5% vs 20.5 ± 11.7%, p = 0.208) and chronic (15.9 ± 8.3% vs 15.8 ± 9.7%, p = 0.943) phases were not different between the groups. No differences between groups were observed for periprocedural microvascular circulation evaluated by Thrombolysis In Myocardial Infarction flow grade, myocardial blush grade, ST-segment resolution, microvascular obstruction on cardiac MRI, or clinical outcomes. In conclusion, early high-dose rosuvastatin therapy in patients with ST elevation myocardial infarction undergoing primary percutaneous coronary intervention did not improve periprocedural myocardial perfusion or reduce infarct volume measured by MRI compared with the conventional low-dose rosuvastatin regimen.","fulltextAvailable":false,"journal":"The American journal of cardiology","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Intervention Studies","uri":{"id":"D016033","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Magnetic Resonance Imaging","uri":{"id":"D008279","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Magnetic Resonance Spectroscopy","uri":{"id":"D009682","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Myocardial Infarction","uri":{"id":"D009203","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Multicenter Studies as Topic","uri":{"id":"D015337","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Percutaneous Coronary Intervention","uri":{"id":"D062645","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Evaluation Studies as Topic","uri":{"id":"D005069","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hypertension","uri":{"id":"D006973","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Maintenance","uri":{"id":"D008283","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Perfusion","uri":{"id":"D010477","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prevalence","uri":{"id":"D015995","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Infarction","uri":{"id":"D007238","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Double-Blind Method","uri":{"id":"D004311","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Female","uri":{"id":"D005260","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Humans","uri":{"id":"D006801","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hypertension","uri":{"id":"D006973","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Magnetic Resonance Imaging","uri":{"id":"D008279","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Male","uri":{"id":"D008297","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Middle Aged","uri":{"id":"D008875","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Myocardial Infarction","uri":{"id":"D009203","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prospective Studies","uri":{"id":"D011446","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Sulfonamides","uri":{"id":"D013449","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Treatment Outcome","uri":{"id":"D016896","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Republic of Korea","uri":{"id":"D056910","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anticoagulants","uri":{"id":"D000925","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Combined Modality Therapy","uri":{"id":"D003131","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Electrocardiography","uri":{"id":"D004562","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Fluorobenzenes","uri":{"id":"D005464","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Placebos","uri":{"id":"D010919","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pyrimidines","uri":{"id":"D011743","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hydroxymethylglutaryl-CoA Reductase Inhibitors","uri":{"id":"D019161","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Drug-Eluting Stents","uri":{"id":"D054855","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Secondary Prevention","uri":{"id":"D055502","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Percutaneous Coronary Intervention","uri":{"id":"D062645","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Anticoagulants","Combined Modality Therapy","Double-Blind Method","Drug-Eluting Stents","Electrocardiography","Female","Fluorobenzenes","Humans","Hydroxymethylglutaryl-CoA Reductase Inhibitors","Hypertension","Magnetic Resonance Imaging","Male","Middle Aged","Myocardial Infarction","Percutaneous Coronary Intervention","Placebos","Prospective Studies","Pyrimidines","Republic of Korea","Secondary Prevention","Sulfonamides","Treatment Outcome"]},"pmid":"24831577","title":"Efficacy of early intensive rosuvastatin therapy in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention (ROSEMARY Study).","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"BACKGROUND AND OBJECTIVES: Drug therapy in patients with advanced heart failure and limited life expectancy may be of no benefit or even inappropriate. The aim of this study was to analyze the appropriateness of medication prescribed to patients with advanced heart failure and limited life expectancy, considering as such an expected median survival of less than 6 months. METHODS: We retrospectively reviewed data on all patients with advanced heart failure who met criteria for limited life expectancy and who died in the geriatric ward of a tertiary hospital over a four-and-a-half-year period. We analyzed treatments prescribed before admission, especially drugs used for prophylaxis or to prolong life. RESULTS: A total of 72 patients were included. The mean age was 85.4 years, and 52.3 % were women. Mean Charlson index was 3.2. Prophylactic medications taken by patients at admission were antiplatelets in 40 patients (55.6 %), oral anticoagulants in 17 (23.6 %), statins in 14 (19.4 %), and osteoporosis medication in nine (12.5 %). Medications taken to prolong survival were angiotensin converting enzyme inhibitors or angiotensin II receptor antagonists in 29 patients (40.3 %). Other medications were iron supplements in 19 patients (26.4 %), vitamins in two (2.8 %), and acetylcholinesterase inhibitors in two (2.8 %). CONCLUSIONS: Our results show that patients with advanced heart failure and limited life expectancy were receiving an excessive number of prophylactic medications, drugs to prolong life, and other inappropriate treatments. These findings emphasize the need to review drug therapy in an individualized manner in elderly patients with advanced stages of heart disease and a poor prognosis.","fulltextAvailable":false,"journal":"Drugs & aging","meshAnnotations":{"@type":"java.util.ArrayList"},"meshHeading":null,"pmid":"24825616","title":"Appropriateness of medications prescribed to elderly patients with advanced heart failure and limited life expectancy who died during hospitalization.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"The main goal of palliative care is to improve quality of life by treating symptoms in patients with life-threatening illnesses. Most patients suffer from more than five severe comorbidities in the last 6 months of life. However, for patients receiving palliative care, interventions to prevent possible long-term complications of these comorbidities are no longer the primary aim of care. This paper aimed to review the literature regarding decision making about medication for comorbid disease at the end of life, defined as a life expectancy <3 months, and to formulate preliminary recommendations based on the existing literature. An integrative review approach was used. We searched the MEDLINE, EMBASE, and CINAHL databases. Papers were included if they had been published in the English language between 1 January 1995 and 31 December 2013, with an abstract. Additional studies were identified by searching bibliographies. Factors to consider when systematically reviewing medications are the goals of care, remaining life expectancy, treatment targets, time until benefit, number needed to treat, number needed to harm, and adverse drug reactions. Existing research focuses particularly on the use of certain drug classes during end-of-life care, including statins, antihypertensive agents, anticoagulants, antihyperglycaemic agents and antibiotics. Based on the results of this review, we made preliminary recommendations for these medication groups. Medication that does not benefit the patient in any way should be avoided. The aim of medication at the end of life should be symptom control. There is a need for prospective trials to give further insight into the decision-making process of medication management at the end of life.","fulltextAvailable":false,"journal":"Drugs & aging","meshAnnotations":{"@type":"java.util.ArrayList"},"meshHeading":null,"pmid":"24825615","title":"Decision making about change of medication for comorbid disease at the end of life: an integrative review.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"BACKGROUND: Aim was to describe the clinical spectrum, therapy, and outcome of ischemic strokes under therapy with new oral anticoagulants (NOAC). METHODS AND RESULTS: A literature research was carried out in PubMed. Clinical trials as well as case reports were included. Four large trials comparing NOAC with warfarin reported 469 ischemic strokes but neither co-medication, nor comorbidities, location, clinical spectrum, therapy, nor outcome are reported. Eleven cases with ischemic strokes under dabigatran from the literature are reported. Six patients received thrombolytic therapy, in three of them unaware dabigatran therapy. Two patients received mechanical recanalization. Two patients died, one due to cerebral hemorrhage after thrombolysis, the other after partial recanalization of the basilar artery. CONCLUSIONS: Little is known about ischemic strokes under NOAC. To increase the knowledge, the data of 469 ischemic strokes which occurred in NOAC-investigating trials should be analyzed. Furthermore ischemic and bleeding events under NOAC outside clinical trials should be reported. An international registry, independent from the pharmaceutical industry for collecting these informations is desirable.","fulltextAvailable":false,"journal":"Neurologia i neurochirurgia polska","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Drug Industry","uri":{"id":"D004345","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Basilar Artery","uri":{"id":"D001488","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cerebral Hemorrhage","uri":{"id":"D002543","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Thrombolytic Therapy","uri":{"id":"D015912","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arteries","uri":{"id":"D001158","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hemorrhage","uri":{"id":"D006470","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Industry","uri":{"id":"D007221","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Literature","uri":{"id":"D008091","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Registries","uri":{"id":"D012042","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Comorbidity","uri":{"id":"D015897","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Knowledge","uri":{"id":"D019359","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"PubMed","uri":{"id":"D039781","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Research Report","uri":{"id":"D058028","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anticoagulants","uri":{"id":"D000925","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Warfarin","uri":{"id":"D014859","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Administration, Oral","uri":{"id":"D000284","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Humans","uri":{"id":"D006801","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anticoagulants","uri":{"id":"D000925","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Brain Ischemia","uri":{"id":"D002545","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Stroke","uri":{"id":"D020521","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Administration, Oral","Anticoagulants","Brain Ischemia","Humans","Stroke"]},"pmid":"24821640","title":"Presentation, therapy and outcome of patients with ischemic stroke under new oral anticoagulants.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"UNLABELLED: Diagnosing Horner Syndrome can be difficult in the setting of an incomplete triad. A 27-year-old man presented with unilateral eyelid droop and intermittent ipsilateral headaches, having already seen 7 physicians. Physical examination revealed unilateral ptosis but no pupillary miosis or facial anhidrosis. Inspection of his clinical photographs revealed elevation of the ipsilateral lower eyelid, suggesting sympathetic dysfunction. On further questioning, he admitted to naphazoline dependence. Reexamination after ceasing the naphazoline unveiled the anisocoria. Vascular imaging subsequently revealed carotid dissection, and the patient was started on anticoagulant and antiplatelet therapy. The ptosis persisted after conjunctival Müllerectomy. External levator resection was recommended, but patient declined. This case underscores the importance of clinical photography, meticulous medical record review, and complete medication history including over-the-counter preparations. Clinicians should meticulously inspect the lower eyelid in cases of atypical blepharoptosis and consider the effects of eye drops when inspecting pupils for miosis.","fulltextAvailable":false,"journal":"Ophthalmic plastic and reconstructive surgery","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Carotid Arteries","uri":{"id":"D002339","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Medical Records","uri":{"id":"D008499","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Physical Examination","uri":{"id":"D010808","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Horner Syndrome","uri":{"id":"D006732","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Ophthalmic Solutions","uri":{"id":"D009883","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Miosis","uri":{"id":"D015877","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Arteries","uri":{"id":"D001158","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Diagnosis","uri":{"id":"D003933","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Dissection","uri":{"id":"D004210","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Eyelids","uri":{"id":"D005143","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"History","uri":{"id":"D006664","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Photography","uri":{"id":"D010781","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Physicians","uri":{"id":"D010820","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Physics","uri":{"id":"D010825","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Syndrome","uri":{"id":"D013577","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Medicalization","uri":{"id":"D062528","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anticoagulants","uri":{"id":"D000925","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Blepharoptosis","uri":{"id":"D001763","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Headache","uri":{"id":"D006261","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hypohidrosis","uri":{"id":"D007007","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Naphazoline","uri":{"id":"D009278","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anisocoria","uri":{"id":"D015875","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Miosis","uri":{"id":"D015877","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"24807801","title":"Naphazoline as a Confounder in the Diagnosis of Carotid Artery Dissection.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"OBJECTIVE: To assess the transplacental pharmacokinetics at term of the oral thrombin inhibitor, dabigatran, and its prodrug, dabigatran etexilate mesylate, to estimate fetal drug exposure. METHODS: Placentae were obtained with informed consent after cesarean delivery of healthy term pregnancies in Toronto, Ontario, Canada. The transplacental transfer of dabigatran and dabigatran etexilate mesylate was separately assessed using the ex vivo dual perfusion of an isolated human placental cotyledon. Dabigatran, at a concentration of 35 ng/mL, was added to the maternal circulation at the start of the experimental phase. Maternal and fetal samples were taken throughout the preexperimental (1 hour) and experimental (3 hours) phases for measurement of dabigatran and markers of placental viability. Separate placenta perfusions with dabigatran etexilate mesylate were conducted at an initial maternal concentration of 3.5 ng/mL. Dabigatran and dabigatran etexilate mesylate were measured using liquid chromatography-tandem mass spectrometry. RESULTS: There was slower transfer of dabigatran compared with antipyrine from the maternal-to-fetal circulation, because the median fetal-to-maternal concentration ratio was 0.33 (interquartile range 0.29-0.38) after 3 hours (n=3). The prodrug, dabigatran etexilate mesylate, had limited placental transfer as characterized by a fetal-to-maternal ratio of 0.17 (interquartile range 0.15-0.17) after 3 hours (n=3). Placental viability markers for all perfusions were within normal ranges. CONCLUSION: This report provides direct evidence of the transfer of dabigatran and its prodrug across the term human placenta from the mother to the fetus. From a clinical perspective, these data suggest that, pending further study, dabigatran should not be used for anticoagulation of pregnant women, because the drug may have an adverse effect on fetal blood coagulation.","fulltextAvailable":false,"journal":"Obstetrics and gynecology","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Reference Values","uri":{"id":"D012016","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Mass Spectrometry","uri":{"id":"D013058","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pregnant Women","uri":{"id":"D037841","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Blood Coagulation","uri":{"id":"D001777","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Fetal Blood","uri":{"id":"D005312","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Informed Consent","uri":{"id":"D007258","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Canada","uri":{"id":"D002170","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pharmaceutical Preparations","uri":{"id":"D004364","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Fetus","uri":{"id":"D005333","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Ontario","uri":{"id":"D009864","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Perfusion","uri":{"id":"D010477","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pharmacokinetics","uri":{"id":"D010599","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Placentation","uri":{"id":"D010929","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pregnancy","uri":{"id":"D011247","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Spectrum Analysis","uri":{"id":"D013057","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Thrombin","uri":{"id":"D013917","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Women","uri":{"id":"D014930","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Cotyledon","uri":{"id":"D018548","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Research Report","uri":{"id":"D058028","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Antipyrine","uri":{"id":"D000983","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Mesylates","uri":{"id":"D008698","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prodrugs","uri":{"id":"D011355","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Female","uri":{"id":"D005260","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Humans","uri":{"id":"D006801","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Maternal-Fetal Exchange","uri":{"id":"D008431","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Perfusion","uri":{"id":"D010477","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Placenta","uri":{"id":"D010920","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pregnancy","uri":{"id":"D011247","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Antithrombins","uri":{"id":"D000991","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Benzimidazoles","uri":{"id":"D001562","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Fetus","uri":{"id":"D005333","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pregnancy Complications, Hematologic","uri":{"id":"D011250","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Prodrugs","uri":{"id":"D011355","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pyridines","uri":{"id":"D011725","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"beta-Alanine","uri":{"id":"D015091","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Antithrombins","Benzimidazoles","Female","Fetus","Humans","Maternal-Fetal Exchange","Perfusion","Placenta","Pregnancy","Pregnancy Complications, Hematologic","Prodrugs","Pyridines","beta-Alanine"]},"pmid":"24807346","title":"Transfer of dabigatran and dabigatran etexilate mesylate across the dually perfused human placenta.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":null,"fulltextAvailable":false,"journal":"Journal of gerontological nursing","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anticoagulants","uri":{"id":"D000925","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Adult","uri":{"id":"D000328","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pharmaceutical Preparations","uri":{"id":"D004364","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anticoagulants","uri":{"id":"D000925","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Aged","uri":{"id":"D000368","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Aged, 80 and over","uri":{"id":"D000369","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Humans","uri":{"id":"D006801","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anticoagulants","uri":{"id":"D000925","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Medication Errors","uri":{"id":"D008508","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Aged","Aged, 80 and over","Anticoagulants","Humans","Medication Errors"]},"pmid":"24802992","title":"Inappropriate use of anticoagulant drugs in older adults.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"BACKGROUND: Using aspirin, heparin, or both in women with unexplained recurrent miscarriage could be useful, because this problem might be initiated by thrombosis in decidual vessels. OBJECTIVE: To investigate the association between thrombophilia and unexplained recurrent miscarriage and to evaluate the efficacy of anticoagulant treatment. MATERIALS AND METHODS: In this quasi experimental, we enrolled 520 women, who had a history of recurrent miscarriage. Two hundred fifty two women with unexplained recurrent miscarriage were assigned to receive aspirin (80 mg daily) for two month before pregnancy and after confirmation of a viable pregnancy until 36 weeks of gestation or receive aspirin, as the same, plus heparin (5000 unit twice a day) subcutaneously after confirmation of viable pregnancy until 4 weeks after delivery. Type of medication was chosen for each woman according to number of abortion and age. RESULTS: Live-birth rates did not different significantly among the two study groups. The proportions of women who gave birth to a live normal infant were 74.5% in the group receiving aspirin plus heparin (combination-therapy group) and 79.8% in the aspirin group. CONCLUSION: Live-birth rates did not different significantly among the two study groups. So, using aspirin or aspirin plus heparin did not change pregnancy rate in these patients. Using aspirin is easier than injecting heparin which should be chosen case by case. This article extracted from M.Sc. thesis. (Tahereh Jahaninejad) REGISTRATION ID IN IRCT: IRCT2013102315123N1.","fulltextAvailable":false,"journal":"Iranian journal of reproductive medicine","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pregnancy Rate","uri":{"id":"D018873","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Abortion, Habitual","uri":{"id":"D000026","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Evaluation Studies as Topic","uri":{"id":"D005069","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Heparin","uri":{"id":"D006493","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"History","uri":{"id":"D006664","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Infant","uri":{"id":"D007223","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pregnancy","uri":{"id":"D011247","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Recurrence","uri":{"id":"D012008","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Thrombosis","uri":{"id":"D013927","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Women","uri":{"id":"D014930","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Living Wills","uri":{"id":"D016224","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Medicalization","uri":{"id":"D062528","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Abortion, Spontaneous","uri":{"id":"D000022","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anticoagulants","uri":{"id":"D000925","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Aspirin","uri":{"id":"D001241","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Injections","uri":{"id":"D007267","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Thrombophilia","uri":{"id":"D019851","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"24799864","title":"Effectiveness of aspirin compare with heparin plus aspirin in recurrent pregnancy loss treatment: A Quasi experimental study.","year":"2014"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"OBJECTIVES AND BACKGROUND: Rivaroxaban, an oral direct factor Xa-inhibitor was non-inferior to adjusted dose warfarin in the prevention of stroke and embolism among patients with atrial fibrillation (AF) in the ROCKET-AF trial and has been approved for stroke prevention in AF. CASE REPORT: A 88-years-old female (body-mass-index = 19.95) with AF, hypertension and diabetes mellitus, hospitalized because of heart failure and a non-convulsive epileptic state, was treated by valproate, mirtazepin, nebivolol, digitoxin, lisinopril, gliclazide and amlodipine. Irrespective of renal insufficiency, rivaroxaban 15 mg/d was started. After 3 days rivaroxaban was stopped because of concerns about the bleeding risk. Coagulation tests 28 h after rivaroxaban-intake showed INR 2.26, PT 35%, aPTT 38.3 s and anti-Factor Xa-activity 2.00 U/ml. Explanations for the prolonged anticoagulant activity of rivaroxaban comprise renal failure, the low body-mass-index, the advanced age and drug-drug interactions of rivaroxaban with mirtazepin, valproate and amlodipine. CONCLUSION: Health care providers should consider renal function, concomitant medication, polymorbidity and age prior to prescribing rivaroxaban. Care has to be taken when prescribing rivaroxaban to patients who are different from those included in the ROCKET AF trial.","fulltextAvailable":false,"journal":"Heart & lung : the journal of critical care","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Health Care","uri":{"id":"health_care_category","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Atrial Fibrillation","uri":{"id":"D001281","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Delivery of Health Care","uri":{"id":"D003695","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Diabetes Mellitus","uri":{"id":"D003920","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Health Personnel","uri":{"id":"D006282","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Heart Failure","uri":{"id":"D006333","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Renal Insufficiency","uri":{"id":"D051437","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Aged","uri":{"id":"D000368","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Female","uri":{"id":"D005260","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hemorrhage","uri":{"id":"D006470","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hospitalization","uri":{"id":"D006760","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hospitals","uri":{"id":"D006761","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hypertension","uri":{"id":"D006973","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Patients","uri":{"id":"D010361","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Amlodipine","uri":{"id":"D017311","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Medicalization","uri":{"id":"D062528","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anticoagulants","uri":{"id":"D000925","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Digitoxin","uri":{"id":"D004074","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Gliclazide","uri":{"id":"D005907","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Valproic Acid","uri":{"id":"D014635","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Warfarin","uri":{"id":"D014859","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Lisinopril","uri":{"id":"D017706","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"International Normalized Ratio","uri":{"id":"D019934","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Aged, 80 and over","uri":{"id":"D000369","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Epilepsy","uri":{"id":"D004827","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Female","uri":{"id":"D005260","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Heart Failure","uri":{"id":"D006333","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Humans","uri":{"id":"D006801","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Thiophenes","uri":{"id":"D013876","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anticoagulants","uri":{"id":"D000925","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Atrial Fibrillation","uri":{"id":"D001281","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Drug Interactions","uri":{"id":"D004347","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Morpholines","uri":{"id":"D009025","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Valproic Acid","uri":{"id":"D014635","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Stroke","uri":{"id":"D020521","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Renal Insufficiency","uri":{"id":"D051437","namespace":"MeSH:"}}]},"meshHeading":{"@type":"java.util.ArrayList","@items":["Aged, 80 and over","Anticoagulants","Atrial Fibrillation","Drug Interactions","Epilepsy","Female","Heart Failure","Humans","Morpholines","Renal Insufficiency","Stroke","Thiophenes","Valproic Acid"]},"pmid":"24794785","title":"Prolonged anticoagulant activity of rivaroxaban in a polymorbid elderly female with non-convulsive epileptic state.","year":"2014 May-Jun"}
{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$Document","documentAbstract":"BACKGROUND: Inadequate lab monitoring of drugs is a potential cause of ADEs (adverse drug events) which is remediable. OBJECTIVES: To determine the effectiveness of computerized drug-lab alerts to improve medication-related outcomes. DATA SOURCES: Citations from the Computerized Clinical Decision Support System Systematic Review (CCDSSR) and MMIT (Medications Management through Health Information Technology) databases, which had searched MEDLINE, EMBASE, CINAHL, Cochrane Database of Systematic Reviews, International Pharmaceutical Abstracts from 1974 to March 27, 2013. STUDY SELECTION: Randomized controlled trials (RCTs) of clinician-targeted computerized drug lab alerts conducted in any healthcare setting. Two reviewers performed full text review to determine study eligibility. DATA ABSTRACTION: A single reviewer abstracted data and evaluated validity of included studies using Cochrane handbook domains. DATA SYNTHESIS: Thirty-six studies met the inclusion criteria (25 single drug studies with 22,504 participants, 14 targeting anticoagulation; 11 multi-drug studies with 56,769 participants). ADEs were reported as an outcome in only four trials, all targeting anticoagulants. Computerized drug-lab alerts did not reduce ADEs (OR 0.89, 95% CI 0.79-1.00, p=0.05), length of hospital stay (SMD 0.00, 95%CI -0.93 to 0.93, p=0.055, 1 study), likelihood of hypoglycemia (OR 1.29, 95% CI 0.31-5.37) or likelihood of bleeding, but were associated with increased likelihood of prescribing changes (OR 1.73, 95% CI 1.21-2.47) or lab monitoring (OR 1.47, 95% confidence interval 1.12-1.94) in accordance with the alert. CONCLUSIONS: There is no evidence that computerized drug-lab alerts are associated with important clinical benefits, but there is evidence of improvement in selected clinical surrogate outcomes (time in therapeutic range for vitamin K antagonists), and changes in process outcomes (lab monitoring and prescribing decisions).","fulltextAvailable":false,"journal":"International journal of medical informatics","meshAnnotations":{"@type":"java.util.ArrayList","@items":[{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Length of Stay","uri":{"id":"D007902","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Eligibility Determination","uri":{"id":"D004608","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Drug Monitoring","uri":{"id":"D016903","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Biomedical Technology","uri":{"id":"D020811","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Health Information Management","uri":{"id":"D063025","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Length of Stay","uri":{"id":"D007902","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Vitamin K","uri":{"id":"D014812","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Confidence Intervals","uri":{"id":"D016001","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Drug-Related Side Effects and Adverse Reactions","uri":{"id":"D064420","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Medical Informatics","uri":{"id":"D008490","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Decision Support Systems, Clinical","uri":{"id":"D020000","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Abstracting and Indexing as Topic","uri":{"id":"D000043","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Classification","uri":{"id":"D002965","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Delivery of Health Care","uri":{"id":"D003695","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Pharmaceutical Preparations","uri":{"id":"D004364","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Evaluation Studies as Topic","uri":{"id":"D005069","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hemorrhage","uri":{"id":"D006470","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hospitalization","uri":{"id":"D006760","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hospitals","uri":{"id":"D006761","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Technology","uri":{"id":"D013672","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Therapeutics","uri":{"id":"D013812","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Vitamins","uri":{"id":"D014815","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Research Report","uri":{"id":"D058028","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Text Messaging","uri":{"id":"D060145","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Medicalization","uri":{"id":"D062528","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Anticoagulants","uri":{"id":"D000925","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"Hypoglycemia","uri":{"id":"D007003","namespace":"MeSH:"}},{"@type":"edu.cmu.lti.oaqa.bio.bioasq.services.PubMedSearchServiceResponse$MeshAnnotation","termLabel":"MEDLINE","uri":{"id":"D016239","namespace":"MeSH:"}}]},"meshHeading":null,"pmid":"24793784","title":"The effectiveness of computerized drug-lab alerts: a systematic review and meta-analysis.","year":"2014"}